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ABSTRACT 
Alzheimer’s disease is neuropathologically characterized by extracellular accumulation of 
amyloid ȕ plaques and intracellular aggregation of misfolded tau proteins, which eventually 
lead to neurodegeneration and cognitive impairment. With the recent advances in 
neuroimaging, these two proteinopathies can now be studied in vivo using positron emission 
tomography (PET). Combining this imaging technique with functional magnetic resonance 
imaging has consistently revealed a spatial overlap between amyloid ȕ accumulates and 
functional connectivity networks (Buckner et al., 2009; Grothe et al., 2016), indicating 
functional connectivity as mechanistic pathway in the distribution of neuropathologies. While 
the infiltration of these neuronal networks by amyloid ȕ deposits seems uniform across 
individuals with Alzheimer’s disease, there nevertheless exists inter-individual differences in 
the clinical expression of the disease despite similar pathological burden (Stern, 2012). This 
observation has fuelled the concept of existing resilience mechanisms, which are supported by 
lifetime and –style factors and, which magnitude varies between individuals, contributing to 
the clinical heterogeneity seen in Alzheimer’s disease.  
Even though the spreading and resilience mechanisms in the phase of amyloid ȕ accumulation 
are now better understood, no information on tau pathology in vivo were available in this regard 
until recently. Given the recent introduction of tau PET compounds, this thesis therefore aimed 
to address two questions: 1) whether functional connectivity contributes to the distribution of 
tau pathology across brain networks, and 2) whether the consequence of tau pathology on 
cognitive and neuronal function is mitigated by a resilience proxy, namely education. Using 
[18F]-AV-1451 PET imaging to quantify tau pathology in a group of Alzheimer’s disease 
patients, we observed that tau pathology arises synchronously in independent components of 
the brain, which in turn moderately overlap with known functional connectivity networks. This 
suggest that functional connectivity may act as contributing factor in the stereotypical 
distribution of tau pathology. Moreover, the results of this thesis demonstrate that the 
consequence of regional tau pathology on cognition differs depending on the level of education. 
Despite equal clinical presentation, higher educated patients can tolerate more tau pathology, 
already in regions related to advanced disease stage, than lower educated patients. Furthermore, 
tau pathology is less paralleled by neuronal dysfunction at higher levels of education. Thus, 
higher educated individuals show a relative preservation of neuronal function despite the 
aggregation of misfolded tau proteins. This maintenance of neuronal function may in turn 
explain the relative preservation of cognitive function albeit progressive tau pathology 
aggregation. 
Taken together, the results of this thesis provide novel insights into the spreading mechanisms 
and the role of resilience factors towards tau pathology aggregation, which may not only be 
relevant for Alzheimer’s disease, but other neurodegenerative diseases, in particular, 
ii 
 
tauopathies. Better understanding of the spreading mechanisms in these diseases will permit a 
more precise prediction of disease progression and will thus be valuable for disease monitoring. 
Concomitantly, the development of sensitive biomarkers for disease monitoring is crucial for 
the evaluation of anti-tau-based therapies. Regarding the development of pharmacological 
strategies, the current results also indicate that proxy measures of resilience, such as education, 
need to be considered when allocating patients to treatment groups. Biased allocation may 
otherwise lead to a misinterpretation of observed effects that are not due to the drug but the 
group characteristics. Aside from this, sensitive tools for the early identification of at-risk 
individuals with high resilience need to be established to allow for a timely intervention. 
Current hypothesis is that an early intervention has the highest chance of success in modifying 
the disease course. However, as demonstrated by this work, individuals with high resilience 
remain undiagnosed until late in the disease course. Further research into resilience mechanisms 
may thus support the development of sensitive diagnostic tools and additionally offer potential 
targets that can be harnessed for novel treatment strategies. Hopefully, one day supporting the 
development of effective disease-modifying treatments. 
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ZUSAMMENFASSUNG  
Die Alzheimer-Erkrankung ist neuropathologisch gekennzeichnet durch die extrazelluläre 
Ansammlung von Amyloid ȕ Plaques und die intrazelluläre Aggregation von fehlgefalteten 
Tau-Proteinen, die schließlich zu Neurodegeneration und charakteristischen kognitiven 
Beeinträchtigungen führen. Mit den neuesten Fortschritten in der Hirnbildgebung können diese 
Proteinopathien in vivo mittels der Positronen-Emissions-Tomographie (PET) untersucht 
werden. Die Kombination dieser Bildgebungstechnik mit der funktionellen 
Magnetresonanztomographie hat dabei konsistent eine räumliche Überlappung zwischen 
Amyloid ȕ Akkumulationen und funktionellen Konnektivitätsnetzwerken bei Patienten/Innen 
mit einer Alzheimer-Erkrankung ergeben (Buckner et al., 2009; Grothe et al., 2016). Diese 
räumliche Überlappung weist darauf hin, dass die funktionelle Konnektivität zur Verteilung 
von Neuropathologien beiträgt. Während die Infiltration dieser neuronalen Netzwerke durch 
Amyloid ȕ Plaques bei Individuen mit einer Alzheimer-Krankheit konsistent erscheint, gibt es 
dennoch interindividuelle Unterschiede zwischen der pathologischen Belastung und dem 
klinischen Ausdruck der Erkrankung (Stern, 2012). Diese Beobachtung deutet auf 
Resilienzmechanismen hin, die durch Lebensstilfaktoren unterstützt werden, und deren 
Ausmaß individuell variiert und dadurch zur klinischen Heterogenität der Alzheimer-
Erkrankung beiträgt.  
Auch wenn die Ausbreitungs- und Resilienzmechanismen der Amyloid ȕ Pathologie 
inzwischen besser erforscht sind, lagen diesbezüglich bis vor Kurzem keine Informationen über 
die in vivo Tau-Pathologie vor. Angesichts der jüngsten Verfügbarkeit von Tau-PET-
Substanzen in klinischen und Forschungseinrichtungen war daher das Ziel dieser Dissertation 
folgende Fragestellungen zu untersuchen: 1. ‚Trägt die funktionelle Konnektivität zur 
Verteilung der Tau-Pathologie entlang bestimmter Gehirnnetzwerke bei?‘; β. ‚Wird die 
Konsequenz der Tau-Pathologie in Bezug auf die kognitive und neuronale Funktion durch ein 
Resilienzmaß, nämlich Bildungsniveau, gemildert?‘. Die Analyse von [18F]-AV-1451 PET-
Bildgebungsdaten zur Quantifizierung der Tau-Pathologie bei einer Gruppe von Alzheimer-
Patienten/Innen ergab, dass die Tau-Pathologie synchron in unabhängigen Komponenten des 
Gehirns auftritt, die wiederum moderat räumlich mit bekannten funktionellen 
Konnektivitätsnetzwerken überlappen. Dies deutet darauf hin, dass die funktionelle 
Konnektivität als beitragender Faktor für die stereotype Verteilung der Tau-Pathologie fungiert. 
Darüber hinaus zeigen die Ergebnisse dieser Arbeit, dass die Konsequenzen der regionalen Tau-
Pathologie für die Kognition abhängig vom Bildungsniveau sind. Trotz gleicher klinischer 
Schwere können hoch gebildete Patienten/Innen eine schwerwiegendere Tau-Pathologie 
tolerieren als niedrig gebildete Patienten/Innen. Zusätzlich scheint der neurotoxische Effekt der 
Tau-Pathologie bei einem höheren Bildungsniveau weniger stark ausgeprägt zu sein. So zeigen 
hochgebildete Patienten/Innen eine relative Erhaltung der neuronalen Funktion trotz der 
Aggregation der Tau-Pathologie. Diese Präservation der neuronalen Funktion ermöglicht 
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vermutlich wiederum die relative Erhaltung der kognitiven Funktion trotz erhöhter Tau-
Pathologie-Last. 
Insgesamt dienen die Ergebnisse dieser Arbeit einem besseren Verständnis des 
Ausbreitungsmechanismus der Tau Pathologie und dem Beitrag von Resilienzfaktoren zur 
Aggregation der Tau-Pathologie, die nicht nur für die Alzheimer-Erkrankung, sondern auch für 
andere neurodegenerative Erkrankungen, insbesondere Tauopathien, relevant sein können. Ein 
erweitertes Verständnis der Ausbreitungsmechanismen dieser Krankheiten wird eine genauere 
Vorhersage des Krankheitsverlaufs ermöglichen und somit für das Krankheitsmonitoring 
wertvoll sein. Gleichzeitig ist die Entwicklung sensitiver Biomarker für das 
Krankheitsmonitoring entscheidend für die Auswertung von anti-Tau-basierten Therapien. Im 
Hinblick auf die Entwicklung von pharmakologischen Strategien deuten die aktuellen 
Ergebnisse darauf hin, dass bei der Zuordnung von Patienten/Innen zu Behandlungsgruppen 
Annäherungsmaße der Resilienz, wie z.B. Bildung, berücksichtigt werden müssen. Eine 
einseitig vorgenommene Zuordnung kann ansonsten zu einer Fehlinterpretation der 
beobachteten Effekte führen, die nicht auf das Medikament, sondern auf die 
Gruppeneigenschaften zurückzuführen sind. Darüber hinaus müssen sensitive Instrumente für 
die frühzeitige Identifizierung von Risikopersonen mit hoher Resilienz entwickelt werden, um 
eine rechtzeitige Intervention zu ermöglichen. Die aktuelle Hypothese ist, dass eine frühzeitige 
Intervention die höchste Erfolgschance in der Modifikation des Krankheitsverlaufes besitzt. 
Wie diese Arbeit jedoch zeigt, werden Personen mit einer hohen Resilienz erst zu einem späten 
Zeitpunkt im Krankheitsverlauf diagnostiziert. Insgesamt kann die Erforschung von 
Resilienzmechanismen zur Entwicklung von sensitiven Diagnoseinstrumenten beitragen. 
Zusätzlich bieten identifizierte Resilienzmechanismen potenzielle Ansätze, die für neue 
Behandlungsstrategien genutzt werden können. Die Ergebnisse werden hoffentlich eines Tages 
auch die Entwicklung effektiver krankheits-modifzierender Behandlungsstrategien 
unterstützen. 
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INTRODUCTION 
“Where are you right now?” 
 
„Here and everywhere. Here and now. You must not think badly of me." 
 
        Alois Alzheimer & Auguste D. 
 
It has been more than a century since Alois Alzheimer first reported on the case of Auguste D., 
who showed a progressive loss of memory and speech as well as agitation. The brain autopsy 
of Auguste D. revealed an accumulation of senile plaques, neurofibrils, and general atrophy, 
which Alois Alzheimer concluded to cause the clinical symptoms. Several years later, Emil 
Kraepelin introduced the term “Alzheimer’s disease”, which was initially considered a rare 
disease, but has become the most common neurodegenerative disease world-wide, currently 
affecting around 50 million people above the age of 65 (Gaugler et al., 2019). With the 
demographic change in Western societies, it is anticipated that the prevalence will triple by 
2050, increasing the societal and economic burden tremendously. Despite all efforts, there is 
still no disease-modifying treatment available. Consensus is that only an early diagnosis and 
intervention has the highest chance of success in modifying this devastating disease. 
The incremental growth in scientific knowledge about Alzheimer’s disease over the past 
decades has revealed that the neuropathological hallmarks of Alzheimer’s disease, namely 
amyloid ȕ plaques and neurofibrillary tangles (composed of misfolded tau proteins), begin to 
accumulate more than 20 years before initial clinical symptoms occur. Importantly, these 
neuropathological characteristics can nowadays be visualized and studied in vivo using positron 
emission tomography (PET). Especially the recent introduction of tau PET compounds has 
opened new possibilities in research and clinical settings. By means of tau PET imaging, 
information on the molecular mechanisms and distribution patterns of tau pathology in 
Alzheimer’s disease and its interaction with other pathophysiological processes can now be 
gathered in vivo. This is further important for the identification of underlying resilience 
mechanisms against the spatial evolution of tau pathology and its neurotoxic effects given the 
heterogeneity in clinical expressions seen in Alzheimer’s disease. Some individuals can tolerate 
more neuropathology albeit similar clinical severity than others and some never even develop 
clinical symptoms despite showing the neuropathological hallmarks of Alzheimer’s disease 
(Stern, 2012). Understanding the mechanisms driving this resilience against brain pathology is 
crucial for the development of sensitive diagnostic and prognostic biomarkers as well as novel 
treatment strategies. 
This dissertation is intended to examine the role of functional connectivity as potential 
spreading mechanism of tau pathology employing tau PET imaging ([18F]-AV-1451) in 
combination with resting-state functional magnetic resonance imaging (MRI). Moreover, this 
thesis work elucidates the contribution of a resilience surrogate, namely education, concerning 
the impact of tau pathology aggregation on cognition and neuronal function. This investigation 
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is important on the one hand regarding the understanding of the mechanistic pathways of the 
pathophysiological processes in Alzheimer’s disease, and on the other hand concerning the 
interpretation of potential resilience mechanisms modifying the clinical expression of 
Alzheimer’s disease.  
In the introduction of this dissertation, a brief overview on the current knowledge about the 
neuropathological hallmarks of Alzheimer’s disease, their temporo-spatial evolution and a 
description of potential mechanisms supporting resilience against these pathologies is provided, 
with an emphasis on PET imaging studies. The introduction is followed by three publications, 
which focus on the role of functional connectivity and education regarding the spread and 
neuronal consequences of tau pathology. Finally, the papers will be discussed in a larger 
context. 
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CLINICAL PRESENTATIO N AND DIAGNOSIS 
OF ALZHEIMER’S DISEA SE 
Sporadic late-onset Alzheimer’s disease usually occurs in individuals older than 65 years and 
accounts for more than 95% of all cases with Alzheimer’s disease (Gaugler et al., 2019). The 
remaining cases relate to familial and early-onset forms of Alzheimer’s disease with an age of 
onset ranging from 30 to 65 years. Within the realm of this dissertation, the term Alzheimer’s 
disease will refer to sporadic late-onset Alzheimer’s disease.  
The cardinal symptom of Alzheimer’s disease is a progressive loss of memory, with subsequent 
appearance of executive, visual-spatial, language and neuropsychiatric impairments. At 
advanced stages of the disease, motor symptoms such as difficulties with swallowing and 
walking may also occur. Despite the typical presentation of Alzheimer’s disease, also atypical 
forms exist. These atypical forms present the same neuropathological characteristics, namely 
amyloid ȕ plaques and misfolded tau proteins, but are characterized by different clinical 
phenotypes. These variants have been associated with an earlier disease onset (Snowden et al., 
2007; Koedam et al., 2010) and encompass posterior cortical atrophy (PCA), the logopenic 
variant and the dysexecutive/ behavioural variant of Alzheimer’s disease. PCA is characterized 
by predominant visual-spatial deficits, the logopenic variant by language difficulties and the 
behavioural variant by deficits in executive function. Independent of the typical or atypical 
phenotype of Alzheimer’s disease, the clinical symptoms eventually interfere with activities of 
daily living, rendering the individual with Alzheimer’s disease dependent on others. The 
average life-expectancy after the diagnosis of Alzheimer’s disease is about 8-10 years, but 
significantly depends on how impaired the individual already is at the point of diagnosis (Larson 
et al., 2004; Helzner et al., 2008). 
At present, the clinical diagnosis of Alzheimer’s disease is based on the recommended 
diagnostic National Institute on Aging and Alzheimer's Association (NIA-AA) guidelines from 
2011 (Albert et al., 2011; Jack Jr et al., 2011; McKhann et al., 2011; Sperling et al., 2011) and 
the international working group criteria on Alzheimer’s disease (Cummings et al., 2013; Dubois 
et al., 2014). According to the NIA-AA guidelines, Alzheimer’s disease is a continuum, which 
can be categorized into three stages: preclinical, mild cognitive impairment (MCI), and 
Alzheimer’s dementia. In the preclinical stage, molecular changes are detected including 
amyloid ȕ build-up, but no significant cognitive deficits are yet observable (Sperling et al., 
2011). In the MCI stage, initial memory impairments occur that are greater than of an age-
matched person, but which do not yet interfere with daily living (Albert et al., 2011). In addition 
to the accumulation of amyloid ȕ, a marker of neuronal injury including tau becomes abnormal, 
which can be assessed using PET or cerebrospinal fluid (CSF) markers (Albert et al., 2011). In 
the final stage, Alzheimer’s dementia, cognitive deficits interfere with the person’s ability to 
function independently and both biomarkers are abnormal (McKhann et al., 2011). Importantly, 
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the guidelines for the symptomatic stages were intended to support the clinical diagnosis, 
whereas the preclinical definition was meant to offer researchers a common definition for the 
identification of participants, who show abnormal Alzheimer’s disease biomarkers in absence 
of clinical symptoms. Moreover, the integration of Alzheimer’s disease biomarkers in form of 
PET imaging or CSF analysis is considered as aid for the clinical setting, but the recommended 
guidelines are primarily based on clinical criteria. 
The current diagnostic guidelines have therefore shifted from a syndromal to a biological 
construct, which have recently been outlined in a new research framework (Jack Jr et al., 
2018a). In this framework, the presence or absence of abnormal Alzheimer’s disease biomarker 
profiles are the building blocks used to describe the Alzheimer’s disease spectrum, while 
considering cognitive impairment as the result of the disease rather than its definition. The 
workgroup suggested the so-called A-T-N classification scheme, which is based on brain 
imaging (i.e., PET or MRI) and CSF biomarkers. “A” refers to amyloid pathology, “T” to tau 
pathology, and “N” to neurodegeneration. In addition to the presence or absence of these three 
markers, a fourth factor namely the cognitive continuum can be included. Importantly, in 
contrast to the NIA-AA guidelines, a clear distinction is set between tau pathology and 
neurodegeneration/neuronal injury. The A-T-N classification states that abnormal amyloid and 
tau levels are a necessary condition for Alzheimer’s disease, whereas neurodegeneration is not 
specific to Alzheimer’s disease. As it is currently only a research framework, it still needs to be 
validated in clinical settings. However, so far, it appears to be a well-suited tool for the 
biological diagnosis of Alzheimer’s disease by taking advantage of the currently available 
biomarkers for the quantification of the neuropathological hallmarks of Alzheimer’s disease. 
NEUROPATHOLOGICAL HA LLMARKS  
OF ALZHEIMER’S DISEA SE 
Alzheimer’s disease is a dual proteinopathy characterized by the extracellular deposition of 
amyloid ȕ in senile plaques and the intracellular aggregation of neurofibrillary tangles (NFTs). 
According to the prominent amyloid cascade hypothesis (Hardy and Higgins, 1992), amyloid ȕ 
deposition is the initial event, which triggers the formation of senile plaques and NFTs. This in 
turn leads to neuronal death and ultimately to dementia. Much support has been provided for 
this hypothesis. Nonetheless, there remain objections against it – one being that no phase 3 
clinical trial targeting amyloid ȕ plaques has yet been successful in modifying the disease course 
(Gilman et al., 2005; Doody et al., 2014; Salloway et al., 2014; Siemers et al., 2016; Honig et 
al., 2018) and another one being that these two proteinopathies may actually act independently 
with tau pathology preceding amyloid ȕ deposition, as recently suggested by autopsy data (Jack 
Jr et al., 2013). Despite the uncertainties regarding the temporal trajectory of the pathogenesis 
of Alzheimer’s disease, there is no doubt that the two neuropathological hallmarks take on a 
key role in the pathogenic cascade of Alzheimer’s disease, as elucidated in the following. 
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Amyloid ȕ 
The extracellular accumulation of amyloid ȕ peptides was first discovered as main constituents 
of senile plaques in Alzheimer’s disease and Down’s Syndrome (Glenner and Wong, 1984; 
Masters et al., 1985a; Masters et al., 1985b). A while later, genetic studies on familial 
Alzheimer’s disease found that mutations in genes encoding the amyloid precursor protein 
(APP) (Goate et al., 1991), preselin-1 and preselin-2 (Levy-Lahad et al., 1995; Sherrington et 
al., 1995) were associated with elevated levels of amyloid ȕ. It is now known that preselin-1 
and -2 are involved in the APP processing pathway. Although the functional role of APP itself 
remains unresolved, much knowledge has been gathered about the formation of amyloid ȕ 
deposits: 
The amyloid ȕ peptide is derived from APP, a transmembrane protein which can undergo two 
proteolytic pathways, the α-pathway or ȕ-pathway. The former represents the non-
amyloidogenic and the latter the amyloidogenic pathway (see Figure 1). In the non-
amyloidogenic process, APP is sequentially cleaved close to the membrane by α-secretase, 
liberating sAPPα and generating an alpha-C-terminal fragment (CTFα). Cleavage of CTFα by 
Ȗ-secretase generates a small p3 fragment and a cytosolic element, the APP intracellular domain 
(AICD), which remains bound to the membrane and carries a role in signal transduction (Chen 
et al., 2017). The catalytic subunit of Ȗ-secretase is encoded by either presilin-1 or presilin-2. 
In the amyloidogenic pathway, APP is cleaved by ȕ-secretase, which results in a large 
derivative, sAPPȕ, and a beta-C-terminal fragment (CTFȕ) that remains bound to the membrane 
(Selkoe, 1994; Olsson et al., 2014). CTFȕ is then cleaved by Ȗ-secretase, which results in the 
soluble amyloid ȕ peptide and the membrane-bound AICD. 
 
 
Figure 1– Proteolytic pathways of the transmembrane amyloid precursor protein (APP). In the non-amyloidogenic 
pathway, APP is cleaved by α-secretase generating sAPPα and CTFα followed by cleavage of Ȗ-secretase, 
liberating pγ and producing AICD. In the amyloidogenic pathway, ȕ -secretase cleavage results in sAPPȕ and a 
larger CTFȕ fragment followed by Ȗ-secretase producing amyloid ȕ and AICD. CTF = C-terminal fragment; 
AICD= APP intracellular domain. Adapted from Cheignon et al., 2018. 
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As the cleavage process in the amyloidogenic pathway is somewhat imprecise, numerous 
species of amyloid ȕ exist (Takami et al., 2009). The most common species are amyloid ȕ40 
and amyloid ȕ42, which are more hydrophobic and fibrillogenic than shorter forms of amyloid 
ȕ (Takami et al., 2009). It is assumed that the deposition of amyloid ȕ is likely a consequence 
of impaired clearance and degradation mechanisms, which promote the assembly of amyloid ȕ 
monomers to oligomers, protofibrils and eventually to amyloid plaques in the brain parenchyma 
(Mawuenyega et al., 2010). Importantly, it was recently reported that the soluble forms of 
amyloid ȕ are more toxic to neuronal cells than senile plaques (Bao et al., 2012; Esparza et al., 
2013). Given their solubility, these forms can spread throughout the brain (Chen et al., 2017), 
disrupt synaptic function and trigger downstream toxic pathways (Mucke and Selkoe, 2012). 
Moreover, in accordance with the amyloid cascade hypothesis, transgenic experiments 
demonstrated that soluble amyloid ȕ forms increase tau phosphorylation (Seino et al., 2010) 
and induce tau aggregation and seeding (De Felice et al., 2008; Seino et al., 2010; Vergara et 
al., 2019), which represents the second neuropathological hallmark of Alzheimer’s disease. 
Neurofibrillary tangles 
Neurofibrillary tangles (NFTs) are intracellular aggregates, which are composed of the 
hyperphosphorylated tau protein. The tau protein in its native form is abundant in the axons of 
neurons and carries an important role in the stabilization of the microtubules and axonal 
transport (Morris et al., 2011). It is encoded by the microtubule-associated tau protein (MAPT) 
gene (Weingarten et al., 1975; Grundke-Iqbal et al., 1986) and contains four areas: an N-
terminal region, a proline-rich domain, a microtubule-binding domain, and a C-terminal 
projection region (Mandelkow et al., 1996). In the adult human brain six isoforms of tau are 
present, which are produced by alternative splicing of exon 2, 3, and 10 (see Figure 2). These 
isoforms can further be separated based on the length of their repeat binding domain, namely 
three or four carboxy repeat domains (3R and 4R). In the adult human brain, the 3R and 4R 
forms of tau are equally expressed, but this ratio changes in neurodegenerative diseases (Gao 
et al., 2018). Tau aggregation is not only a characteristic hallmark of Alzheimer’s disease, but 
also other neurodegenerative diseases known as tauopathies (e.g., progressive supranuclear 
palsy (PSP) or corticobasal degeneration (CBD)). These tauopathies can be classified based on 
the overexpression of the tau isoforms, namely: 3R-tauopathies (e.g., Pick’s disease), 4R-
tauopathies (e.g., PSP or CBD), and 3R/4R tauopathies, to which Alzheimer’s disease belongs. 
Albeit the differences in tau isoform expression, the pathological tau lesions are highly 
phosphorylated across tauopathies, whereby in Alzheimer’s disease both forms of tau (γR and 
4R) undergo hyperphosphorylation (Buée et al., 2000). The exact mechanism leading to this 
hyperphosphorylation remains elusive. But given that various kinases and phosphatases 
regulate tau phosphorylation in the normal state, it has been suggested that an imbalance 
between these enzymes causes hyperphosphorylation of tau (Noble et al., 2013). 
Importantly, the hyperphosphorylation of tau appears to precede the aggregation of misfolded 
tau proteins into paired helical filaments and then into insoluble NFTs (Alonso et al., 2001; 
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Chohan et al., 2005). The aggregation process, in turn, is facilitated through mechanisms such 
as impaired degradation, truncation, or missorting of tau (Guillozet‐Bongaarts et al., 2006; 
Dickey et al., 2007). Regarding the truncation of tau, it was shown that it suppresses the 
formation of the so called paperclip structure, which usually hinders tau to aggregate 
(Jeganathan et al., 2006). Notably, tau in its native form is unfolded and does not tend to 
aggregate (Mukrasch et al., 2009). However, through the truncation process, tau loses the 
paperclip formation, which in turn promotes the aggregation of tau proteins. Moreover, recent 
studies showed that the hyperphosphorylation of tau can lead to missorting of tau from the axon 
to the somato-dendritic compartment (Thies and Mandelkow, 2007; Hoover et al., 2010; 
Zempel et al., 2010; Zempel et al., 2017), which can cause synaptic dysfunction (Thies and 
Mandelkow, 2007; Hoover et al., 2010). 
Overall, a multitude of processes involved in the hyperphosphorylation and aggregation of 
misfolded tau proteins have been identified so far (for a detailed review see Morris et al., 2011; 
Wang and Mandelkow, 2016). Nevertheless, the exact trigger of tau pathology in Alzheimer’s 
disease remains unknown as the MAPT gene is not genetically linked to Alzheimer’s disease. 
This lack of genetic association to Alzheimer’s disease suggests that tau pathology is a 
downstream process of the amyloid ȕ- induced neurodegenerative cascade – a cascade, which 
is further characterized by pathophysiological alterations including the loss of synapses, initial 
hippocampal and later general atrophy, neuroinflammation in form of reactive astrocytes and 
activated microglia, and depletion of distinct neurotransmitter systems (Luca et al., 2018). 
Importantly, with the developments in PET imaging, several processes of this 
pathophysiological cascade can nowadays be visualized and studied in vivo. The principle of 
PET imaging and the main PET compounds used in Alzheimer’s disease research and diagnosis 
will therefore be discussed in the next section. 
 
 
Figure 2 - The human microtubule-associated tau protein (MAPT) gene and its isoforms. Representation of the 
six isoforms of the tau protein produced by alternative splicing of exon 2 ,γ, and 10 is illustrated. In Alzheimer’s 
disease, 3R and 4R isoforms are equally hyperphosphorylated. N= N-terminal; R = microtubule-binding repeat 
domain. Adapted from Wang and Mandelkow, 2016. 
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POSITRON EMISSION TOMOGRAPHY  
IN ALZHEIMER’S DISEASE  
Positron emission tomography (PET) is an imaging technique permitting the visualization of 
molecular changes and protein aggregations in vivo by injection of radioactively labelled tracers 
into the blood, which bind to the biomolecules of interest. Briefly, PET imaging is based on the 
following technique: The radioactively labelled tracers contain short-lived positron-emitting 
radionuclides such as fluorine-18 or carbon-11. The beta decay of these radionuclides (e.g., 18F) 
attached to the target biomolecule (e.g., glucose) results in the emission of a positron that 
annihilates with an electron after travelling less than 1mm in the tissue. The annihilation process 
results in two gamma-photons being emitted in opposite directions. These gamma-rays are then 
detected by scintillation detectors, which register the annihilation photons in coincidence and 
store the events. Finally, using computer analysis, the PET activity distributions are 
reconstructed as three-dimensional images based on the coincidence events. The final images 
are then used for diagnostic or research purposes. 
Up to now, several PET tracers have been developed, which can cross the blood brain barrier 
and visualize Alzheimer’s disease-related pathophysiological changes. The most commonly 
used tracers, which will be discussed in the following, can visualize amyloid pathology, tau 
pathology and changes in glucose metabolism (see Figure 3).  
Amyloid PET 
The most widely studied amyloid tracer is [11C]-Pittsburgh Compound B ([11C]-PiB), which 
was developed by Chet Mathis and William Klunk in 2002 (Mathis et al., 2002). This tracer 
shows high affinity and selectivity to fibrillar amyloid in senile plaques (Mathis et al., 2002; 
Cohen et al., 2012). However, given the short half-life of [11C]-PiB of only 20 minutes, its use 
is limited to centres that have a cyclotron and a department of radiochemistry on-site. Due to 
this limitation, F18-labelled tracers with similar affinity profiles, but a half-life of around 120 
minutes, were developed, among them: [18F]Florbetapir (Wong et al., 2010), [18F]Florbetaben 
(Rowe et al., 2008), and [18F]Flutemetamol (Rinne et al., 2012). Ever since these amyloid 
tracers have been available, a large body of evidence has been gathered supporting the utility 
of these tracers as diagnostic tool for dementia due to Alzheimer’s disease. In addition, these 
tracers have been useful for patient selection and the evaluation of drug efficacy in clinical trials 
(Fleisher et al., 2011). However, the drawback of the currently available amyloid tracers is that 
they only bind to insoluble plaques and not to the more toxic and soluble forms of amyloid ȕ 
(Haass and Selkoe, 2007). Moreover, albeit its major role in defining Alzheimer’s disease, 
amyloid PET imaging appears not to be suitable for the short-term prediction of individuals 
converting from prodromal stages or MCI to Alzheimer’s dementia (Iaccarino et al., 2017). 
Furthermore, amyloid PET shows relatively low correlation with clinical and cognitive 
parameters (Brier et al., 2016), indicating that this PET modality is less well-suited for staging 
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of the disease. Thus, for better information regarding the progression and staging of the disease, 
[18F]-Fluorodeoxyglucose ([18F]-FDG) PET and more recently tau PET compounds have been 
considered. 
Tau PET  
The complexity of the tau protein given its heterogenous isoforms and its intracellular location 
have been major challenges in the development of selective tau PET tracers. Overcoming these 
challenges, several radioactive substances have recently been developed. The most widely 
studied are: [18F]-THK5117 (Harada et al., 2015), [18F]-THK5351 (Harada et al., 2016), [18F]-
AV-1451 (Chien et al., 2014), and [11C]-PBB3 (Maruyama et al., 2013). Before that time, solely 
CSF measures could provide information on abnormalities in tau phosphorylation in the central 
nervous system, but no information on the regional distribution of tau pathology could be 
obtained. The introduction of tau PET tracers has therefore led to new possibilities for 
diagnostic and research-oriented considerations (van Eimeren et al., 2017). A progressively 
accumulating body of evidence suggests that tau PET is a suitable progression and staging 
marker, because it is more closely associated with neurodegeneration and cognitive decline than 
amyloid PET (Bischof et al., 2016; Brier et al., 2016; Ossenkoppele et al., 2016; Schöll et al., 
2016; Schwarz et al., 2016). Additionally, recent longitudinal tau PET studies have provided 
first insights into the pathogenic cascade of Alzheimer’s disease (Chiotis et al., 2018a; Jack Jr 
et al., 2018b; Southekal et al., 2018). Importantly, in contrast to amyloid PET, tau PET allows 
differentiation between typical and atypical phenotypes of Alzheimer’s disease, and primary 
tauopathies from secondary tauopathies1 (Kikuchi et al., 2016; Ossenkoppele et al., 2016; 
Dronse et al., 2017; Hammes et al., 2017; Passamonti et al., 2017; Whitwell et al., 2017; 
Whitwell et al., 2018b). It is thus a meaningful biomarker for differential diagnosis. However, 
despite the advances of tau PET imaging, an unresolved issue of the first-generation tau PET 
tracers remains the off-target binding to subcortical structures (Marquié et al., 2015; Lowe et 
al., 2016; Ng et al., 2017) and the lower affinity to different tau isoforms (Smith et al., 2017). 
Therefore, second-generation tracers have been developed with improved binding properties 
and lower off-target signal, among them [18F]-PI-2620 (Mueller et al., 2017) and [18F]-MK-
6240 (Walji et al., 2016). These tracers are currently under investigation for their clinical and 
research utility (Hostetler et al., 2016; Villemagne et al., 2018). Aside from this, tau PET 
imaging provides unique information on underlying disease mechanisms, which are not only 
relevant for Alzheimer’s disease but also for other tauopathies. 
FDG PET 
The PET compound with the longest history in the investigation and diagnosis of 
neurodegenerative diseases is FDG PET, which is sensitive to changes in glucose metabolism. 
                                                             
1
 Primary tauopathies are considered diseases with misfolded tau proteins being the predominant pathological 
signature such as PSP or CBD. Secondary tauopathies account for diseases such as Alzheimer’s disease, which 
are characterized by tau aggregation in combination with other toxic accumulates such as amyloid ȕ plaques.  
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It has been postulated that FDG PET measures synaptic function rather than overall neuronal 
function (Harris et al., 2012). Thus, a decrease in FDG PET signal (i.e., hypometabolism) 
reflects an index of synaptic failure (Iaccarino et al., 2017). Over the past two decades, FDG 
PET has been demonstrated to provide high diagnostic accuracy. Like tau PET, FDG-PET can 
aid in the differential diagnosis given that it offers information on the underlying pattern of 
neuronal dysfunction (Foster et al., 2007). Accordingly, distinct regional patterns of 
hypometabolism have been observed for the clinical phenotypes of Alzheimer’s disease 
(Ossenkoppele et al., 2016; Dronse et al., 2017). Moreover, a close spatial relationship between 
the tau PET signal and the FDG PET signal has been reported by several studies, whereas this 
is not the case for amyloid PET (Bischof et al., 2016; Brier et al., 2016; Ossenkoppele et al., 
2016). However, in contrast to amyloid and tau PET, FDG imaging does not provide any 
information on the underlying neuropathology. Therefore, an additional marker such as liquor 
measurements or PET imaging is necessary to confirm the diagnosis of Alzheimer’s disease or 
another neurodegenerative disease. Despite this, FDG PET may nevertheless be preferred to 
novel and more expensive PET compounds in the clinical setting given that it comes at 
relatively low costs in comparison to other PET tracers (van Eimeren et al., 2017).  
Collectively, the use of these three PET modalities provide unique information on the evolution 
of the molecular characteristics in Alzheimer’s disease. The additional use of other PET 
compounds in research settings, for example for the visualization of neuroinflammation (e.g., 
[11C]-PBR28) and changes in synaptic density (e.g., [11C]-UCB-J), permits the investigation of 
the temporo-spatial relationship between these markers in the pathogenic cascade of 
Alzheimer’s disease. In addition, combining these PET modalities with neuroimaging 
techniques such as diffusion tensor imaging (DTI) or functional MRI (fMRI) allows the 
investigation of spreading mechanisms across structural and functional pathways, which will 
support better understanding of this complex neurodegenerative disease (Bischof et al., 2019). 
 
 
 
Figure 3– Illustration of PET tracers and their binding sites. AV-1451 is used to visualize paired helical filaments 
and neurofibrillary tangles in the neuron. C-PiB binds to amyloid ȕ plaques in the extracellular space and FDG 
is a marker of metabolic consumption mainly at the synapse. The pathological processes of Alzheimer’s disease 
are accompanied by the accumulation of reactive astrocytes and activated microglia, which can also be 
visualized using different PET compounds. C-PiB = Pittsburgh compound B; FDG = fluorodeoxyglucose. 
Created with BioRender.com. 
The picture was blackened due to copyright rights. 
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TEMPORAL EVOLUTION  
OF ALZHEIMER’S DISEA SE BIOMARKERS 
An ever-increasing body of evidence suggests that the two neuropathological hallmarks of 
Alzheimer’s disease appear to evolve in temporal order with a long preclinical phase (Braak et 
al., 2011). In 2010, Jack and colleagues introduced a hypothetical model of Alzheimer’s disease 
biomarker evolution for the in vivo staging of Alzheimer’s disease. This model was based on 
evidence from cross-sectional, longitudinal and autopsy studies (Jack Jr et al., 2010). Three 
years later the model was revised to incorporate the observed variability in clinical expressions 
despite similar pathological burden and to specify the temporal ordering of certain biomarkers 
(Jack Jr et al., 2013). According to this well-established model (see Figure 4), abnormalities in 
amyloid ȕ42 in the CSF followed by abnormalities in amyloid PET imaging are detected up to 
two decades before clinical symptom onset. Following amyloid ȕ accumulation, abnormalities 
in tau CSF become apparent closely followed by biomarker abnormalities of neuronal function, 
such as measured with FDG PET, or of atrophy, as quantified by structural MRI. The 
trajectories of tau pathology, neuronal dysfunction and atrophy patterns are thereby more 
closely associated in time with the onset of clinical symptoms. By the time cognitive symptoms 
occur, amyloid pathology begins to plateau, whereas tau pathology and neurodegeneration 
continue to disperse. The onset of clinical symptoms can differ between individuals as 
represented by two trajectories relating to cognitive decline over time for individuals at low and 
high risk of developing mild cognitive impairment and Alzheimer’s dementia. Importantly, all 
trajectories are considered to be sigmoidal implying an initial phase of acceleration followed 
by a deceleration and plateau.  
 
 
Figure 4 – Update on hypothetical model of Alzheimer’s disease biomarkers (Jack Jr et al., 2013). Temporal 
evolution of currently available Alzheimer’s disease biomarkers, which are colour- coded as depicted in the upper 
left corner. CSF = cerebrospinal fluid; Aȕ = amyloid ȕ; FDG = fluorodeoxyglucose; MRI = magnetic resonance 
imaging; PET = positron emission tomography;MCI = mild cognitive impairment. 
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Notably, the model is based on currently available and detectable abnormalities in Alzheimer’s 
disease biomarkers based on CSF, PET or structural MRI, which may not be sensitive enough 
to detect the earliest changes in the neurodegenerative cascade of Alzheimer’s disease. This 
may explain the discrepancy to recent autopsy studies, which suggested that tau pathology 
already appears in young people below 30 years of age, whereas amyloid ȕ plaques start 
accumulating in the fourth age-decade (Braak et al., 2011). Based on this evidence, it was 
proposed that tau and amyloid ȕ may represent independent pathophysiological processes 
sharing an upstream causative factor, as also proposed by the dual pathway hypothesis (Small 
and Duff, 2008). Further investigations are required to proof or refute this assumption. Yet, the 
current body of evidence is unambiguous regarding the fact that Alzheimer’s disease has a long 
preclinical phase and that by the time initial clinical symptoms occur, amyloid pathology is 
already widely distributed across many brain regions, whereas tau pathology and 
neurodegeneration continue to spatially disperse in a stereotypical manner.  
SPATIAL DISTRIBUTION  
OF ALZHEIMER’S DISEA SE BIOMARKERS 
One of the most puzzling features of the amyloid cascade hypothesis remains the spatial 
disconnection between amyloid ȕ and tau pathology. Autopsy studies and recent PET imaging 
studies indicate that both proteinopathies follow distinct topographies, which initially occur in 
distal regions of each other. The stereotypical distribution patterns have been summarized for 
amyloid pathology by the Thal phases (Thal et al., 2002) and for tau pathology by the Braak 
stages (Braak and Braak, 1991; Braak et al., 2006), which are both based on autopsy data. 
According to the Thal phases, amyloid ȕ initially occurs in the neocortex, in particular in frontal 
areas (Phase 1), followed by accumulation in the hippocampus and entorhinal cortex (Phase 2), 
the basal ganglia (Phase 3), the brainstem (Phase 4), and finally the cerebellum (Phase 5). In 
contrast, tau pathology first gradually deposits in the transentorhinal cortex (Braak I) from 
where it spreads to the entorhinal region and hippocampal formation (Braak II), to temporal 
areas (Braak III), the precuneus (Braak IV), the parietal, occipital, and frontal regions (Braak 
V) and finally to the somatosensory cortex (Braak VI). Braak stages I-II represent the prodromal 
phase, Braak sages III-IV the early-moderate phase, and Braak V-VI the advanced and final 
stage of the disease. More recently, it was suggested that tau pathology may already start in the 
locus coeruleus and spread from there to subcortical and neocortical regions in a stereotypical 
manner (Braak et al., 2011).  
Both staging systems suggest a well-defined neuroanatomical propagation pattern of the two 
proteinopathies (see Figure 5). However, interestingly, studies comparing autopsy data and in 
vivo imaging revealed that the earliest Thal phases cannot be visualized using amyloid PET 
(Murray et al., 2015; Thal et al., 2015). In contrast, tau PET imaging studies consistently 
showed that tau pathology in vivo follows the neuropathologically defined Braak stages (Schöll 
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et al., 2016; Schwarz et al., 2016; Hoenig et al., 2017). Moreover, the spread of tau pathology 
is spatially more closely related with measures of neuronal dysfunction and neurodegeneration 
than the amyloid distribution patterns. This is the case for typical and atypical forms of 
Alzheimer’s disease such as PCA, the logopenic and the dysexecutive variant as illustrated in 
Figure 6 (Bischof et al., 2016; Ossenkoppele et al., 2016; Dronse et al., 2017; Whitwell et al., 
2018).  
Up to date, several factors and hypotheses have been considered concerning the stereotypical 
spread of these neuropathologies, such as susceptibility of distinct neuron groups (Shen et al., 
2016), gene expression patterns (Grothe et al., 2018; Sepulcre et al., 2018), and cell-to-cell 
transmission processes (Clavaguera et al., 2009; De Calignon et al., 2012). Furthermore, 
multimodal imaging studies consistently reported that the topographies of neurodegenerative 
disease pathologies overlap with large-scale neuronal networks (Drzezga, 2018). This suggests 
that functional and structural connectivity between regions promotes the distribution of these 
pathologies across neuronal networks, an observation that is summarized by the network 
degeneration hypothesis (Palop et al., 2006; Seeley et al., 2009), which will be elaborated on 
in the following. 
 
 Amyloid β distribution - Thal phases  
 
 
  
 Tau tangle distribution - Braak stages  
 
 
  
 
Figure 5 – The stereotypical distribution pattern of amyloid and tau pathology in Alzheimer’s disease. Brain 
regions of initial amyloid accumulation contain the frontal cortex (dark yellow) from where it spreads throughout 
the neocortex to subcortical regions and cerebellar regions. Tau pathology initially occurs in the entorhinal cortex 
(dark blue) from where it spreads to limbic and neocortical regions. The spatial distribution of amyloid plaques 
is defined by the Thal phases (top row) and the tau pathology distribution pattern is defined by the Braak stages 
(bottom row). The highlighted regions represent the newly affected region. FC= frontal cortex; EC=entorhinal 
cortex. 
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THE NETWORK DEGENERA TION HYPOTHESIS  
An accumulating body of evidence indicates that neurodegenerative diseases do not randomly 
spread across the brain, but coincide with specific functional brain networks (Tahmasian et al., 
2016). Based on these observations, the network degeneration hypothesis has been formulated, 
which postulates that neurodegenerative disease pathologies expand along functional networks 
eventually leading to failure of them (Palop et al., 2006; Seeley et al., 2009). Network failure 
ultimately results in clinical symptomatology, which corresponds to the functional network 
being affected. This hypothesis suggests that functional connectivity between cortical nodes of 
neuronal networks acts as driver in the spread of pathology. 
Over the past decade, several functional connectivity networks have been identified such as the 
executive control, language, visual-spatial, and the default mode network (DMN) (Yeo et al., 
2011), each carrying the name of the supporting cognitive domain. Compelling evidence has 
been gathered by studies combining fMRI and structural MRI or FDG PET, which reported a 
susceptibility of the aforementioned networks to neurodegeneration (Desgranges et al., 2002; 
Seeley et al., 2009; Drzezga et al., 2011). In particular, the DMN has consistently been found 
to be disrupted in Alzheimer’s disease (Greicius et al., 2004; Buckner et al., 2005; Buckner et 
al., 2009; Jones et al., 2015). The DMN is a highly active network during rest and is deactivated 
during externally oriented tasks. Interestingly, amyloid PET imaging studies demonstrated 
predominant amyloid accumulation in hubs of the DMN (Buckner et al., 2005), which 
eventually leads to disconnection of this network (Jones et al., 2015). Importantly, although 
some studies have pointed at a susceptibility of amyloid ȕ in hub regions of functional networks, 
network degeneration appears to rather depend on global levels of amyloid ȕ than local levels 
(Drzezga et al., 2011; Iaccarino et al., 2018). This may be due to the location of amyloid ȕ, 
which distributes diffusely in the extracellular space throughout the brain. Therefore, it was 
recently suggested that tau pathology due to its intracellular location, its trans-synaptic 
spreading potential, and its close relationship to neurodegeneration, better relates to network 
dysfunction and degeneration in Alzheimer’s disease. With the recent development of tau PET 
compounds in combination with fMRI, investigation of functional network infiltration by tau 
pathology is now feasible. Indeed, first in vivo studies have documented a close relationship 
between functional networks and tau pathology distribution patterns in typical Alzheimer’s 
disease (Hansson et al., 2017; Jones et al., 2017; Hoenig et al., 2018), as will be elaborated on 
in publication I and the discussion. Whether similar mechanisms also account for atypical forms 
of Alzheimer’s disease still needs to be investigated. However, these atypical forms represent 
characteristic topographic patterns of hypometabolism and tau pathology, which resemble 
known functional connectivity networks (see Figure 6). A PET imaging study combing amyloid 
and FDG PET revealed that these variants are indeed associated with degeneration of 
phenotype-specific networks (Lehmann et al., 2013). In contrast, amyloid deposition only 
accounted for a small proportion in the topographic heterogeneity of the phenotypes (Lehmann 
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et al., 2013). This points towards a role of tau pathology in specific network degeneration in 
atypical Alzheimer’s disease, as will be discussed later.  
Generally, it is not yet clear why brain pathologies affect distinct brain networks. It could be 
explained by a combination of cell-to-cell transmission processes, inherent genetical, 
developmental susceptibility or by the type of underlying pathological aggregation (Drzezga, 
2018). Notably, the consequences of the observed network degeneration differ between 
individuals. For example, it was recently shown that modulation in efficacy of affected 
networks supports maintenance of cognitive performance in the phase of Alzheimer’s disease- 
related brain pathology (Weiler et al., 2018). Some individuals are thus capable of coping with 
network dysfunction or degeneration, thereby contributing to the clinical heterogeneity seen in 
Alzheimer’s disease. 
 
 
 
Figure 6 – Pathophysiological topographies and their overlap with functional connectivity networks in the 
clinical phenotypes of Alzheimer’s disease. Illustrated are the distribution patterns of amyloid pathology 
(yellow), tau pathology (blue), neuronal dysfunction (red), and resembling functional connectivity networks 
(green) for typical and atypical phenotypes of Alzheimer’s disease. Tau pathology and neuronal dysfunction 
patterns appear closely associated with distinct functional networks, but with predominant susceptibility of the 
posterior DMN across phenotypes. AD = Alzheimer’s disease; bvAD = behavioural variant of Alzheimer’s 
disease; lpAD = logopenic variant of Alzheimer’s disease; PCA = posterior cortical atrophy; DMN = default 
mode network. This figure was adapted from the originally published figure (courtesy of Merle Hönig) in the 
Journal of Nuclear Medicine. Drzezga A. The Network Degeneration Hypothesis: Spread of Neurodegenerative 
Patterns Along Neuronal Brain Networks. J Nucl Med. 2018; 59(11): 1645-8. © SNMMI. 
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THE HETEROGENEITY IN CLINICAL EXPRESSION S OF 
ALZHEIMER’S DISEASE  -  THE ROLE OF RESILIEN CE 
Already in the late 80s, Katzman and colleagues reported a disparity between the extent of brain 
pathology and the individual clinical expression in patients with dementia (Katzman et al., 
1988). Over the past decades, it turned out that the rate of cognitive decline given a certain level 
of pathological burden is highly variable between individuals. This notion has been 
acknowledged, among other things, by the revision of the Jack model integrating two 
trajectories for low and high risk of cognitive decline (Jack Jr et al., 2013). These trajectories 
are based on coping mechanisms, which are associated with factors such as greater educational 
attainment, higher IQ and grey matter volume. As several terms have been used across studies 
to define the disparity between brain pathology and clinical symptoms, a framework was 
recently published to harmonize terminologies (Arenaza-Urquijo and Vemuri, 2018). 
According to this framework, resistance is defined as a mechanism to avoid brain pathology, 
thus preventing Alzheimer’s disease-related pathology aggregation. In contrast, resilience is 
referred to coping with Alzheimer’s disease-related pathology. This framework further 
incorporates the concepts of cognitive reserve, brain reserve and brain maintenance, while 
simultaneously distinguishing between the presence and relative absence of brain pathology 
(Arenaza-Urquijo and Vemuri, 2018). An overview of the framework on resistance and 
resilience is provided in Figure 7. Importantly, within the realm of this dissertation, the focus 
will be laid on resilience mechanisms as the studies conducted as part of this dissertation are 
based on data of individuals, which already present Alzheimer’s disease pathology.  
In the following, the potential coping mechanisms in form of cognitive reserve, brain reserve 
and maintenance will be elucidated in more detail: 
Cognitive reserve 
Cognitive reserve (CR) refers to the adaption of cognitive processes in the presence of brain 
pathology (Stern, 2002, 2009; Stern et al., 2018a). Most commonly used surrogate measures of 
CR are education, occupation, lifetime experience, verbal and general IQ (Yoo et al., 2015). It 
is believed that CR acts through the more efficient use and modulation of distinct brain 
networks or recruitment of additional brain areas in the phase of pathology aggregation. Recent 
imaging studies support this assumption (Morbelli et al., 2013; Yoo et al., 2015; Franzmeier et 
al., 2017a; Franzmeier et al., 2017b; Stern et al., 2018b; Weiler et al., 2018). In particular, these 
studies showed that network adaptations and compensation are associated with higher levels of 
educational attainment (Morbelli et al., 2013; Yoo et al., 2015; Franzmeier et al., 2017a; 
Franzmeier et al., 2017b; Stern et al., 2018b; Weiler et al., 2018). The adaptation of network 
efficacy and recruitment of additional brain areas may in turn provide a coping mechanism for 
increased pathological burden as reported by recent PET studies. These studies demonstrated 
that individuals with higher levels of education can maintain higher cognitive function at similar 
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levels of amyloid burden than lower educated individuals (Roe et al., 2008). Likewise, 
individuals with higher CR can tolerate more amyloid pathology (Kemppainen et al., 2008), 
hippocampal atrophy (Vuoksimaa et al., 2013) and hypometabolism in temporo-parietal areas 
than lower educated individuals with similar clinical impairment (Kemppainen et al., 2008; 
Ewers et al., 2013; Morbelli et al., 2013). Information regarding tau pathology load in vivo and 
CR is still relatively limited due to the only recent availability of tau PET compounds (Hoenig 
et al., 2017; Rentz et al., 2017; Shimada et al., 2017). Publication II of this dissertation is one 
study investigating the association between level of education, as proxy measure of CR, and 
tau pathology in Alzheimer’s disease. 
Brain reserve 
Although the observations relating to CR may be explained by network adaptations, it needs to 
be noted that these adaptations would not be possible without a biological foundation such as 
neuroplasticity, which in turn relates to the concept of brain reserve (BR). BR thereby refers to 
the neurobiological capital, hence brain integrity, of an individual (Stern et al., 2018a). The 
concept of BR is based on a threshold model, which states that an individual with high BR can 
tolerate greater amounts of brain damage or brain pathology than individuals with low BR 
before showing clinical symptoms (Stern, 2002). This is because an individual with high BR 
obtains enough neuronal substrate to compensate the brain damage or pathology. Most 
commonly, grey matter volume, intracranial volume, but also head circumference have been 
used as surrogate measures of BR. Several structural MRI studies have provided support for the 
concept of BR using these proxies and further implicated higher education with better brain 
integrity (Schofield et al., 1997; Perneczky et al., 2010; Chang et al., 2016; Groot et al., 2018). 
Thus, highly educated individuals presenting greater pathology burden may not only possess 
higher CR, but also better brain integrity to cope with the harmful effects of neuropathology. 
In publication III, this assumption is elaborated on by assessing the effects of tau pathology on 
neuronal function at different levels of education (Hoenig et al., 2019). 
 
 
Figure 7 – The framework of resistance and resilience in Alzheimer’s disease. Contributing factors that support 
resilience and resistance mechanisms are for example lifestyle factors or distinct genes. Resistance is associated 
with brain maintenance, whereas resilience is closely associated with brain reserve and cognitive reserve. These 
three concepts in turn modulate the relationship between pathology build-up, neuronal dysfunction and 
cognition. Adapted from Arenaza-Urquijo and Vemuri, 2018. 
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Brain maintenance 
Importantly, the current definition of BR also encompasses processes that support maintenance 
of the neuronal substrate, thus interconnecting the concept of brain maintenance (BM). 
Accordingly, BM relates to neuroprotective mechanisms (Stern et al., 2018a), and thus to 
resistance based on the framework of Arenaza-Urquijo and Vemuri. Possible BM mechanisms 
may encompass clearance mechanisms of tau and amyloid that prevent the accumulation of 
these proteinopathies. Several epidemiology studies have shown that higher education and 
better lifestyles are associated with a lower risk of developing dementia (Mortimer et al., 2003; 
Verghese et al., 2003; Brayne et al., 2010) – a finding which could relate to BM mechanisms. 
Like BR, BM appears to be modifiable by lifetime experience. However, while BR is associated 
with brain integrity at a specific point in time, BM relates to mechanisms that reduce age-related 
changes over time (Stern et al., 2018a). Hence, BR can be measured in cross-sectional studies, 
whereas BM can only be investigated in longitudinal designs. Nonetheless, BM and BR are 
interconnected concepts since higher BR is likely sustained by better BM (Stern et al., 2018a). 
Summing up these three concepts in a more metaphorical way (see Figure 7), CR can be 
considered as the software of the brain, which can be adapted or ‘updated’ in the phase of brain 
pathology. In contrast, BR represents the hardware of the brain as it is based on the 
neurobiological capital of an individual. Both concepts are interconnected via the wetware since 
CR could not exist without a biological foundation. Likely, BM mechanisms foster the build-
up of CR and BR. These BM mechanisms can be regarded as the antivirus software of the brain. 
All three concepts are associated with lifetime factors including education, risk factors (genetic 
risk i.e., apolipoprotein E4 (ApoE 4), or vascular risk), and sex. These factors contribute to 
resilience, thus coping mechanisms against brain pathology (BR & CR) but can also support 
resistance against the aggregation of brain pathology (BM & BR). These mechanisms overall 
modulate the relationship between pathology build-up, subsequent neuronal dysfunction and 
cognitive impairment. Thus, the clinical expression of Alzheimer’s disease patients depends on 
the individual magnitude of the underlying resilience, but also resistance capacity. Independent 
of the terminologies used to describe these mechanisms, the existence of protective factors 
influencing the manifestation and the course of Alzheimer’s disease represents an important 
field of research, as will further be elaborated in the discussion of this dissertation. 
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RATIONALES AND AIMS OF THE DISSERTATION 
The overall aim of this dissertation is to elucidate the role of functional connectivity and the 
influence of a resilience surrogate measure, namely education, concerning the spread of tau 
pathology and its effects on neuronal function using PET imaging. To address these aims, three 
manuscripts have been published as part of this thesis project. A brief overview on the specific 
rationales, research questions and main methods for each publication are mentioned below. 
Please note that the publications are not listed in chronological order, but in order of content. 
 
Rationale & Aim I 
The stereotypical propagation pattern of tau pathology in Alzheimer’s disease is indicative of 
misfolded tau proteins disseminating across interconnected regions. Indeed, recent evidence 
from cellular and rodent studies suggest that misfolded tau proteins can spread trans-
synaptically from neuron-to-neuron in a stereotypical fashion (Clavaguera et al., 2009; Guo and 
Lee, 2014; Guo et al., 2016). Importantly, these experiments further demonstrated that 
misfolded tau proteins are released in an activity-dependent manner (Pooler et al., 2013; Wu et 
al., 2016). These findings point towards a contribution of functional connectivity in the 
spreading of tau pathology across connected brain regions of neuronal networks. This 
infiltration likely results in the degeneration of the affected network, as postulated by the 
network degeneration hypothesis. Given that no information on the relationship between tau 
pathology distribution and the functional connectome was available in vivo, the first aim of this 
dissertation was to assess the spatial overlap of tau pathology distribution patterns and 
functional connectivity networks, using [18F]-AV-1451 PET in a group of Alzheimer’s disease 
patients and resting-state fMRI in a group of young healthy controls, respectively.  
Publication I 
Title: Networks of tau distribution in Alzheimer’s disease 
Research question: Does tau pathology arise in independent networks, which overlap 
with functional connectivity networks? 
Methods: Independent component analysis (Gift toolbox), seed-based functional 
connectivity analysis (DPARSF toolbox), dice similarity coefficient (MATLAB) 
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Rationale & Aim II 
Even though the spatiotemporal disease mechanisms in Alzheimer’s disease are now better 
understood, a striking feature remains the observed disparity between brain pathology burden 
and clinical expression in individuals with Alzheimer’s disease, which might be driven by 
resilience factors such as CR or BR. In case of amyloid ȕ pathology and neurodegeneration it 
has already been reported that individuals with higher education can tolerate more pathology 
burden and neurodegeneration than lower educated with similar cognitive impairment 
(Kemppainen et al., 2008; Ewers et al., 2013; Morbelli et al., 2013; Vuoksimaa et al., 2013). 
Information regarding the relationship between the level of education, a proxy of resilience, 
and in vivo tau pathology were lacking until recently. The investigation of possible associations 
between resilience and tau pathology load, however, is important, as the extent of tau pathology 
in the brain, in contrast to amyloid ȕ, correlates strongly with the degree of cognitive 
impairment and neurodegeneration (Nelson et al., 2012). Thus, the second aim of this 
dissertation was to examine the association between a surrogate measure of resilience, namely 
education, and tau burden in individuals with Alzheimer’s disease. 
Publication II 
Title: Tau pathology and cognitive reserve in Alzheimer’s disease 
Research question: Do higher educated Alzheimer’s disease patients show more tau 
pathology than lower educated Alzheimer’s disease patients with similar cognitive 
impairment? 
Methods: Region-of-interest analysis based on the neuropathologically defined Braak 
stages (MATLAB), whole-brain voxel-wise analysis (SPM8) 
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Rationale & Aim III 
According to current concepts of CR, BR and BM, two potential assumptions can be formulated 
explaining why higher educated individuals can tolerate more neuropathology than lower 
educated Alzheimer’s disease patients with similar clinical expression. Concerning the concept 
of CR, it can be assumed, based on previous research (for review Stern, 2012), that higher 
educated people can better compensate for the harming effects of pathology for example 
through the more efficient use of neuronal resources. On the other hand, one may speculate that 
the effects of brain pathology on neuronal function are less harmful in patients, who have been 
physically and cognitively active throughout their lives, either due to BR-associated 
mechanisms such as higher neuron count or synaptic density and/or due to BM-associated 
neuroprotective mechanisms. These mechanisms may in turn support neuronal resilience to 
brain pathology. Importantly, both assumptions are not exclusive of each other. However, the 
second assumption can be assessed by means of FDG PET imaging, which represents an index 
of synaptic function. Combining FDG PET with tau PET imaging, the third aim of this 
dissertation was to investigate whether glucose metabolism remains relatively preserved at 
higher levels of education despite tau pathology aggregation. Thus, we assessed whether the 
consistently reported relationship between tau pathology and neuronal dysfunction is mitigated 
by a resilience proxy. 
Publication III 
Title: Level of education mitigates the impact of tau pathology on neuronal function 
Research question: Can higher educated Alzheimer’s disease patients tolerate more tau 
pathology, because the effects of tau pathology on neuronal function are less 
pronounced at higher levels of education? 
 Methods: Volume-based approach (MATLAB, SPM12)  
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PUBLICATION I  
Networks of tau distribution in Alzheimer's disease 
 
Hoenig MC, Bischof GN, Seemiller J, Hammes J, Kukolja J, Onur ÖA, Jessen F, Fliessbach K,  
Neumaier B, Fink GR, van Eimeren T, Drzezga A.  
Brain 2018 
 
 
 
 
 
 
 
 
 
 
 
 
Summary: To determine whether tau pathology arises in independent networks of the brain, 
and coincides with functional connectivity networks, we performed an independent component 
analysis on [18F]-AV-1451 PET data of Alzheimer’s disease patients. Based on the resulting 
components, the seeds of maximal tau pathology were extracted and used in a subsequent 
functional seed-based connectivity analysis based on data of young healthy controls. Finally, 
the spatial overlap between the tau pathology networks, the seed-based networks and already 
known resting-state functional connectivity networks was quantified using the dice similarity 
coefficient. We observed a fair-to-moderate overlap between the tau pathology networks and 
the seed-based networks, which in turn coincided with known functional networks such as the 
DMN and the executive control network. Tau burden in these independent components 
correlated with disease progression and global cognitive decline. Overall, the results of this 
study suggest that tau pathology arises synchronously in independent pathways, which overlap 
with known functional connectivity networks and are associated with disease progression. 
These findings are in line with the network degeneration hypothesis and provide a possible 
mechanistic pathway in the spread of tau pathology.  
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Contribution to this work 
This work was a team-effort of the Multimodal Neuroimaging Group, Department of Nuclear 
Medicine, University Hospital Cologne in collaboration with Joseph Seemiller from the 
Geisinger Commonwealth School of Medicine, Scranton PA, USA and the Departments of 
Neurology, Psychiatry and Radiochemistry of the University Hospital Cologne and the 
Department of Neurodegenerative Diseases and Geriatric Psychiatry of the University Hospital 
Bonn. Merle Hönig, Dr. Gérard Bischof, Joseph Seemiller, Prof. Dr. Thilo van Eimeren, and 
Prof. Dr. Alexander Drzezga were involved in the conception and design of the study and 
drafting the manuscript. Merle Hönig had full access to the data in the study and performed the 
analyses. Dr. Jochen Hammes supported the implementation of MATLAB scripts required for 
the data analysis. The remaining co-authors were involved in the acquisition of the data and 
drafting of the manuscript. Publication of the results approximately took one year starting with 
the initial analyses in fall 2016 and receiving the acceptance letter from Brain (impact factor: 
11.81) for publication end of November 2017. Given the invitation to draft a cover image, Merle 
Hönig designed the “independent highways of tau pathology”, which was accepted as cover art 
for the February issue of Brain in 2018 (Brain, Volume 141, Issue 2, February 2018, 
https://academic.oup.com/brain/issue/141/2,  depicted on previous page). 
 
Additional information 
Dr. Jennifer Whitwell wrote a scientific commentary on this article, which is listed in the 
reference list under “Whitwell, 2018a”. 
 
The publication can be found in the attachments under Appendix – B1. 
 
  
  
27 
 
PUBLICATION II  
Tau pathology and cognitive reserve in Alzheimer's disease 
 
Hoenig MC, Bischof GN, Hammes J, Faber J, Fliessbach K, van Eimeren T, Drzezga A.  
Neurobiology of Aging 2017 
 
 
 
 
 
 
 
 
 
 
 
 
Summary: To investigate whether higher educated Alzheimer’s disease (HEAD) patients can 
tolerate more tau pathology than lower educated Alzheimer’s disease (LEAD) patients with 
similar clinical severity, we performed, based on [18F]-AV-1451 data, a voxel-wise whole brain 
analysis and a region-of-interest (ROI) analysis using the neuropathologically defined Braak 
stages as ROIs. We compared tau pathology load across the brain and in the ROIs between three 
groups, the HEAD, LEAD and an age-matched healthy control (HC) group. The results yielded 
higher and more wide-spread tau pathology in the HEAD (dark orange in graph above) than the 
LEAD (orange in graph above) and HC (light orange in graph above) groups. The HEAD group 
already presented tau pathology in advanced Braak stages, whereas tau pathology in the LEAD 
group was still confined to temporal areas when compared to HC, respectively. Overall, the 
results are in line with the concept of CR given that HEAD patients can tolerate more tau 
pathology than LEAD patients with similar cognitive impairment. 
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Contribution to this work 
The study was conducted in collaboration of the Multimodal Neuroimaging Group, Department 
of Nuclear Medicine, University Hospital Cologne and the Department of Neurodegenerative 
Diseases and Geriatrics, University Hospital Bonn. Merle Hönig, Dr. Gérard Bischof, Prof. Dr. 
Thilo van Eimeren and Prof. Dr. Alexander Drzezga were involved in the conception and design 
of the study and drafting the manuscript. Dr. Jochen Hammes helped with the implementation 
of MATLAB scripts required for the data analysis. Merle Hönig was responsible for the 
information collection on the educational attainment of the patients, had full access to the data 
in the study and performed the analyses. The remaining co-authors were involved in the 
acquisition of the imaging data and drafting of the manuscript. The initial analyses were 
conducted in May 2016. The paper was submitted end of December 2016 to Neurobiology of 
Aging (impact factor: 5.15) and published in May 2017. 
 
Additional information 
This work has been awarded with two poster prizes, one at the Alzheimer’s Association 
International Conference (AAIC), 2017 in London, UK, and one at the 1st International 
Conference for Cognitive Reserve in Dementias (ResDem), 2017 in Munich, Germany. 
 
The publication can be found in the attachments under Appendix-B2. 
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PUBLICATION III  
Level of education mitigates the impact of tau pathology  
on neuronal function 
 
Hoenig MC, Bischof GN, Onur ÖA, Kukolja J, Jessen F, Fliessbach K, Neumaier B,  
Fink GR, Kalbe E, Drzezga A, van Eimeren T.  
European Journal of Nuclear Medicine and Molecular Imaging 2019 
 
 
 
 
 
 
 
 
 
Summary: To examine whether the harmful effects of tau pathology ([18F]-AV-1451 PET) on 
neuronal function ([18F]FDG PET) are mitigated by the level of education, we used a novel 
volume-based approach on PET data from patients with typical and atypical Alzheimer’s 
disease. The volume-based approach comprised the following technique: all PET scans were z-
score standardized and thresholded at a z-score >= 3.0 using an FDG and tau PET template 
based on data of an age-matched healthy control sample. Three volumes were extracted based 
on the z-maps: 1) the tau-specific volume (i.e., regions with only tau), 2) the overlap volume 
(i.e., regions with both tau and changes in neuronal function), 3) the FDG-specific volume (i.e., 
regions with only changes in neuronal function). Regression analyses were performed including 
the respective volumes and the z-scores within these volumes as dependent variables and 
education as predictor. We found that higher education is associated with a greater tau-specific 
volume (depicted in blue in picture above) and greater tau burden in the overlap volume 
(depicted in green in picture above). The results indicate that tau pathology is less paralleled by 
neuronal dysfunction at higher education, which may explain why higher educated patients can 
tolerate more tau pathology than lower educated patients albeit similar cognitive impairment 
levels. These findings further support the concepts of BR and BM mechanisms. 
  
30 
 
Contribution to this work 
This study was performed in collaboration of the Multimodal Neuroimaging Group, 
Department of Nuclear Medicine, University Hospital Cologne with the Departments of 
Neurology, Psychiatry, Radiochemistry and Medical Psychology, University Hospital Cologne 
and the Department of Neurodegenerative Diseases and Geriatric Psychiatry, University 
Hospital Bonn. Merle Hönig, Dr. Gérard Bischof, Prof. Dr. Alexander Drzezga and Prof. Dr. 
Thilo van Eimeren were involved in the conception and design of the study and drafting the 
manuscript. Merle Hönig had full access to the data in the study and performed the analyses. 
The co-authors contributed to the content of the manuscript and gave valuable feedback to the 
current work. The paper was submitted end of February 2019 to the European Journal of 
Nuclear Medicine and Molecular Imaging (impact factor: 7.23) and accepted for publication in 
April 2019. 
 
Additional information 
This work has been ranked under the 15 best papers of young researchers at the European 
Association of Nuclear Medicine (EANM) conference, 2018 in Dusseldorf, Germany, and has 
been awarded with the junior faculty award at the Alzheimer’s and Parkinson’s disease congress 
(ADPD), 2019 in Lisbon, Portugal. 
 
The publication can be found in the attachments under Appendix-B3. 
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DISCUSSION 
By means of multimodal imaging, a potential mechanism in the spread of misfolded tau proteins 
and the role of a resilience proxy, namely education, were examined as part of this thesis, 
resulting in the following findings:  
1) Tau pathology arises synchronously in independent components of the brain, which 
coincide with functional connectivity networks, and which are associated with disease 
progression and global cognitive dysfunction (Hoenig et al., 2018). 
 
2) Higher educated Alzheimer’s disease patients present more extended tau pathology, 
already in advanced Braak stages, than lower educated Alzheimer’s disease patients 
despite similar cognitive impairment (Hoenig et al., 2017). 
 
3) At higher levels of education, the extent of tau pathology is less paralleled by a reduction 
in glucose metabolism (i.e., neuronal dysfunction) and more tau pathology appears 
necessary to induce neuronal dysfunction (Hoenig et al., 2019).  
Collectively, the results of this doctoral thesis suggest that the spread of misfolded tau proteins 
is facilitated by functional connectivity between brain regions belonging to distinct neuronal 
networks. The more affected these networks are by tau pathology, the further the disease has 
already progressed, and global cognitive function declined. The early lifetime factor education, 
in turn, appears to alter the deleterious consequence of tau pathology on the disease 
manifestation. The current findings indicate that higher educated individuals with Alzheimer’s 
disease can tolerate more tau pathology while maintaining their cognitive function up to a 
certain extent. A possible explanation for this observation relates to the final finding of this 
thesis, namely that the effects of tau pathology appear less harmful to neuronal function at 
higher levels of education. 
In the following, these results will be discussed in the context of a) factors contributing to the 
spreading of tau pathology, b) distinct network susceptibility, and c) resilience factors that 
potentially modify the pathophysiological consequences of tau pathology. Lastly, d) the role of 
education as resilience proxy will be considered in more detail. 
Spreading mechanisms of tau pathology 
Given the spatial and temporal lag of the neuropathological hallmarks of Alzheimer’s disease, 
and the previous lack of methods to assess cerebral tau deposition in vivo, it remained unknown 
not until just recently, whether tau pathology also follows distinct connectivity networks. In the 
first publication of this dissertation we therefore addressed the role of functional connectivity 
in the spread of tau pathology in patients with Alzheimer’s disease employing the data-driven 
approach of independent component analysis (ICA). We observed tau pathology networks 
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(TPNs) comprising regions not anatomically adjacent to each other and which coincided with 
functional connectivity networks, which have previously been reported to be impaired in 
Alzheimer’s disease (Hoenig et al., 2018). This signifies that tau pathology arises 
synchronously, but not homogenously in independent compartments of the brain, which in turn 
relate to distinct functional networks. The observation of synchronous aggregation of tau 
pathology in distal brain regions points towards a common mechanism, which contributes to 
the coherent aggregation of tau pathology. According to the assumptions of ICA, regions within 
an independent component can be inferred to be spatially correlated, either by structural or 
functional connections (Cohen et al., 2008). Hence, the topographic characteristics of the 
identified TPNs potentially reflect the underlying neural architecture of existing structurally or 
functionally linked networks. In this study, we showed the contribution of functional 
connectivity to tau spread, whereas the role of structural connectivity still needs to be 
investigated, as detailed below. 
Prion-like spreading mechanisms of tau pathology 
Over the years, persuasive evidence in support of prion-like spreading of tau has been gathered 
indicating that pathogenic forms of tau are capable to seed into tau aggregates, which can induce 
further aggregation of non-aggregated tau and be transmitted trans-synaptically (for review see 
Soto, 2012; Mudher et al., 2017). Repetition of this seeding process potentially results in the 
infestation of synaptically linked networks (Mudher et al., 2017). Supporting the prion-like 
seeding behaviour, several studies have demonstrated that injection of pathogenic tau forms 
from different tauopathies or brain homogenates of Alzheimer’s disease patients into the brain 
of transgenic and wild-type mice led to the expression of the corresponding tauopathy’s 
inclusion (De Calignon et al., 2012; Liu et al., 2012; Clavaguera et al., 2013; Guo et al., 2016; 
He et al., 2018). Importantly, it was not only reported that injection of brain homogenates of 
tau led to tau seeding, but also to a time-dependent spread of tau pathology across structurally 
connected regions (De Calignon et al., 2012; Liu et al., 2012; Clavaguera et al., 2013; Guo et 
al., 2016; He et al., 2018). Moreover, the distribution of tau pathology is associated with 
synaptic connectivity, thus structural connections, rather than spatial proximity (Ahmed et al., 
2014). The suggested prion-like spreading of tau pathology across structural connections likely 
contributed to the observation of distinct TPNs in publication I, which involved remote brain 
areas. In addition, the time-dependent seeding process of tau may further explain why the TPNs 
were characterized by varying loads of tau pathology and associated with disease progression. 
Hence, TPNs with low levels of tau burden may represent regions that are affected later in the 
disease than TPNs with higher tau burden. The more severe these networks are affected, the 
further has the disease progressed. However, as we only had cross-sectional data available, 
these assumptions remain speculative and require longitudinal assessment. Up to date, 
longitudinal evidence regarding the structural distribution of tau pathology in patients with 
Alzheimer’s disease is still sparse. Recently, Jacobs and colleagues, employing DTI and tau 
PET imaging, reported that tau tangles distribute from the hippocampus to the parietal cortex 
via axonal pathways in amyloid positive individuals (Jacobs et al., 2018). In line with this, 
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Strain and colleagues found that tau pathology was closely associated with a decline in white 
matter integrity in anterior temporal regions (Strain et al., 2018). These studies overall offer 
first insights into the mechanistic pathways of structural connectivity in the distribution of tau 
pathology. Furthermore, these findings may provide an explanation of the spatial pattern and 
load of tau pathology of the identified TPNs in publication I. Notably, further investigation on 
the actual underlying structural connectivity patterns of the TPNs are required using for 
example tract -based analysis based on DTI data. Additionally, investigation of tract alterations 
such as changes in fractional anisotropy (i.e., a measure of white matter integrity) and their 
association with tau pathology aggregation in regions connected downstream to the region of 
maximal tau pathology within a respective TPN will provide further insights into the spreading 
mechanisms across these networks. 
The role of functional connectivity in the spread of tau pathology 
Importantly, in contrast to structural connectivity analyses, which reflect the presence of 
anatomical linkage, functional connectivity analyses provide insights on the functional 
interaction of specific brain regions. Here, we observed a spatial link between the TPNs and 
tau-dependent seed-based functional connectivity networks indicating that functional 
connectivity between regions supports the distribution of tau pathology across these 
connections. The investigation of functional connectivity as a driver of tau pathology spread 
has recently been expanded upon. Results from our group in collaboration with the Faculty of 
Mathematics and Natural Sciences of the University Cologne suggest that the spread of tau 
pathology and tau burden of the affected regions depends on the overall functional in-/output 
(functional weights) rather than the metabolic rate of that region (Weller et al., 2019). This is 
in line with a recently published study demonstrating that strongly connected regions 
accumulate more tau pathology in Alzheimer’s disease independent of the metabolic demands 
(Cope et al., 2018). Also, in animal models, exacerbated pathological tau aggregation in vivo 
was found upon increased neuronal activity (Wu et al., 2016) and normal tau was released in 
an activity-dependent manner (Pooler et al., 2013). Together these findings suggest that 
synchronous neuronal activity, thus the temporal coherence between functionally connected 
regions, may act as an amplifier enhancing tau pathology to accumulate in functionally 
connected brain sites. The tau maxima of the TPNs identified in the current study, which 
corresponded to highly functionally connected brain regions such as the precuneus or the 
posterior cingulum, may thereby act as “susceptibility seeds” and relays for tau aggregates to 
further propagate along connected regions of neuronal networks. Arguably, the prion-like 
spreading mechanisms are rather in support of structural connectivity in the distribution of tau. 
However, functional connectivity is associated with higher synaptic activity and thereby with 
greater axonal transport, which may ultimately lead to increased release of tau aggregates into 
the synaptic cleft (Soto, 2012). Functional connectivity between structurally connected regions 
may thus stimulate the synchronous propagation of tau along these connections. Indeed, it was 
just recently shown that higher functional connectivity between regions was related to similar 
tau levels in these regions in MCI and Alzheimer’s disease patients (Franzmeier et al., 2019). 
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This may also explain the synchronous aggregation of tau pathology in the identified 
independent components of publication I.  
Overall, the results of publication I and other recent studies on functional connectivity and tau 
pathology (Hansson et al., 2017; Jones et al., 2017; Cope et al., 2018; Franzmeier et al., 2019) 
offer one potential mechanistic perspective for the spreading of tau pathology in Alzheimer’s 
disease by means of which synchronous oscillatory activity between connected brain regions 
contributes to the propagation of tau pathology within distinct neural networks. However, 
despite the investigation of structural and functional connectivity patterns, also the role of 
neuroinflammation and genetic vulnerability factors need to be considered in the spread of tau 
pathology, which shall briefly be mentioned below. 
Factors beyond structural and functional connectivity 
Recently, it was suggested that neuroinflammatory processes may actually precede tau seeding 
and overt tau pathology (Wang and Mandelkow, 2016). Concordantly, also PET imaging 
studies proposed that neuroinflammatory processes may peak early in the temporal evolution 
of Alzheimer’s disease-related pathophysiological processes (Rodriguez-Vieitez et al., 2016). 
Furthermore, a close relationship between microglia activation and tau aggregation patterns has 
been observed (Dani et al., 2018; Terada et al., 2019). Thus, patterns of neuroinflammation 
may represent an early marker of subsequent network infiltration by tau pathology. However, 
these findings need to be cautiously interpreted, as it remains still unknown whether the 
observed patterns are a cause or a consequence of tau pathology aggregation. To address the 
questions of the temporal sequence of biomarkers and network susceptibility to 
neuroinflammation, it will be crucial to develop sensitive PET ligands for the visualization of 
neuroinflammatory processes in cognitively normal individuals at risk of developing 
Alzheimer’s disease (e.g., ApoE 4 carriers). After two decades of research, a challenge remains 
the development of sensitive ligands for neuroinflammation since it is a complex, dynamic and 
multicellular process. Currently available tracers such as the translocator protein-18 kDa 
(TSPO) compounds, which are used to quantify microglia activation, lack cellular specificity 
and present difficulties in quantification (Narayanaswami et al., 2018). Thus, radiotracer 
development for neuroinflammation beyond the TSPO ligands represents an important field of 
research since neuroinflammatory constitutes potentially provide viable targets for the 
treatment of Alzheimer’s disease and insights into its cascade (Narayanaswami et al., 2018).  
Aside from the neuroinflammatory signatures potentially preceding overt tau pathology, it has 
recently been shown that connected brain regions belonging to certain brain networks, present 
similar gene-expression patterns (Richiardi et al., 2015). Depending on the gene-expression 
patterns in these regions, the susceptibility of Alzheimer’s disease pathology may in turn 
increase (Grothe et al., 2018; Sepulcre et al., 2018). Indeed, according to these studies, regional 
expression levels of the APP gene were associated with amyloid deposition as measured with 
[18F]AV45 PET, but not neurodegeneration as quantified by structural MRI (Grothe et al., 
2018). Furthermore, regional MAPT gene expression patterns predicted the spreading of tau 
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pathology, measured with longitudinal [18F]-AV-1451 PET in cognitively normal older 
individuals (Sepulcre et al., 2018). These studies suggest that regional vulnerability in addition 
to functional and structural correlates relate to the expression and stereotypical distribution of 
Alzheimer’s disease-related pathology. Arguably, these studies are based on post-mortem gene 
expression patterns of six adult individuals from the Allen brain atlas, which were related to in 
vivo brain pathology of different individuals. Hence, a direct assessment of in vivo brain 
pathology and subsequent post-mortem investigation of gene expression patterns is still 
pending. 
Nonetheless, collectively, the results of publication I and the above-mentioned in vivo studies 
suggest that the distribution of tau pathology is partly driven by mechanistic pathways in terms 
of structural and functional connectivity, but also by predetermined regional susceptibility to 
Alzheimer’s disease pathology. Future longitudinal multimodal studies using DTI, fMRI and 
PET tracers are necessary to elucidate the structural and functional underpinnings contributing 
to the propagation of misfolded tau proteins within neuronal networks and its interaction with 
amyloid ȕ accumulation, neuroinflammation, and genetic vulnerability. This will shed light into 
the pathogenic cascade of Alzheimer’s disease, which is crucial for the development and timing 
of target-specific interventions (Bischof et al., 2019). Additionally, better understanding of the 
spreading mechanisms of tau pathology in Alzheimer’s disease may also be relevant for other 
tauopathies and the monitoring and diagnosis of these diseases. 
Susceptibility of the default mode network to tau pathology 
Regarding the evolution of pathogenic events, evidence from molecular studies suggests that 
tau seeding does not affect a certain cell population, but rather commences in a vulnerable 
location from where its spreads via neuronal connections (Guo and Lee, 2014; Goedert, 2015). 
This is in line with several studies on network degeneration suggesting that pathologies 
distribute along functional networks from a central starting point (Drzezga, 2018). In the first 
study of this thesis, we observed TPNs that coincided with known resting-state networks such 
as the DMN, salience or higher-visual network (Hoenig et al., 2018). This indicates that tau 
pathology does not only affect one distinct network but accrues in different neuronal networks 
depending on the most vulnerable locations. In accordance with this, recent imaging studies 
examining tau-dependent functional network infiltration observed that tau pathology arises in 
various functional networks, but also reported a particular vulnerability of the DMN (Hansson 
et al., 2017; Jones et al., 2017). This accords with the results of publication I as several of seed-
based derived networks overlapped with the DMN.  
So far, it remains unknown why the DMN is particularly affected in this disease. Several 
explanations and hypotheses have been put forward, such as the role of developmental, 
evolutionary, and metabolic aspects (Buckner and Krienen, 2013). The DMN is an association 
network, which is phylogenetically relatively young, potentially rendering these regions more 
vulnerable to disease-related changes. Moreover, the “wear and tear” hypothesis suggests that 
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excessive use of neuronal resources leads to their dysfunction and destruction (Swaab, 1991). 
As the DMN is a highly active network during rest, its continuous activation throughout life 
may render it vulnerable according to this hypothesis. Differences in network activation 
throughout life may also explain resilience to disease-related changes late in life. Although 
speculative, individuals with low cognitive engagement (e.g., low resilience) may be prone to 
the development of Alzheimer’s disease, because of high DMN activation throughout life 
leading to pathology accumulation and concomitant failure of this network. In contrast, 
individuals with high resilience may more efficiently switch between networks allowing for a 
more balanced energy consumption across networks reducing the risk of “network tearing” or 
disconnection and slowing brain pathology accumulation. Despite the “wear and tear” 
hypothesis, another explanation for the susceptibility of the DMN may signify the initial starting 
point of pathophysiological changes, which determines the distribution of tau pathology in a 
posterior-anterior fashion across this network as seen in Alzheimer’s disease (Jones et al., 
2015). Notably, the mentioned explanations are not exclusive of each other and may 
collectively lead to an increased susceptibility of the DMN to tau pathology, as observed in 
publication I. 
Interestingly, the posterior part of the DMN is not only affected in typical, but also in atypical 
Alzheimer’s disease (see Figure 8). Following the idea of a central starting point in the spread 
of tau pathology and concomitant network degeneration, we performed a preliminary analysis 
to elucidate whether differential susceptibility of the posterior DMN can explain the clinical 
phenotypes of Alzheimer’s disease (Appendix – Abstract A1, page 64). The results suggest that 
the peak of tau pathology in the posterior DMN regionally differs between the clinical 
phenotypes. In turn, these peaks of tau pathology are functionally associated with connectivity 
networks outside the posterior DMN that correspond to the respective clinical phenotype e.g., 
visuo-spatial network in PCA. This suggests that the tau-peak in the posterior DMN may 
determine the spread of tau pathology across distinct functional networks (Hönig et al., 2019). 
According to the network degeneration hypothesis, the spread of tau along these networks 
eventually results in network dysfunction and cognitive decline relating to the clinical 
phenotype.  
 
 
Figure 8 – Regional susceptibility of the posterior default mode network in phenotypes of Alzheimer’s disease. 
The tau pathology distribution pattern for each phenotype is depicted in blue. In addition, the topography of the 
posterior default mode network (in green) is superimposed on the respective tau distribution patterns. 
AD=Alzheimer’s disease; bvAD=behavioural variant of Alzheimer’s disease; lpAD = logopenic variant of 
Alzheimer’s disease; PCA = posterior cortical atrophy. 
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There remain several unanswered questions and somehow contrasting evidence regarding the 
network degeneration seen in Alzheimer’s disease and other neurodegenerative diseases. For 
example, it needs to be elucidated why in similar neurodegenerative diseases such as primary 
tauopathies different network pathways are affected (Drzezga, 2018). Moreover, it remains 
unknown how the spreading theory of tau pathology along functional connectivity networks is 
compatible with the stage-wise progression according to the neuropathological Braak stages, 
which have been replicated in vivo by tau PET imaging studies (Schöll et al., 2016; Schwarz et 
al., 2016). Work from our group, which is currently under revision, indicates that tau spreading 
from lower to higher Braak stages is mediated by intrinsic functional connectivity, partly 
supporting the network degeneration hypothesis (Seemiller et al., 2019).  
Albeit these uncertainties, multimodal imaging studies including our study have consistently 
shown a relation between distribution patterns of neurodegenerative diseases, functional 
networks, and network dysfunction supporting the current hypothesis of network degeneration 
(for a more detailed discussion see Drzezga, 2018). Importantly, recent fMRI studies indicate 
that network signatures derived from ICA may provide a non-invasive biomarker of 
neurodegenerative diseases (Zhou et al., 2010). This suggest that multimodal imaging of 
network degeneration carries potential in the classification of neurodegenerative diseases and 
likely also for the monitoring of disease progression. In line with this, TPNs identified in 
publication I were associated with disease progression and varying loads of tau pathology 
indicating that tau burden within these TPNs provide information on the progression of the 
disease. The data-driven approach of ICA hereby offers a suitable tool to define characteristic 
network patterns as it is not based on predefined significance thresholds, but a blind source 
separation technique. Furthermore, independent components derived from tau or amyloid PET 
imaging may yield a marker with the potential to detect disease-related network changes before 
the degenerative process emerges, which will be important for the early diagnosis and 
intervention. In addition, this hypothesis-free approach can be used to elucidate distinct network 
signatures depending on the level of resilience that an individual possesses. Thus, comparison 
of network signatures derived from structural/functional MRI or PET may provide information 
on differences in network flexibility and vulnerability depending on the level of resilience. 
Overall, reliable discrimination patterns for neurodegenerative diseases, including the influence 
of resilience mechanisms, will be important for diagnostic and prognostic purposes. 
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Resilience against the evolution of tau pathology 
Over the past decade, resilience mechanisms have received increased interest as they may 
account for the clinical heterogeneity and are hence important for the diagnosis and prognosis 
of the Alzheimer’s disease. In studies on resilience, parameters of individuals’ lifetime 
experiences including education, occupation as well as leisure activities have been discussed as 
surrogate measures of resilience. However, no information had yet been available regarding the 
relation between these measures and tau pathology in Alzheimer’s disease. In publication II, 
we showed that higher education is associated with the relative preservation of cognitive 
performance in the phase of tau pathology aggregation (Hoenig et al., 2017). Moreover, as 
shown in publication III, there appears to be a longer temporal delay between tau pathology 
aggregation and concomitant neuronal dysfunction at higher levels of education, potentially 
explaining the prior finding (Hoenig et al., 2019). In the following, these findings will be 
discussed in the light of mechanisms associated with the concepts of CR and BR, animal models 
for the investigation of resilience and the significant contribution of early lifetime factors, such 
as education, to protective or compensatory mechanisms late in life.  
An interpretation based on cognitive reserve and brain reserve 
Our finding of higher educated patients being able to tolerate more advanced tau burden than 
lower educated patients with similar cognitive impairment may be due to an adaptation of 
cognitive processes, as defined by the concept of CR (Hoenig et al., 2017). This adaptation of 
cognitive processes likely occurs through the modulation of brain networks and additional 
recruitment of brain areas. Importantly, Neitzel and colleagues recently demonstrated that left 
frontal connectivity mitigated the deleterious effects of tau pathology on cognitive function in 
non-demented elderly and MCI patients (Neitzel et al., 2019). This region has also been 
demonstrated to provide compensation in the phase of emerging neuronal dysfunction 
(Franzmeier et al., 2017b). Presumably, similar mechanisms may have acted in the patient 
cohort assessed in publication II. But it remains to be assessed whether the reported effects by 
Neitzel et al. are transferrable to patients who have already advanced to Alzheimer’s disease. It 
will thus be of interest to investigate how this potential CR mechanism changes in the course 
of the disease from MCI to Alzheimer’s dementia, thus whether it is up- or downregulated as 
the disease progresses and at which point of the disease course the compensatory effect fails to 
work. As recently suggested, CR mechanisms support cognitive maintenance in prodromal 
phases of Alzheimer’s disease, but from the onset of diagnosis cognitive function declines more 
rapidly in individuals with higher reserve, likely because a certain threshold is reached at which 
compensatory CR effects fail (van Loenhoud et al., 2019). 
Importantly, while CR mechanisms can be quantified with fMRI or DTI, current imaging 
techniques of BR allow for a crude estimation of BR based on grey matter or intracranial 
volume analyses in humans (Chang et al., 2016; Groot et al., 2018). However, also FDG PET 
measures may provide a surrogate measure of BR. Using this technique, we demonstrated in 
publication III that education mitigates the spatial relationship between tau pathology 
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aggregation and neuronal dysfunction (Hoenig et al., 2019). In addition, we observed that more 
tau burden is required to induce neuronal dysfunction at higher levels of education. These 
observations may be driven by individual differences in brain integrity (i.e., BR), such as 
synaptic density, which permits compensation for the effects of tau pathology on neuronal 
function and, in turn, influences the FDG signal. However, no direct conclusion regarding the 
underlying neuronal composition, hence number of synapses, can be drawn by means of FDG 
PET and is thus still pending. Intriguingly, the newly introduced PET imaging technique for 
the visualization of synaptic density, such as the SV2A PET tracer (Chen et al., 2018; Finnema 
et al., 2018), has opened a new avenue to study the compensatory effects of BR. Using this 
technique, quantification of the underlying synaptic density is now feasible and the effects of 
tau pathology on neuronal and cognitive function in groups with high and low synaptic density 
can directly be assessed. Quantifying BR based on the underlying synaptic density may thereby 
provide novel insights into the effects of lifetime and environmental factors on disease-related 
changes late in life. 
Animal models for the investigation of resilience and maintenance mechanisms 
Aside from the novel developments in PET imaging, rodent models exposed to enriched 
environments may yield another possibility to study the effects of lifelong cognitive and 
physical engagement on the molecular and cellular level, which may then be transferrable to 
humans. Using these paradigms, researchers reported increased synaptogenesis, neurogenesis, 
gliogenesis and angiogenesis after exposing the animals to enriched environments (for detailed 
review see Gelfo et al., 2018). Moreover, in terms of BM mechanisms, these studies 
demonstrated a reduction of amyloid ȕ burden (Berardi et al., 2007) and mitigation of the 
neurotoxic effects of tau pathology (Belarbi et al., 2011). Additionally, an up-regulation of 
neurotrophic factors such as the brain-derived neurotrophic factor (BDNF) was consistently 
observed (Wolf et al., 2006; Hu et al., 2013). Also, epigenetic modifications (i.e., gene-
environment interactions) in form of non-coding RNAs, histone modifications or DNA 
methylation patterns have been found after exposure to environmental enrichment paradigms, 
and which were associated with beneficial effects on cognition (for review see Fischer, 2014). 
Whether these findings can be translated to humans, and thus to the findings of publication II-
III, still needs to be assessed. However, recent imaging studies reported a relationship between 
lifestyle factors, BDNF, vascular and insulin growth factor levels, better cognition, and greater 
brain volume in humans (Coelho et al., 2014; Westwood et al., 2014; Hohman et al., 2015). In 
particular, lifelong physical exercise appears to be associated with an upregulation of BDNF in 
brain tissue and peripheral blood samples (Szuhany et al., 2015; Håkansson et al., 2017). 
Interestingly, the BDNF Val66Met polymorphism appears to moderate the relationship between 
resilience and executive function (Ward et al., 2015). Thus, for future assessments on BR, 
serum levels of BDNF as well as polymorphisms of the gene encoding BNDF may be used as 
proxy measures. Aside from this, Pereira and colleagues derived an imaging correlate of 
exercise-induced neurogenesis for humans based on observations in mice (Pereira et al., 2007). 
The group found that dentate gyrus cerebral blood volume as measured with MRI correlated 
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with post-mortem measurements of neurogenesis in mice and cardiopulmonary and cognitive 
function in exercising humans.  
Taken together, there are a multitude of molecular and cellular factors that appear to be 
modulated by lifestyle and environmental factors and which may have contributed to the 
findings of this thesis work. The abovementioned studies indicate that by means of translational 
research novel mechanisms of brain resilience can be derived, which can be employed as better 
measures of BR in humans. Importantly, across these studies it was reported that the quantity 
of cognitive and physical activity appears to be essential regarding the upregulation of these 
factors. Nonetheless, also the timing may play a pivotal role (Nithianantharajah and Hannan, 
2009), which will briefly discussed in the following. 
The role of early lifetime intervention 
Findings from rodent and clinical studies suggest that resilience can be built up over a long 
period of time and may prevent aging- or disease-related processes late in life 
(Nithianantharajah and Hannan, 2009). In particular, early lifetime exposure to enriched 
environments appear to have long-lasting impact on the function of the brain in rodents (Wagner 
et al., 2000; Bloss et al., 2011). In our studies, we used education as proxy variable of resilience, 
which is an early lifetime factor occurring when the brain is still developing and most plastic 
(Hoenig et al., 2017). It is closely related with beneficial mid- and late-life factors (Jefferson et 
al., 2011). In line with this, a recent imaging study reported that early lifetime factors are 
positively associated with age-related structural brain trajectories and cognitive function late in 
life (Walhovd et al., 2016). This indicates that these factors contribute to the build-up of 
resilience mechanisms crucial for late life cognition and complies with the findings from the 
aforementioned animal studies (Wagner et al., 2000; Bloss et al., 2011). However, these early 
lifetime factors such as education have also consistently been associated with higher IQ, 
healthier lifestyles, less chronic stress and higher socioeconomic status (Fritsch et al., 2007) 
and may also relate to genetic predispositions (Rowe et al., 1998). Thus, early lifetime factors 
are interrelated with several societal, familial, genetic and environmental factors throughout life 
rendering it difficult to decipher the actual contribution of early lifetime exposure to late- life 
brain health. Nonetheless, these factors may lay the foundation for the build-up of resilience 
and resistance mechanisms that become crucial as we age and are therefore valuable proxies 
for late life functional and structural differences, as also indicated by the publications of this 
dissertation. 
Implications of resilience for the diagnosis, prognosis and drug evaluation 
The abovementioned studies including ours document that early lifetime factors, as education, 
contribute to the shaping of the brain in a way to protect it against or to cope with disease-
related changes. Importantly, not only can these factors alter brain structure and function in the 
phase of pathology through mechanisms associated with CR and BR, these factors also support 
maintenance of the neuronal substrate over life, thereby on the one hand decreasing the risk of 
developing dementia (Stern et al., 1994; Dekhtyar et al., 2016; Wang et al., 2017) and on the 
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other hand slowing the accumulation of brain pathology (Landau et al., 2012; Brown et al., 
2013; Wirth et al., 2014).  
Important implications can be drawn from this regarding the clinical diagnosis and prognosis, 
the evaluation and development of drug therapies, and the general conception of the disease: 
1) Concerning the clinical diagnosis and prognosis, consistent evidence (including publication 
II) signifies that individuals with high education remain under the diagnostic radar for a 
longer time as indicated by the more advanced pathology burden at the point of diagnosis. 
Hence, it will be important to develop sensitive diagnostic tools for the identification of 
individuals with high levels of resilience, who are still in the prodromal phase of the disease. 
This is particularly crucial given that a person with high resilience tends to decline quicker 
from the point of diagnosis, likely because of the high pathological burden (Stern et al., 
1999; Scarmeas et al., 2006; van Loenhoud et al., 2019). Detecting individuals with high 
resilience at the earliest stages of the disease, which requires neuropsychological tests with 
high ceiling effects, is also crucial for the early intervention with pharmacological 
treatments. 
 
2) Regarding the development of pharmacological strategies, proxy measures of resilience such 
as education need to be considered when allocating patients to treatment groups of drug-
based therapies. Results may otherwise lead to a biased interpretation of the results or an 
observation of effects that is not due to the drug, but resilience capacity interfering with 
pathophysiological processes. Aside from that, novel drugs could be developed that directly 
tackle maintenance and resilience mechanisms thereby yielding a treatment to either prevent 
or prolong the neurodegenerative disease process. Also, lifestyle, cognitive and physical 
intervention strategies in mid-life and late-life may offer potential to prolong the onset of the 
disease. 
 
3) Moreover, resilience factors need to be considered in the general conception of the disease. 
The results of publication III suggest that the consistently reported relationship between tau 
pathology aggregation and neuronal dysfunction differs depending on the level of education. 
This is in line with other findings suggesting a slowing in pathophysiological processes at 
higher levels of resilience (Landau et al., 2012; Brown et al., 2013; Wirth et al., 2014). 
Therefore, the currently discussed trajectories for the temporal and spatial evolution of 
Alzheimer’s disease biomarkers should not be considered uniform across patients (as shortly 
discussed in the next chapter).  
Overall, further investigation is necessary to determine direct neuronal mechanisms of 
resilience and resistance. Multimodal approaches including neuroimaging in combination with 
genetic and epigenetic screenings and lifestyle assessments will provide novel insights in this 
regard. In particular, the investigation of individuals who show exceptional cognitive 
performance and lower than expected brain pathology will be essential as these individuals 
  
42 
 
must obtain mechanisms allowing them to become so-called super-agers. Indeed, lower DNA 
damage, high genomic stability, telomere maintenance has been observed in these individuals 
(Wagner et al., 2018). Interestingly, also lower frequencies of tau tangles were found in super 
agers when compared to typical agers in a histopathological study (Gefen et al., 2015). Hence, 
super-agers represent a model of successful aging as they have avoided or postponed age-
related diseases. In contrast, patients with Alzheimer’s disease represent the model for 
unsuccessful and unhealthy aging. Comparison of both extremes (i.e., super-aging and 
Alzheimer’s disease) with a multimodal approach may thus provide information on underlying 
mechanisms preventing or fostering the accumulation of aging-related damage in healthy aging 
and disease. Overall, identified factors such as for example epigenetic modifications may 
thereby be harnessed in therapeutic interventions that may not only be relevant for Alzheimer’s 
disease, but other aging-related diseases such as vascular diseases or other forms of dementia. 
Resilience mechanisms prompt refinement of current model of Alzheimer’s 
disease biomarkers 
In terms of explaining the results of publication II and III, the focus was put on the current 
framework of resistance vs. resilience introduced by Arenaza-Urquijo & Vemuri in 2018 as it 
comprehensively summarizes the common terms used in this field of research (Arenaza-Urquijo 
and Vemuri, 2018). In the past months, recent discussions have come up arguing for and against 
a revision of terminologies in the field of resilience such as the introduction of the term 
‘neurocognitive reserve’ instead of ‘cognitive and brain reserve’ (Cabeza et al., 2018, 2019; 
Stern et al., 2019). While a consistent and well-defined nomenclature is important for study 
designs and interpretation of results and mechanisms, it is even more important to address the 
implications of the studies’ findings concerning the conception of the disease, namely 
identifying factors that prevent from or modulate the course of Alzheimer’s disease. As 
elucidated above, more and more progress has been made in this regard. Consideration of these 
factors has among other things led to revision of the well-established model of Alzheimer’s 
disease biomarkers (Jack Jr et al., 2013). However, the accumulating body of evidence on 
resilience prompts for further refinement of this current model. Dichotomizing individuals into 
low- and high-risk groups based on the extent of pathophysiological changes may not be 
sufficient given that the temporal and spatial evolution of Alzheimer’s disease biomarkers and 
the disease trajectories may differ depending on the resilience capacity an individual possesses.  
In Figure 9, a hypothetical model of the temporal evolution of Alzheimer’s disease and the 
disease course for individuals with low and high resilience is depicted. According to this model, 
there exists a temporal delay in individuals with high resilience concerning the initial 
accumulation of amyloid and tau pathology, and subsequent neuronal dysfunction. Moreover, 
the temporal association between tau pathology and neuronal dysfunction is closer at lower 
levels of resilience. Importantly, at the point of initial symptom occurrence, individuals with 
high resilience show more brain pathology than individuals with lower levels of resilience. 
Consequently, the prodromal phase is longer at high levels of resilience. But from the point of 
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diagnosis individuals with high resilience tend to decline more rapidly. This accelerated 
deterioration is likely due to greater pathological burden at the point of diagnosis.  
Notably, this hypothetical model is based on the current body of evidence concerning resilience 
mechanisms mostly evaluated in cross-sectional designs and based on educational attainment 
levels. Moreover, the term “resilience” is used to encompass various mechanisms contributing 
to the slowing of pathology build-up (i.e., resistance), its effects on neuronal function and 
cognition. Longitudinal approaches are certainly necessary to underpin the assumptions of this 
model. Nonetheless, it may provoke discussions concerning the currently tested model of 
Alzheimer’s disease biomarkers. These discussions may overall refine the current conception 
of the disease, lead to the development of diagnostic tests for the early diagnosis of individuals 
with high resilience and potentially foster novel research ideas and approaches. Furthermore, it 
may lead to the establishment of more precise measures of resilience in contrast to the currently 
used surrogate measures such as education. 
 
 
 
 
Figure 9 – Hypothetical model on the evolution of Alzheimer’s disease biomarkers based on the level of 
resilience. At high levels of resilience, the onset of pathophysiological processes of Alzheimer’s disease is 
temporally delayed and slowed down including a longer prodromal phase in comparison to individuals with low 
resilience. Moreover, the temporal relationship between tau pathology and neuronal dysfunction is less close at 
higher levels of resilience. At the point of initial symptom occurrence, individuals with high resilience show 
greater levels of amyloid ȕ and tau pathology, a faster disease progression and cognitive decline. MCI = mild 
cognitive impairment. 
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From education towards a more direct measure of resilience 
In the discussed studies of publication II and III, we employed education as surrogate marker 
of resilience like numerous other studies on resilience. However, education only represents an 
indirect measure of resilience, which is influenced by several other lifetime factors. In addition, 
considering that in the younger generations more and more individuals tend to graduate at 
higher levels of education as compared to the older generations, education may become a less 
meaningful surrogate measure in the future. Aside from this, it was recently reported that 
general cognitive ability measured early in life was a better predictor of late-life cognition than 
education (Kremen et al., 2019). Nonetheless, early lifetime factors such as education or general 
IQ are static and are based on one single value measured at a single point in time. They may 
thus not capture the entire picture and are less dynamic. Therefore, a residual approach has 
recently been introduced. This approach considers the variance in cognition that is not explained 
by demographic and brain predictors such as grey matter volume or pathology burden as 
measure of CR (see Figure 10A) (Stern et al., 2018a). To measure BR, the variance in grey 
matter volume that is not explained by demographic and brain pathology needs to be derived 
when using the residual method (see Figure 10B). Studies employing this approach so far 
showed a close association between derived CR residuals and changes in network  integrity 
(Lee et al., 2019) and the level of education (van Loenhoud et al., 2017; Lee et al., 2019). 
Moreover, the residual approach has been suggested to be more dynamic in terms of change 
over time as it allows the continuous quantification of resilience at different disease stages 
(Arenaza-Urquijo and Vemuri, 2018). In line with this, recent studies demonstrated that the 
residuals derived from different time points were better predictors for cognitive deterioration 
and disease progression over time than education (Reed et al., 2010; Zahodne et al., 2015; van 
Loenhoud et al., 2017).  
In a subproject of this thesis, we employed this approach to investigate whether residuals 
derived from amyloid PET and cognitive variables are associated with years of education and 
changes in intrinsic connectivity based on resting-state fMRI (Appendix – Abstract A2, page 
65). By means of this approach we aimed to identify a neuronal correlate of CR. The results 
yielded a relationship between the CR residuals and education. More importantly, we found an 
association between the CR residuals and regional upregulation in intrinsic connectivity of the 
right hippocampus in preclinical and clinical phases of Alzheimer’s disease. The positive 
correlation between the residuals and intrinsic connectivity of the right hippocampus was 
stronger in the early Alzheimer’s disease group than the amyloid-positive cognitively normal 
group, indicating that the early Alzheimer’s disease patients have a higher need for CR. The 
results suggest that cognition may be maintained by upregulations of this area, representing a 
potential CR support mechanism.  
Taken together, the accumulating body of evidence signifies that the residual approach could 
be used to study resilience mechanisms more directly and dynamically than when using 
education as proxy (Stern et al., 2018a). However, it contains a major drawback, namely that it 
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is primarily based on the error that is not explained by the model (Arenaza-Urquijo and Vemuri, 
2018). To increase the predictive power of the residuals, numerous variables need to be included 
and there is no proof that these variables can sufficiently explain the relationship of interest. 
Poorly defined models may therefore result in noisy residuals that are not associated with 
resilience, but other factors that had not been considered. Moreover, caution needs to be taken 
when modelling certain relationships and deriving the residuals from them since these 
associations may not be purely linear, but of exponential or cubic nature. In our preliminary 
study, we therefore performed a model fit to address at least this issue of the residual approach 
and used the best fit to derive the residuals. 
Despite these disadvantages, the current evidence suggests that the residual approach can be 
used to measure resilience-related mechanisms. Importantly, with the advances in 
neuroimaging, even better measures of resilience can be established. For example, with the 
recent development of PET tracers for the visualization of changes in synaptic density (Chen et 
al., 2018; Finnema et al., 2018), an opportunity is provided to directly investigate BR 
mechanisms. Moreover, recent fMRI studies have determined a task-invariant covariance 
network (Stern et al., 2018b). The activation or deactivation of this network during a task may 
represent a direct measure of CR according to the authors (Stern et al., 2018b). Overall, 
employment of brain imaging methods will facilitate better knowledge on potential mechanisms 
contributing to resilience to Alzheimer’s disease and provide better means of quantifying 
resilience in comparison to the currently available surrogate measures. 
 
A) B) 
 
 
Figure 10 – Illustration of the residual approach for the quantification of cognitive and brain reserve. A) 
Residuals represent the variance in cognition that is not explained by the neuropathological burden. Residuals 
above the slope relate to better than predicted cognitive performance (i.e., high cognitive reserve, dark blue) 
and residuals below the slope indicate lower than expected cognitive performance (i.e., low cognitive reserve, 
light blue). B) Residuals represent the variance in brain volume that is not explained by the neuropathological 
burden. Residuals above the slope indicate relative maintenance of brain volume at a given level of 
neuropathological burden (i.e., high brain reserve, dark green), while residuals below the slope indicate 
greater volume loss than predicted (i.e., low brain reserve, light green). CR = cognitive reserve; BR = brain 
reserve. 
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LIMITATIONS 
A few general methodological limitations and caveats should be considered regarding the 
discussion of the results of publication I-III. 
First generation tau PET tracers 
First, all three publications included the data analysis of the first-generation tau PET tracer 
[18F]-AV-1451. Although this tracer was reported to show high affinity for Alzheimer’s disease 
tauopathy in form of 3R/4R tau (Marquié et al., 2015), off-target binding to subcortical 
structures, especially in the basal ganglia has consistently been observed in healthy controls and 
Alzheimer’s disease patients. This off-target potential is not only observed in case of [18F]-AV-
1451, but all current first-generation tau PET tracers (Chiotis et al., 2018b). A potential binding 
site may represent monoamine oxidase (MAO) A and B activity (Lemoine et al., 2017; Saint-
Aubert et al., 2017), but results have so far been inconsistent (Xia et al., 2013; Hansen et al., 
2018). Despite off-target binding to these subcortical regions, also vascular structures such as 
the choroid plexus and the dural venous sinuses are affected (Marquié et al., 2015; Lowe et al., 
2016). Given the close proximity of the choroid plexus to the hippocampus, spill-over effects 
might bias the quantification of tracer retention in the hippocampus (Lemoine et al., 2018). 
Therefore, partial volume corrections are recommended when considering this region in 
analyses. In our studies, we carefully inspected each image to rule out significant off-target 
signal in this area and signal retention in the hippocampus was considered with caution. In 
addition to this caveat, off-target binding in the dural venous sinuses may lead to an 
underestimation of the tracer retention in cortical regions given its close location to the 
cerebellum, which is commonly used as reference region (Lemoine et al., 2018). Despite the 
limitations of this tracer, in vitro and in vivo evidence exists demonstrating binding of [18F]-
AV-1451 to paired helical filaments containing tau (Smith et al., 2016). Moreover, currently 
available studies on tau PET suggest that these tracers coincide with the regional distribution 
of tau pathology in Alzheimer’s disease as determined by histopathological studies (Schöll et 
al., 2016; Schwarz et al., 2016). Also, in publication II of this study, we observed tracer binding 
that resembled the neuropathological Braak stages. It remains to be elucidated, which factors 
cause the off-target binding of the first-generation tau PET tracers. The recent introduction of 
second-generation tau PET tracers, which show lower off-target binding to subcortical 
structures, may provide better means to quantify tau pathology in Alzheimer’s disease and other 
tauopathies. Nonetheless, further comparisons are necessary to determine whether these novel 
tracers are superior to the first-generation tracers. 
Current lack of longitudinal tau PET studies 
Given the novelty of tau PET imaging, most studies including ours are restricted to the analysis 
of cross-sectional data. Thus, no interferences can be drawn regarding the spread of tau 
pathology along functional networks as well as how this spread is modulated by resilience 
  
47 
 
mechanisms over time. So far, first longitudinal studies demonstrated that tau pathology arises 
uniformly in certain regions of the brain outside the medial temporal lobe (Jack Jr et al., 2018b). 
Moreover, a time lag was observed between tau pathology aggregation and changes in neuronal 
function confirming the current model of Alzheimer’s disease biomarkers (Chiotis et al., 
2018a). But these longitudinal studies are currently limited to follow-up assessments of 1 to 1.5 
years. Therefore, the effect of change over time may be relatively small. Despite this, 
longitudinal tau PET may potentially be used in the evaluation of drug efficacy, although 
currently available tracers may not be sufficient for the determination of the earliest 
accumulation of tau pathology such as abnormal phosphorylation of tau (Hansson and 
Mormino, 2018). Moreover, the methodology of tau PET needs to be further assessed, in 
particular regarding the processing of longitudinal data including the determination of 
appropriate reference regions and methods for partial volume effects (Southekal et al., 2018). 
Given the availability of tau PET compounds for more than five years now, it is expected that 
more longitudinal studies with longer follow-up periods will soon be conducted allowing for a 
better understanding of the intracerebral progression of tau pathology and the methodological 
caveats associated with longitudinal tau PET. Moreover, future tau PET imaging studies with 
longitudinal designs will allow to investigate whether tau pathology is triggered, accelerated or 
independent of amyloid ȕ accumulation (Villemagne et al., 2017) and how resilience influences 
the progression of tau pathology over time. 
Proxies of resilience 
Finally, regarding the investigation of resilience mechanisms, we employed the indirect 
measure of educational attainment as proxy for resilience, which is correlated with other 
lifestyle factors rendering the investigation of the sole contribution of education to late-life 
effects difficult. To gain further insights into lifestyle factors associated with resilience, more 
elaborate information on lifetime experience such as physical activity or nutrition needs to be 
gathered. By means of this, specific lifestyle components could be extracted and set in relation 
to a distinct resilience mechanism. Potentially, physical activity is more closely associated with 
better vascular systems or neurogenesis factors, whereas education or lifetime cognitive 
stimulation is more closely associated with adaptations of network structures and functions. 
Moreover, most studies have, so far, mainly focused on the maintenance of cognitive function 
and less studies have focused on the actual underlying brain mechanisms such as changes in 
neuronal plasticity. The use of the residual approach in a different way as it has previously been 
used, may yield novel insights into resilience based on brain measurements. Hence, instead of 
taking cognitive function as the dependent variable, one may instead examine a distinct brain 
measurement such as synaptic density and test which factors are associated with maintenance 
of this measurement. Overall, with the advancements in the research field of resilience and 
resistance, the focus will eventually shift from observational studies towards the development 
of intervention therapies and prevention strategies (Arenaza-Urquijo and Vemuri, 2018).  
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CONCLUSION & OUTLOOK  
It is certainly of utmost importance to understand the pathophysiological mechanisms and risk 
factors of a given disease in order to find an effective treatment. In the past decades, researchers 
have continuously accumulated knowledge regarding the underlying mechanisms of 
Alzheimer’s disease. Despite the ever-increasing knowledge of the disease mechanisms, a cure 
has not been found yet. Striving to find the trigger of the disease may be one option in the 
development of effective treatment strategies. Another approach, however, lies in the 
identification of mechanisms that protect against or prolong the detrimental effects of 
neuropathology. The development and use of innovative neuroimaging techniques and the 
advancement of PET tracer development offer new avenues to study the in vivo characteristics 
of Alzheimer’s disease and factors that protect against the progression of the disease, as 
signified by this thesis work. Combination of these neuroimaging techniques with blood-based 
markers, epi-/genetic screenings and neuropsychological testing will provide a better 
understanding of the disease mechanisms and the contribution of resilience factors in the 
conception of the disease. To extend on the current knowledge on Alzheimer’s disease, we are 
therefore collecting data on several lifestyle factors including physical activity, occupation, 
social environment, stress resilience and nutrition and assessing their relation to epigenetic 
changes. In combination with PET imaging, this study may further provide insights into the 
underlying disease mechanisms of Alzheimer’s disease and determine protective molecular 
mechanisms.  
Importantly, the results of thesis and the ongoing study may not only bear crucial implications 
for the treatment of Alzheimer’s disease, but other age-related neurodegenerative diseases, in 
particular, tauopathies. Better understanding of the spreading mechanisms in these diseases will 
permit a more precise prediction of disease progression and will thus be valuable for disease 
monitoring. Moreover, identified resilience mechanisms may potentially be transferable to 
other neurological conditions. Several studies have shown that early lifetime factors such as 
education are associated with protection of performance in the face of brain pathology such as 
in small-vessel disease (Zieren et al., 2013; Pinter et al., 2015), stroke (Nunnari et al., 2014), 
multiple sclerosis (Sumowski et al., 2009; Benedict et al., 2010), fronto-temporal dementia 
(Premi et al., 2013) and Parkinson’s disease (Guzzetti et al., 2016; Hindle et al., 2016). Thus, 
mechanisms associated with resilience may be harnessed for their therapeutic treatment across 
neurological conditions. This will hopefully one day contribute to the development of effective 
disease-modifying treatments.  
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A1.) Abstract I 
Title: Regional susceptibility of the default mode network is associated with clinical 
phenotypes of Alzheimer’s disease (Hönig et al., 2019) 
Authors: Hoenig MC, Bischof GN, Onur ÖA, Jessen F, Fließbach K, Neumaier B, van Eimeren 
T, Drzezga A 
Presented at: Deutsche Gesellschaft für Nuklearmedizin, 2019, Bremen, Germany (talk) 
Background: Alzheimer’s disease (AD) is characterized by heterogeneous clinical phenotypes, 
which present distinct tau-pathology patterns. The posterior default mode network (pDMN) 
seems, however, to be similarly affected by tau-pathology across clinical phenotypes. In this 
study, we investigated whether the tau-peaks in the pDMN of AD variants are associated with 
different functional connectivity networks. 
Methods: We included three age-matched groups: a typical AD group (n=14), a group with the 
logopenic variant (n=6), and a group with posterior cortical atrophy (n=6). For all patients, an 
[18F]AV-1451 scan was available, which was normalized, intensity-standardized to the 
cerebellum, and z-transformed employing a [18F]AV-1451 template of a healthy control 
sample.  Following the z-standardization, one-sample t-tests were performed (p < .0001) for 
each group, respectively, in SPM12. The coordinate of maximum t-value coinciding in the 
pDMN was extracted for each group and used in a seed-based analysis conducted on functional 
imaging data of a healthy control group (FWE corrected). Finally, using the dice similarity 
coefficient, the spatial overlap was computed between the seed-based networks (SBNs), known 
functional connectivity networks, and the thresholded t-maps of the three groups. 
Results: The three seeds were located in middle-superior temporal and parietal regions. The 
AD-derived SBN fairly overlapped with the executive control network (Dice=35%), the PCA-
derived SBN overlapped well with the visuospatial network (Dice=51%), and the SBN of the 
logopenic group coincided with the language network (Dice=24%). The respective SBNs 
poorly-to-fairly overlapped with the group-specific tau-pathology patterns (Dice=9-27%). 
Conclusion: The tau-peak in the pDMN may determine the spread of tau-pathology across 
distinct functional networks, which are associated with clinical phenotypes of AD.  
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A2.) Abstract II 
Title: Hippocampal intrinsic connectivity supports cognitive reserve in amyloid-positive 
cognitively normal subjects and Alzheimer’s disease patients 
Authors: Hoenig MC, Bischof GN, Lopes Alves I, Ahlswede M, Sakagiannis P, Jessen F, 
Schmidt M, Barkhof F, van Eimeren T, Drzezga A for the AMYPAD Consortium 
Presented at: AAIC, 2019, L.A., USA (poster presentation) 
Background: Cognitive reserve (CR) accounts for maintaining functionality despite brain 
pathology. Recently, a residual approach was introduced as a more specific measure of CR. 
This approach considers the variance in cognition not being explained by demographic and 
neuroimaging predictors as CR measure. Here, we aimed to determine a functional neuronal 
correlate of CR from resting-state functional MRI (rs-fMRI). 
Methods: 103 cognitively normal subjects (mean age 72.01 ± 5.98) and 36 early amyloid-
positive Alzheimer’s disease (AD) patients (74.08 ± 7.33) were included, for whom 
neuropsychological data, an amyloid PET, and a rs-fMRI scan were available at the Open 
Access Series of Imaging Studies (OASIS; https://www.oasis-brains.org/). Information on 
global amyloid load was assessed based on the Freesurfer-ROIs available in OASIS. Cognition 
residuals were computed regressing global amyloid, ApoE status, age and sex onto cognitive 
test performance using an exponential model fit. Positive residuals indicate higher cognitive 
performance than predicted. Intrinsic connectivity (IC) maps were extracted based on the pre-
processed rs-fMRI data using the CONN toolbox. Using general linear modeling in SPM12 (p 
< .0001, uncor.), we first examined the voxel-based association between the individual IC maps 
and the cognition residuals in the early AD group, assuming this group requires a high need for 
reserve. To determine if the identified neuronal CR correlate extends to the preclinical phase of 
AD, we extracted the beta values of IC of the identified neuronal CR correlate in the amyloid-
positive cognitively normal group (SUVR > 1.1., n=57) and examined the relationship between 
cognition residuals and IC. 
Results: Only increased IC in the right hippocampus was associated with higher residuals in 
the early AD group. In the amyloid-positive cognitively normal group, the IC in this area was 
also correlated with greater residuals (r=.34, p<.05). The effect of the neuronal correlate and 
the residuals was stronger in the AD group when comparing both groups in terms of their 
correlation strengths. 
Conclusion: The findings indicate that intrinsic hippocampal connectivity might contribute to 
CR seen in both preclinical and clinical phases of AD. Moreover, the residual approach proves 
to be sensitive to compensatory effects of IC in the face of AD-pathology. 
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Abstract 
A stereotypical anatomical propagation of tau pathology has been described in Alzheimer’s 
disease. According to recent concepts (network degeneration hypothesis), this propagation is 
thought to be indicative of misfolded tau proteins possibly spreading along functional networks. 
If true, tau pathology accumulation should correlate in functionally connected brain regions. 
Therefore, we examined whether independent components could be identified in the 
distribution pattern of in vivo tau pathology and whether these components correspond with 
specific functional connectivity networks. 22 [18F]AV-1451 PET scans of patients with 
amnestic Alzheimer’s disease (M(Age)= 66.00 ± 7.22 years, 14M/8F) were spatially 
normalized, intensity standardized to the cerebellum, and z-transformed using the mean and 
deviation image of a healthy control sample to assess Alzheimer’s disease-related tau 
pathology. First, to detect distinct tau pathology networks, the deviation maps were subjected 
to an independent component analysis. Second, to investigate if regions of high tau burden are 
associated with functional connectivity networks, we extracted the region with the maximum 
z-value in each of the generated tau pathology networks and used them as seeds in a subsequent 
resting-state functional MRI analysis, conducted in a group of healthy adults (n=26) who were 
part of the 1000 Functional Connectomes Project. Third, to examine if tau pathology co-
localizes with functional connectivity networks, we quantified the spatial overlap between the 
seed-based networks and the corresponding tau pathology network by calculating the dice 
similarity coefficient. Additionally, we assessed if the tau-dependent seed-based networks 
correspond with known functional resting-state networks. Finally, we examined the relevance 
of the identified components in regard to the neuropathological Braak stages. We identified 10 
independently coherent tau pathology networks with the majority showing a symmetrical bi-
hemispheric expansion and coinciding with highly functionally connected brain regions such 
as the precuneus and cingulate cortex. A fair to moderate overlap was observed between the tau 
pathology networks and corresponding seed-based networks (Dice range: 0.13-0.57), which in 
turn resembled known resting-state networks, particularly the default mode network (Dice 
range: 0.42-0.56). Moreover, greater tau burden in the tau pathology networks was associated 
with more advanced Braak stages. Using the data-driven approach of an independent 
component analysis, we observed a set of independently coherent tau pathology networks in 
Alzheimer’s disease which were associated with disease progression and coincided with 
functional networks previously reported to be impaired in Alzheimer’s disease. Together, our 
results provide novel information regarding the impact of tau pathology networks on the 
mechanistic pathway of Alzheimer’s disease.  
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Keywords: Tau pathology networks, PET, independent component analysis, resting-state 
networks. 
Abbreviations 
Aβ - amyloid beta 
CSF - cerebrospinal fluid 
DMN – default mode network 
DSC – dice similarity coefficient 
ICA – independent component analysis 
ROI – region of interest 
rs-fMRI – resting-state functional MRI 
TPN – tau pathology network 
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Introduction 
Alzheimer’s disease is characterized by two neuropathological hallmarks, i.e., the 
accumulation of extracellular β-amyloid (Aβ) plaques and the intracellular aggregation of 
misfolded tau proteins in form of neurofibrillary tangles. Aβ pathology initially spreads across 
neo- and allocortical brain regions and only propagates downstream to the brainstem in late 
stages of the disease (Thal et al., 2002), whereas tau pathology first occurs in the locus coeruleus 
and the entorhinal cortex from where it expands upstream to limbic and isocortical regions 
(Braak and Braak, 1991; Braak and Braak, 1995). Several hypotheses have been suggested to 
explain the spreading and distribution of these pathologies across the brain. One prominent 
proposal is the network degeneration hypothesis, which postulates that neurodegenerative 
disease pathologies expand along functional networks, consequently leading to failure of these 
networks (Palop et al., 2006; Seeley et al., 2009). Network dysfunction then in turn likely 
provokes clinical symptomatology. In the past decade, multimodal imaging studies have 
provided compelling evidence in support of the network degeneration hypothesis: A spatial 
overlap between the deposition of Aβ plaques and neuronal networks, in particular the default 
mode network (DMN), has been reported (Buckner et al., 2005; Buckner et al., 2009; Grothe 
and Teipel, 2016; Jones et al., 2016). Similar results were obtained when investigating the 
convergence between Alzheimer’s disease-related grey matter volume reduction and large-
scale networks (Seeley et al., 2009). Furthermore, it was suggested that elevated Aβ deposition 
in regions of the DMN in asymptomatic cognitively normal individuals could serve as an 
indicator of incipient Alzheimer’s disease (Sperling et al., 2009). So far, it remains unknown 
whether tau pathology similarly expands along functional networks as the visualization of tau 
pathology in vivo has only recently become available. However, the stereotypical anatomical 
distribution pattern of tau pathology is indicative of misfolded tau proteins spreading 
throughout interconnected regions (Clavaguera et al., 2009). This assumption is supported by 
recent findings from studies in rodent models of early Alzheimer’s disease proposing that 
neurofibrillary tangles may exhibit prion-like properties (Clavaguera et al., 2009; de Calignon 
et al., 2012; Liu et al., 2012). These properties may foster the spreading of tau pathology 
through axons and across synapses to other neurons, potentially consecutively affecting 
connected brain regions and eventually leading to severe neurodegeneration that causes 
cognitive impairment. 
With the development of PET ligands for the visualization of tau depositions, disease-
specific distribution patterns of tau pathology can now be detected and studied in humans in 
vivo. The radioactive tracer [18F]AV-1451 appears especially useful for the visualization of 
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separate patterns of tau pathology distribution within the Alzheimer’s disease spectrum 
(Ossenkoppele et al., 2016; Dronse et al., 2017), and across different tauopathies (Passamonti 
et al., 2017). In order to assess distinct pathways of Alzheimer’s disease-related tau pathology 
based on [18F]AV-1451 PET imaging data, the multivariate approach of an independent 
component analysis (ICA) may represent a particularly well-suited tool. ICA is a blind source 
separation technique used to establish common features within a given dataset by decomposing 
the data into independent patterns (McKeown et al., 2003). ICA is based on a whole-brain data-
driven approach that is not limited to a set of pre-defined regions of interest (Fan et al., 2008). 
Even though ICA has often been used to study properties of brain networks based on functional 
MRI (fMRI) data (Calhoun and Adali, 2012), several studies also confirmed the utility of ICA 
for the analysis of PET data (Illán et al., 2011; Di et al., 2012; Toussaint et al., 2012; Shaffer 
et al., 2013; Yakushev et al., 2013; Savio et al., 2017). For example, ICA identified distinct 
metabolic networks in [18F]Fluorodeoxyglucose- PET scans, which resembled known resting-
state functional connectivity networks (Di et al., 2012; Yakushev et al., 2013; Savio et al., 
2017).  
Using ICA within the realm of structural or functional brain imaging analyses, regions 
within an independent component can be inferred to be spatially correlated either through 
structural or functional connections (Cohen et al., 2008; Di et al., 2012). However, the detection 
of independent components in PET imaging data does not necessarily allow drawing 
conclusions about the functional or structural connections of the associated brain regions within 
a given independent components. Consequently, systematic comparison of such components 
with information on existing functional or structural networks is required. 
Here, in order to gain insights into the mechanistic pathways of tau pathology and to 
identify independent tau pathology networks (TPNs), we employed an ICA approach on 
[18F]AV-1451 tau-PET imaging data of 22 patients with mild to moderate amnestic Alzheimer’s 
disease. Subsequently, we systematically assessed the relationships between the identified 
TPNs and the functional network architecture of the brain. For this purpose, we first extracted 
the region of maximum tau deposition from each of the generated TPNs. Next, we employed 
these regions as seeds for a seed-based resting-state fMRI (rs-fMRI) analysis in a group of 
healthy control subjects (derived from the 1000 Functional Connectomes Project). The seed-
based networks were established to identify regions of strongest connections to the seed of tau 
pathology of a given TPN. We assessed the spatial conformity of these (tau-dependent) 
functional connectivity networks with the detected TPNs as well as with established functional 
resting-state networks (Shirer et al., 2012). Finally, we assessed whether higher tau burden in 
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the identified TPNs was associated with a more advanced Braak stage as well as global 
cognitive dysfunction as assessed by the Mini Mental State Examination (MMSE). We 
hypothesized that the ICA would yield TPNs that coincide with functionally connected 
networks resembling known resting-state networks, such as the DMN. Moreover, we assumed 
that increased tau burden within distinct TPNs would be associated with a more advanced Braak 
stage and negatively correlate with global cognitive function. 
 
Materials & Methods 
Participants 
We included 22 patients with typical amnestic Alzheimer’s disease (Table 1) who were 
diagnosed with probable Alzheimer’s disease dementia according to the recommended NIA-
AA guidelines (McKhann et al., 2011) and based on the results of diagnostic PET imaging and 
cerebrospinal fluid (CSF) measurements. Out of the 22 patients, 16 patients were amyloid 
positive (based upon their amyloid PET scan). In addition, three patients were amyloid positive 
based upon the assessment of their CSF. In the remaining three patients, diagnosis of 
Alzheimer’s disease was established without assessment of amyloid status, based on the NIA-
AA guidelines. All patients underwent an [18F]AV-1451 PET scan as part of their clinical 
evaluation in the Department of Nuclear Medicine at the University Hospital Cologne, 
Germany, and gave informed consent for the scientific evaluation and publication of their data. 
Key inclusion criteria for the patient sample were: 1) diagnosis of probable typical Alzheimer’s 
disease according to the NIA-AA criteria, 2) age range: >55 ≤ 80, and 3) evaluable [18F]AV-
1451 scan. The study was performed according to the Declaration of Helsinki and was in 
compliance with the requirements of the ethics board of the Faculty of Medicine at the 
University of Cologne and of the responsible local regulatory authorities. 
Characteristic Mean ± SD Min Max 
Age 66.00 ± 7.22 55 75 
Education 13.80 ± 3.11 8 18 
MMSE 24.45 ± 4.38 15 30 
Sex M=14; F=8   
Race Caucasian   
Table 1 – Demographic characteristics. The range and average age 
in years, years of education, level of cognitive dysfunction as 
assessed by the MMSE, sex distribution, and race are listed in this 
table. SD = Standard deviation; M = Male; F=Female; MMSE = 
Mini Mental State Examination. 
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PET data 
The PET scans were collected from a PET-CT Siemens Biograph mCT Flow 128 Edge 
(Siemens, Knoxville, TN). A low dose transmission scan was performed with CT for 
attenuation correction prior to the beginning of the PET scanning. PET scans were acquired in 
list mode (15 minutes) 90 minutes after an intravenous injection of a mean dose of 230 MBq of 
[18F]AV-1451. The scans were iteratively reconstructed using a 3D OSEM algorithm of four 
iterations and 12 subsets, and were smoothed with a Gaussian filter of 5 mm FWHM on a 
128x128 matrix. 
 
Rs-fMRI data 
To identify functional networks in a group of healthy adults, we employed the publically 
available rs-fMRI dataset by Berlin-Margulies (Rohr et al., 2013), which is part of the 1000 
Functional Connectomes Project (http://www.nitrc.org/frs/?group_id=296). The dataset 
included 26 healthy controls (13M/13F) aged between 23 and 44 years (M(Age)=29.77 ± 5.21 
years). The rs-fMRIs were acquired on a 3T Trio Tim Siemens Magnetom (Siemens, Erlangen, 
Germany). The scanning protocol was as follows: repeat time (TR) = 2300 ms, echo time (TE) 
= 30 ms, time points =195, slice number= 34, flip angle = 90°, voxel size = 3x3x4 mm3, field 
of view (FOV) = 192 x 192. 
 
PET image preprocessing 
The [18F]AV-1451 PET scans were preprocessed using Statistical Parametric Mapping 
(SPM) version 8 (Wellcome Trust Centre for Neuroimaging, Institute of Neurology, University 
College London). The images were spatially normalized to a tau template of a healthy control 
group. This template was previously established by our group based on a dataset of [18F]AV-
1451 PET scans from 19 healthy controls (M(Age)=56.63 ± 16.65 years) provided by Avid 
Radiopharmaceuticals, Inc, Philadelphia (Bischof et al., 2016; Hammes et al., 2017). The 
normalized PET scans were smoothed using a Gaussian filter of 12 mm FWHM. Using the 
whole cerebellum as reference region, standard uptake value ratios (SUVRs) images were 
computed utilizing in house scripts in MATLAB R2016a (The MathWorks, Inc., Natick, MA, 
USA). To assess specific Alzheimer’s disease-related tau pathology patterns, images were z-
transformed using the mean and deviation image from a healthy control sample. A detailed 
description of the sample and z-transformation can be found elsewhere (Bischof et al. 2016). 
The generated z-transformed images were then subjected to an ICA. 
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Rs- fMRI image preprocessing 
The rs-fMRI dataset was pre-processed using the pipeline of the Data Processing 
Assistant for Resting-State fMRI (DPARSF) toolbox, version 4.3 (Yan and Zang, 2010). The 
pipeline consists of the following steps:  
Initially, the first 10 time points of each subject were removed and the remaining slices 
were processed with slice timing. Second, nuisance variables were regressed including white 
matter, CSF, and global mean signal. To control for head motion, the Friston 24 parameter 
model was applied (Friston et al., 1996). Third, the realigned images were normalized to the 
default EPI template provided by the DPARSF toolbox. In a final step, the images were 
smoothed with a Gaussian filter of 8 mm. All pre-processed images were visually checked to 
assure that the normalization process had not resulted in distorted images. The pre-processed 
images were then used for the seed-based functional connectivity analysis. 
 
Statistical Analysis 
Independent component analysis 
To identify independently coherent TPNs, we performed an ICA on the z-standardized tau-
PET images using the group ICA function of the fMRI Toolbox (GIFT toolbox, version 4.0a, 
2015; MIALAB, The Mind Research Network, University of New Mexico, Albuquerque, NM, 
USA). To avoid overfitting of the data based on the given number of input images and to create 
meaningful orthogonal components, the default setting of 20 components was reduced to 10 
components (Särelä and Vigário, 2003). We then applied the Infomax algorithm implemented 
in the GIFT toolbox to extract common tau pathology features from the PET dataset.  
To support our ICA approach and in order to evaluate the possible influence of confounding 
factors that might bias the results, we performed a series of additional analyses: We ran the ICA 
with different numbers of allowed components (5 and 20 components), with a different 
Gaussian kernel (8mm instead of 12mm), and, in addition, an ICA including only scans from 
patients who were amyloid positive on their amyloid PET scan (n=16). Moreover, we conducted 
a conventional SPM t-test to identify peaks of tau pathology. For this, we compared the 
Alzheimer’s disease group against a group of healthy controls (n=19) using a voxel-based 
independent t-test. The identified peaks of tau pathology were employed as seeds in a following 
seed-based fMRI analysis. 
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Seed-based functional connectivity analysis 
 To assess if regions of high tau burden are involved in functional connectivity networks, 
we conducted a seed-based analysis using the pre-processed rs-fMRI dataset by Berlin-
Margulies (Rohr et al., 2013). As seeds for the functional connectivity analysis, we extracted 
the coordinate of the maximal peak z-score from each generated TPN. The seeds of maximum 
tau burden were each defined as a sphere centered at the respective peak coordinate with a 
radius of 5 mm. Given that we allowed 10 components to be generated by the ICA, we obtained 
10 tau-dependent seeds, which were submitted to the functional connectivity analysis using the 
DPARSF toolbox.  
Following the pipeline of the DPARSF toolbox for the functional connectivity analysis, 
the motion parameters, white matter, CSF, and global mean signal were regressed out. Next, 
the images were band pass filtered at 0.01-0.1 Hz. In order to reduce the number of comparisons 
for the connectivity analysis conducted in SPM 12, we included a grey matter mask. Then, the 
correlation of the rs-fMRI time series between the respective seed and coherently active regions 
were computed for each subject yielding individual functional connectivity maps for each seed. 
In a last step, we conducted one-sample t-tests in SPM 12 (FWE, p < .05) comprising the 
individual functional connectivity maps for each seed. Age and gender were included as 
covariates. The SPM analyses yielded the respective functional connectivity maps for each 
seed. 
 
Evaluation of spatial overlap: Dice Similarity Coefficient 
To examine the overlap between the TPNs and the corresponding tau-dependent seed-
based networks, we next calculated the Dice Similarity Coefficient (DSC). The DSC is a 
measure that quantifies the spatial overlap between two binarized maps and is calculated as 
follows: DSC = 2��(�௫+ �௬) 
where �� denotes the volume intersection between the image volume �௫ and �௬, which is 
divided by the sum of the respective image volumes �௫ and �௬. The DSC thereby yields the 
percentagewise overlap between two maps/networks. It is interpreted as follows: <0.2 reflects 
poor, 0.2-0.4 fair, 0.4-0.6 moderate, 0.6-0.8 good, and > 0.8 near complete overlap (Savio et 
al., 2017). 
In order to calculate the DSC, we first binarized the generated t-maps of the seed-based 
networks. Next, the generated TPNs were binarized at a z-score of z > 2.0. We then compared 
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the spatial overlap between the TPNs and the corresponding seed-based networks. Furthermore, 
to characterize the topography of the seed-based networks, we compared these networks with 
previously established functional connectivity networks obtained by a rs-fMRI study in 27 
healthy subjects at the FIND lab of Stanford University (Shirer et al., 2012). The Stanford 
networks consist of 14 networks, including the DMN, salience network and language network, 
and have consistently been used by other studies to characterize resting-state functional 
connectivity networks (Lehmann et al., 2013; Leonardi et al., 2014; Lim et al., 2014). We 
quantitatively compared the spatial overlap of each binarized seed-based network against all 
binarized resting-state networks. The resting-state network with the highest dice coefficient was 
chosen as best match for the seed-based network. 
 
Relation between Braak stages and tau pathology networks (TPNs) 
To examine the association between tau pathology in the respective TPNs and the 
individual Braak stage of each patient, we extracted mean SUVRs for Braak stages I/II-VI for 
each patient based on the region of interest (ROI)-based Braak staging approach previously 
used (Schöll et al., 2016; Hoenig et al., 2017). Moreover, we computed the median SUVR for 
each Braak stage across the patient sample. Patients, who had a mean SUVR greater than the 
median, were determined to be positive for the respective Braak stage, whereas patients who 
had a lower SUVR than the median were classified as negative. The highest positive Braak 
stage was used for final classification. Patients could obtain a score ranging from 2-6 
(corresponding to Braak stage I/II-VI) and were grouped into either an early Braak (score 2-3) 
or advanced Braak group (stage 4-6). Finally, we compared the mean SUVRs of each TPN 
between the early (n=10) and the advanced (n=12) Braak group. We extracted the mean SUVRs 
for the respective components based on the intensity standardized images using the binarized 
component maps. As the assumptions for normality and homoscedasticity were not given, the 
Mann-Whitney-U test was used for comparison. Results were corrected for multiple 
comparison using Bonferroni correction (p* = .005). 
 
Relation between cognitive function and tau burden in tau pathology networks (TPNs) 
We further examined whether tau burden within distinct TPNs was associated with 
global cognitive dysfunction. We used the MMSE as a measure of global cognitive function 
(Folstein et al., 1975). Both, tau burden within each component and global cortical tau was 
quantified based on the individual SUVR images employing the binarized component maps and 
a whole-brain cortical grey matter ROI, respectively. The extracted SUVRs for each component 
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and for global cortical tau burden of each patient were correlated with the individual MMSE 
scores including age and gender as covariates. The analyses were corrected for multiple 
comparisons using Bonferroni correction (p* = .0045). 
 
Results 
Tau pathology networks (TPNs)  
The ICA resulted in the detection of independent TPNs, which spatially resembled 
established language, frontal control, default mode, visuospatial, and hippocampal networks 
(Fig. 1). Some of the TPNs showed a symmetrical bi-hemispheric expansion (Component 2-
4,6,8, & 10), whereas the remaining components were lateralized (Component 1,5,7, & 9). 
Moreover, the TPNs were characterized by varying 
loads of tau pathology (Table 2). The generated TPNs 
coincided with highly functionally connected regions 
predominantly involving parietal and temporal areas. 
The total percent variance explained by all ten 
components was 95.7%. The topographical 
distributions of the TPNs are depicted in blue in Fig. 3. 
The different ICA settings revealed similar 
components confirming the statistical stability of the 
generated TPNs. Importantly, the ICA including only 
amyloid positive patients resulted in similar 
components as the initial ICA (Supplementary Fig. 4). 
Moreover, the conventional SPM approach using a t-
test yielded four peaks of tau pathology, which 
resembled the tau maxima detected by the ICA 
(Supplementary Table 1). Further details of the 
additional analyses can be found in the supplementary 
data. 
 
Tau-dependent seed-based functional networks 
The tau maxima of the respective TPNs used for the seed-based approach corresponded 
to the following regions; temporal middle gyrus, precentral gyrus, precuneus, superior occipital 
region, fusiform gyrus, posterior cingulate cortex, cuneus, frontal medial orbital region, 
superior temporal gyrus and parahippocampal gyrus (Table 3). The seed-based functional 
TPN Mean SUVR (SE) 
1 1.70 (0.09) 
2 1.66 (0.11) 
3 1.57 (0.12) 
4 1.68 (0.90) 
5 1.52 (0.08) 
6 1.71 (0.10) 
7 1.38 (0.07) 
8 1.42 (0.07) 
9 1.59 (0.09) 
10 1.51 (0.04) 
Table 2 – Tau load of independent tau 
pathology networks. Mean SUVR and 
standard error for each tau pathology 
network are provided. TPN = tau 
pathology network; SUVR = standard 
uptake value ratio; SE = standard error. 
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connectivity analysis resulted in specific functional connectivity networks for each tau maxima. 
For several seed-based analyses, the functional networks included remote brain regions which 
were not anatomically adjacent to the corresponding seed region (seed-based networks: 
1,2,6,8,9, & 10). Furthermore, the tau-dependent seed-based networks were characterized by a 
symmetrical bi-hemispheric functional connectivity pattern. The respective projections of the 
seed-based networks are depicted in red in Fig. 3. 
TPN Max Z-Score Coordinates AAL Region 
X Y Z 
1 5.54 -60 -46 0 L Temporal Middle Gyrus (85) 
2 6.53 -48 0 46 L Precentral Gyrus (1) 
3 5.95 8 -52 52 R Precuneus (68) 
4 7.11 28 -68 26 R Superior Occipital Region (50) 
5 8.06 -40 -66 -12 L Fusiform Gyrus (55) 
6 5.10 0 -46 28 L Posterior Cingulate Cortex (35) 
7 5.32 10 -72 24 R Cuneus (46) 
8 3.96 6 50 -6 R Frontal Medial Orbital Region (26) 
9 6.32 58 -48 16 R Superior Temporal Gyrus (82) 
10 3.93 -24 -5 -22 L Parahippocampal Gyrus (39) 
Table 3- Coordinates and z-scores of the tau pathology networks. The maximum z-score and the peak 
coordinates of each tau pathology network with the corresponding brain region based on the automated 
anatomical labeling atlas are listed (Tzourio-Mazoyer et al., 2002). TPN= tau pathology network; Max 
= Maximum; AAL = Automated anatomical labeling atlas; R = Right; L= Left. 
Spatial overlap between distribution of tau pathology and functional networks 
 The comparison between the identified TPNs and the tau-dependent seed-based 
functional connectivity networks yielded moderate spatial overlap (DSC: 0.4-0.6) for 
components 3, 5, and 10 with their corresponding tau-dependent seed-based functional 
networks. In addition, TPN components 1, 4, 7, 8, and 9 were fairly (DSC: 0.2-0.4) associated 
with the corresponding tau-maximum seeded functional network. Only poor overlap (DSC < 
0.2) was found between the seed-based networks and the remaining components (2 & 6). The 
respective DSCs are reported in Table 4A. 
The comparison between the tau-dependent seed-based networks with known resting-
state functional connectivity networks yielded moderate overlap (DSC: 0.4-0.6) for seed-based 
networks 3,4,6,8, & 9, predominantly with regions associated with the ventral and dorsal DMN. 
Moreover, fair overlap (DSC: 0.2-0.4) was observed between the seed-based networks 1,2,5, 
and 7 and the language, the salience, higher visual, and primary visual network. The seed-based 
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network 10 strongly resembled the hippocampal network. As the hippocampal network is not 
part of the predefined Stanford networks, we could not quantitatively assess the actual spatial 
overlap. The respective DSCs are reported in Table 4B. 
Fig. 2 provides an exemplary illustration of the best overlapping TPN, the corresponding 
seed-based network, and the best matching Stanford resting-state network on a rendered brain 
surface. Fig. 3 illustrates the spatial resemblance between the respective components 
(highlighted in blue) and the corresponding seed-based network (highlighted in red) and the 
best-matching Stanford resting-state network (highlighted in green), respectively. This figure 
further includes the DSCs for the quantification of the spatial overlap between the respective 
TPNs and the seed-based networks (first DSC) and between each seed-based network and the 
corresponding Stanford resting-state network (second DSC). 
 
A. DSC for overlap between 
TPN and SBN 
B. DSC for overlap between 
SBN and RSN 
TPN 1 & SBN 1 0.39 SBN1 & Language Network 0.37 
TPN 2 & SBN 2 0.17 SBN 2 & Salience Network 0.28 
TPN 3 & SBN 3 0.57 SBN 3 & Ventral DMN 0.56 
TPN 4 & SBN 4 0.34 SBN 4 & Ventral DMN 0.42 
TPN 5 & SBN 5 0.41 SBN 5 & Higher Visual Network 0.33 
TPN 6 & SBN 6 0.13 SBN 6 & Dorsal DMN 0.51 
TPN 7 & SBN 7 0.36 SBN 7 & Primary Visual Network 0.23 
TPN 8 & SBN 8 0.25 SBN 8 & Dorsal DMN 0.55 
TPN 9 & SBN 9 0.38 SBN 9 & Language Network 0.52 
TPN 10 & SBN 10 0.46 SBN 10 & Hippocampal Network na 
Table 4 – Dice similarity coefficient for the overlap between networks. The table summarizes the 
quantification of the overlap between the tau pathology network and the corresponding seed-based 
network (A) and the seed-based network and best-matching Stanford resting-state network (B). DSC = 
Dice similarity coefficient; TPN = Tau pathology network; SBN = Seed-based network; RSN = Resting-
state network; DMN = Default mode network; na = Not available. 
 
Relationship between Braak stages and tau pathology networks (TPNs) 
The advanced Braak group showed significantly higher SUVRs in eight components 
when compared to the early Braak group (Fig. 4). Mean SUVRs in component 3 and 7 did not 
significantly differ between groups after correcting for multiple comparison (p* = .005), 
although a trend was observed. A summary of the U-statistics can be found in the supplementary 
data (Supplementary Table 2). 
Tau pathology networks in Alzheimer’s disease 
 
 
 
Cognitive function and tau burden in distinct tau pathology networks (TPNs) 
Global cognitive function was negatively correlated with tau burden in components 4 
(r(18)= -.496, p= .026), 5 (r(18)= -.554, p= .011), and 7 (r(18)= -.641, p= .002). A trend 
significant effect was observed for global cognitive function and component 3 (r(18)= -.440, 
p= .052). Global cortical tau burden, assessed based on a cortical gray matter ROI, was not 
negatively correlated with global cognitive function (r(18)= -.305, p= .190). Exclusively, the 
negative association between global cognitive function and tau burden in component 7 survived 
correction for multiple comparison (p* = .0045). The tau maximum of component 7 coincided 
with cuneal regions, whereas the tau maximum of component 3 was located in precuneal areas, 
of component 4 in superior occipital, and of component 5 in fusiform gyral areas. 
 
Discussion 
 In the current study, we identified a set of independently coherent networks of tau 
pathology in a sample of patients with mild to moderate Alzheimer’s disease. This finding 
supports the idea that the aggregation of tau pathology in the brain follows several independent 
pathways and partly develops coherently in different compartments of the brain. The peaks of 
tau within these detected TPNs included, among others, the precuneus, parahippocampus, and 
posterior cingulate cortex, regions known to be involved in various functional networks. In 
accordance with this, the TPNs overlapped distinctly with seed-based functional connectivity 
networks, some of which have previously been reported to be impaired in Alzheimer’s disease, 
including the DMN (Greicius et al., 2004; Zhang et al., 2010; Zhou et al., 2010) and the frontal 
control network (Lehmann et al., 2013; Agosta et al., 2012; Balthazar et al., 2014). Moreover, 
tau burden within the TPNs was associated with the advancement along Braak stages and global 
cognitive dysfunction, indicating that the identified networks may bear clinical relevance. In 
the following, we discuss our findings in the context of (a) distribution of tau pathology along 
independent pathways, (b) the relevance of TPNs in regard to disease progression and cognitive 
profiles, and (c) the relationship of these TPNs with functional connectivity networks. 
 
Properties of independent tau pathology networks 
 Here, we determined a set of distinct TPNs by means of ICA. Some of the TPNs 
involved regions that were not anatomically adjacent. This is per se of interest as it indicates 
that tau pathology does not distribute homogenously across the brain, but importantly 
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propagates across independent pathways and possibly arises synchronously in different brain 
compartments at certain stages of the disease.  
 Interestingly, several TPNs were characterized by a symmetrical distribution pattern 
across hemispheres, whereas some were asymmetric. This characteristic difference in the 
symmetry of the TPNs may be partly attributed to early disease stage, where tau pathology may 
not have advanced to a symmetric pattern across hemispheres within a given network, but has 
centered on the most susceptible regions of tau accumulation. Indeed, according to recent 
models of tau propagation misfolded tau proteins predominantly spread along the most 
interconnected regions of the seed of tau pathology (Fox et al., 2011; Liu et al., 2012; Menkes-
Caspi et al., 2015). Thus, depending on the stage of the disease and the anatomical location of 
the seed of pathology, which may be represented by the tau maxima of each independent 
component, tau distribution patterns may differ in their symmetry. Moreover, the current 
finding of asymmetric components accords with the known fact that neurodegenerative 
disorders may start in one hemisphere and initially spread dominantly across this hemisphere 
before eventually affecting the other hemisphere in later stages of disease (Shi et al., 2009; 
Claassen et al., 2016). In this regard, the implications of employing ICA as an analysis method 
also need to be considered. ICA is a data-driven approach that is based on the underlying tau 
pathology distribution of the patient sample, which in this study consists of patients with mild 
to moderate Alzheimer’s disease. Consequently, component patterns of coherent tau pathology 
can be identified that may be characterized either by an asymmetric distribution pattern, likely 
reflecting earlier stages of the disease, or by symmetric and bi-hemispheric patterns, potentially 
reflecting a more advanced disease stage. ICA hence defines independent regional patterns of 
coherent tau pathology, which do not necessarily have to be symmetric supporting the current 
finding of asymmetric and symmetric component patterns. 
 As discussed above, ICA can determine unique disease-specific and coherent patterns 
of tau pathology without any a priori knowledge or topographic assumptions (Pagani et al., 
2016). This blind source separation technique contrasts conventional voxel-based statistical 
parametric mapping approaches that are often based on a priori hypotheses regarding the 
cortical disease localization and require categorical distinction into significant and non-
significant voxels depending on the intensity values of the voxels. ICA, on opposite, provides 
a more graduated consideration, where significance is not based on severity but regional 
coherence of pathology and thus regional interrelations. Importantly, ICA does thereby not 
exclusively provide components of highest tau pathology, but can also determine regional 
distribution patterns of lower pathology load, which are nevertheless characterized by 
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synchronous tau pathology aggregation. In compliance with this, in the current study the 
conventional SPM approach only yielded four peaks of tau pathology, whereas by means of 
ICA several additional TPNs were established. Importantly, the TPNs identified by ICA were 
characterized by varying loads of tau pathology pointing towards different susceptibility of 
these TPNs potentially depending on the stage of the disease. Intriguingly, the components 
involving orbito-frontal and cuneal areas showed lowest tau burden. These regions are known 
to be affected relatively late in Alzheimer’s disease according to the neuropathological Braak 
stages (Braak and Braak, 1991; Braak and Braak, 1995). Interestingly, when directly assessing 
the relationship between the neuropathological Braak stages and the identified TPNs, we 
observed that individuals in an advanced Braak stage demonstrated higher tau pathology burden 
in the established TPNs as compared to individuals at an earlier Braak stage. This result 
indicates that the accumulation of tau pathology within the identified TPNs may contribute to 
the advancement along Braak stages. Moreover, in the early Braak stage group highest tau 
burden was observed in the TPN associated with the parahippocampus, whereas the advanced 
Braak stage group presented highest tau pathology in the TPN associated with the posterior 
cingulate cortex. This may suggest that distinct TPNs exist as a determinant of each Braak stage. 
Larger data samples of early and advanced Braak stage groups will be required to investigate 
this assumption further. Overall, the current findings suggest that the differential load of tau 
pathology in the independent TPNs may track the expansion of tau pathology at various disease 
stages.  
 In addition to the implications of the TPNs with respect to the neuropathological Braak 
staging, tau pathology within the TPN including cuneal and primary visual areas was also 
associated with decreased global cognitive function. This finding points towards a specific 
deleterious effect as soon as tau pathology strikes visual cortical brain regions (Braak and 
Braak, 1991; Braak and Braak, 1995) underscoring the regional specificity of a tau-cognition 
relationship. Moreover, these findings are consistent with recent findings reporting a 
relationship between cognitive function and regional tau pathology (Brier et al., 2016; 
Ossenkoppele et al., 2016; Shimada et al., 2016). To achieve a more fine-grained 
characterization of distinct cognitive profiles in Alzheimer’s disease, future studies may employ 
an elaborate neuropsychological assessment and examine its correspondence with the TPNs 
identified here. Alternatively, as atypical cases of Alzheimer’s disease such as posterior cortical 
atrophy or the logopenic variant of Alzheimer’s disease express distinct cognitive profiles, 
which are dissociable from amnestic cases, further investigations are warranted that explore 
whether these clinical variants are also characterized by variant-specific TPNs. 
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 Overall, our results provide first evidence of independently coherent tau pathology 
networks, which not only appear to track disease progression but are also, at least in part, relate 
to global cognitive dysfunction. Importantly, these networks of interrelated tau deposition point 
towards brain regions potentially being synchronously affected by tau pathology in the course 
of the disease, providing new insights into the mechanistic pathway of the disease. Given that 
the identified TPNs differed in their topographical distribution and in the degree of tau 
pathology, it will be of great interest to investigate the influence of additional factors on the 
generation of these networks. In particular, a putative synergistic effect of Aβ and tau pathology 
may be of interest with regard to the propagation of tau pathology along the identified networks. 
Moreover, investigating how the cellular, functional, and structural composition underlying 
specific networks influences the propagation of tau pathology and thereby the generation of 
these distinct TPNs will provide further information on the pathophysiological processes 
underlying Alzheimer’s disease. 
 
Relation between independent tau pathology patterns and functional connectivity 
networks 
 Some of the identified TPNs involved anatomically distant regions, indicating that these 
regions may share a joint mechanism, which could be of structural or functional nature and 
which may contribute to the coherent accumulation of tau pathology in these compartments. In 
the current study we focused on the role of seeded functional connectivity in regard to in vivo 
tau distribution patterns for two reasons: First, seed-based connectivity networks include 
regions which show highest connectivity to the seed and thus comply with recent models of tau 
propagation. Second, functional connectivity hubs have been suggested to be most susceptible 
to the development of neuropathology (Buckner et al., 2009; Drzezga et al., 2011; de Haan et 
al., 2012). From these hubs pathology may then spread to connected brain regions (Buckner et 
al., 2009; Drzezga et al., 2011; de Haan et al., 2012). Indeed, a number of studies consistently 
demonstrated striking similarity and overlap of Aβ plaque pathology with functional 
connectivity networks (Buckner et al., 2005; Buckner et al., 2009; Lehmann et al., 2013; Grothe 
and Teipel, 2016). In accordance with this, we observed tau-dependent seed-based functional 
networks, characterized by a symmetrical bi-hemispheric activation, which in part spatially 
corresponded to the established TPNs. 
 Some of the seed-based networks resembled the salience, the primary visual, the higher 
visual, the language, and the hippocampal network indicating that tau pathology does not 
exclusively distribute along one particular network. This finding is in accordance with recently 
provided evidence demonstrating that the Alzheimer’s disease- associated tau pathology pattern 
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corresponds to several cognition-relevant networks (Hansson et al., 2017). Interestingly, the 
majority of tau-dependent seed-based networks established in the current study predominantly 
overlapped with regions of the ventral and dorsal DMN. This suggests that the DMN may be 
particularly susceptible to not only Aβ pathology, as previously shown (Buckner et al., 2005; 
Buckner et al., 2009; Grothe and Teipel, 2016), but also to tau pathology. Note, however, that 
all identified seed-based networks overlapping with the DMN had different origins, suggesting 
that the networks identified in our study may represent subnetworks of a more superordinate 
network. The existence of such subnetworks within a superordinate network has been recently 
proposed (Doucet et al., 2011). These subnetworks may differently be affected depending on 
the stage of the disease and therefore, by using ICA, several components, each with a different 
pathological load, can actually belong to a more superordinate network. Thus, directly 
comparing the spatial overlap between ICA-derived patterns of tau load and an entire resting-
state network such as the DMN may not be an appropriate comparison, as the ICA patterns may 
only reflect subnetworks of the resting-state networks. Therefore, generating seed-based 
functional connectivity networks from the ICA-derived patterns likely allows to more 
accurately compare the functional networks related to tau pathology distribution patterns. 
 Although we observed an overlap between the TPNs, the tau-dependent seed-based 
networks, and known resting-state networks, the overlap was moderate. Several aspects may 
contribute to this moderate spatial correspondence:  
 As the seed-based functional connectivity networks in the current study were defined 
based on a group of healthy young adults, they likely differed from the functional networks 
present in Alzheimer’s disease patients (Jones et al., 2016; Teipel et al., 2016). Following the 
concept of tau propagation, tau pathology may no longer be able to expand along these networks 
due to disease-related disconnection between regions within a given network, changes in the 
location of network hubs, or functional breakdown of the entire network. Thus, the overlap 
between the tau-dependent seed-based networks and the TPNs may have been moderate due to 
disease-related and/or age-related changes in network architecture. Based on the proposed 
prion-like mechanisms of tau, tau pathology may propagate along reorganized networks that 
may differ from the ones identified in the young.  
 Furthermore, although a close link between structural and resting-state functional 
connectivity has been reported (Greicius et al., 2009), functional connectivity maps only 
capture the superficial structure of regions and collapse several sub-regions into one. Given that 
tau pathology appears to follow synaptic connectivity (Clavaguera et al., 2009; de Calignon et 
al., 2012; Liu et al., 2012), the spreading pattern may depend on structural connectivity rather 
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than functional connectivity. It is thus possible that the overlap between structural networks and 
the established TPNs is more coherent. Future multimodal studies using diffusion tensor 
imaging and fMRI are warranted to understand the structural and functional underpinnings 
contributing to the propagation of misfolded tau proteins within neuronal networks. 
 Finally, we only included patients with mild to moderate Alzheimer’s disease in our 
current analyses. Thus, tau pathology in the current patient cohort may just have started to 
spread from the initial seed, thereby rendering the overlap with the corresponding seed-based 
network rather moderate. Longitudinal studies are necessary to assess whether at advanced 
stages of Alzheimer’s disease, the overlap between the TPNs and the corresponding seed-based 
networks becomes more concordant. 
 Despite these arguments, it appears that the functional connections between regions, 
which are characterized by synchronous oscillatory activity, may provide a pathway 
contributing to the propagation of tau pathology within distinct neural networks. Longitudinal 
tau-PET and functional imaging data from the same Alzheimer’s disease cohort will be 
necessary to establish whether the functional coherence between regions acts as an amplifying 
mechanism for tau pathology to spread. 
 
Limitations 
 A few limitations need to be considered when interpreting our results. First, our analysis 
was restricted to a relatively small PET dataset. Studies that include larger patient cohorts are 
needed to confirm that the established TPNs are characteristic for Alzheimer’s disease patients. 
Secondly, it has to be noted that we employed a rs-fMRI dataset of young healthy controls, 
which was used to establish seed-based functional networks associated with the healthy state. 
Using a rs-fMRI data set of age-matched healthy older controls would have allowed us to 
investigate the possible age-related pattern of tau distribution along neural networks. However, 
including an age-matched control sample would have required additional PET or CSF 
measurements to exclude any existing ageing-related pathology, which may have already 
affected (subclinically) network structures. Moreover, we cannot exclude spill-over effects 
from the choroid plexus influencing the signal in hippocampal regions. However, given that 
only one component was associated with hippocampal regions, we believe that the potential 
influence was marginal at most. Finally, we used a cross-sectional approach to assess the 
existence of TPNs and their relation to functional networks. Longitudinal designs may be better 
suited to explore the temporal spread of tau pathology along functionally connected brain 
regions. 
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Conclusion 
The results of this study indicate that in Alzheimer’s disease, the spatial distribution of 
tau pathology is not homogeneous but seems to progress within independent, coherent 
networks. Moreover, tau pathology load in these identified networks is associated with the 
advancement along Braak stages. In addition, the independent, coherent networks were 
characterized by differential distribution patterns, which in turn partially corresponded with 
functional connectivity networks. The relationship between functional connectivity network 
and TPNs may offer new insights into the possible mechanism of tau propagation across brain 
regions. Longitudinal approaches are warranted to further elucidate the temporal spreading 
pattern of tau pathology across large-scale networks, which will provide important information 
on the mechanisms underlying Alzheimer’s disease and may further inform investigation of 
anti-tau based treatment efficacy. 
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Figures 
 
 
Fig. 1 – Illustration of independently coherent tau pathology networks. The respective region 
corresponding to the peak coordinates of each component and the z-score range are depicted 
below each component. The components are projected on the Colin brain in MNI space. Max 
= Maximum. 
 
 
Fig. 2 – Exemplary illustration of the distribution pattern of respective networks. The networks 
are rendered on the inflated Colin brain in MNI space. Blue = Tau pathology network, Red = 
Seed-based network, Green = Ventral default mode network. DMN = Default mode network. 
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Fig. 3 – Illustration of networks and corresponding dice similarity coefficient. The respective 
tau pathology networks are illustrated in blue, the corresponding seed-based networks in red, 
and the best-matching resting-state Stanford network in green. The first dice similarity 
coefficient per cell represents the spatial overlap between the tau pathology network and the 
seed-based network, the second coefficient relates to the overlap between the seed-based and 
the resting- state Stanford network. All networks are projected on the Colin brain in MNI space. 
DSC = Dice similarity coefficient; TPN = Tau pathology network, SBN = Seed-based network; 
DMN = Default mode network. 
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Fig. 4 – Illustration of tau burden in each independent component for the early and advanced 
Braak group. Mean SUVRs and standard error for each component are depicted for the early 
Braak (blue) and advanced Braak (red) group. Significant differences after multiple 
comparison correction are marked with an asterisk. SUVR = Standard uptake value ratio, TPN 
= Tau pathology network. 
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Supplementary Data 
 
Results of confirmatory ICA analyses 
The ICA with the default setting of 20 components revealed 20 components, out of which 
a few resembled the major components obtained in our initial analysis. Some of the remaining 
components were lateralized and occurred separately for the respective hemisphere, while other 
components involved the same region in both hemispheres (Supplementary Fig. 1).  
Reducing the default setting from 20 components to 5 components yielded similar 
components as the initial analysis thereby confirming the statistical stability of the established 
TPNs. The total variance explained by the components was 84.70%, thus lower than the variance 
of the ICA including 10 components (Supplementary Fig. 2).  
Decreasing the smoothing kernel from 12mm FWHM to 8mm FWHM provided similarly 
looking TPNs explaining 95.16% of the variance, additionally supporting the setting of our ICA 
approach (Supplementary Fig. 3).  
Running an ICA with 8 allowed output components only including patients, from who we 
had obtained a positive amyloid PET scan (n=16), yielded similarly looking TPNs 
(Supplementary Fig. 4). 
 
Results of conventional SPM analysis 
We complemented our analyses with a conventional SPM-based approach to identify tau 
maxima as seeds for a seed-based functional connectivity analysis. To extract the tau maxima, we 
employed a voxel-based t-test comparing tau pathology load between the Alzheimer’s disease 
patients and a group of healthy controls (n=19). Thereby, we were able to identify four peaks of 
tau pathology. Interestingly, these maxima (parahippocampus, fusiform gyrus, cuneus, frontal 
middle gyrus) resembled the tau maxima from the independent components detected by the ICA. 
When submitting these four maxima as seeds to a seed-based functional connectivity analysis of 
resting state fMRI data, we obtained similar networks and dice coefficients as produced by the 
initial seed-based analysis based on the independent components (Supplementary Table 1). 
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Seeds Dice for overlap between SBN & RSN 
L Parahippocampus SBN 1 & dDMN  0.40 
R Fusiform Gyrus SBN2 & dMN  0.07 
R Cuneus SBN3 & vDMN  0.61 
R Frontal Middle Gyrus SBN4 & ECN 0.27 
Supplementary Table 1 – Seed regions and overlapping seed-based and resting-state 
networks derived from a conventional SPM-approach. SBN = Seed-based network, RSN 
= Resting-state network, DMN = Default mode network, ECN = Executive control 
network, na = Not available 
 
Results of comparison tau load per component between early and advanced Braak group 
A significant difference between the two groups was observed for 8 components after correcting 
for multiple comparisons (p* = .005). The table below provides the U-statistics of the comparisons. 
Significant differences are marked with an asterisk. 
Component 1 U = 5, p < .001* 
Component 2 U = 3, p < .001* 
Component 3 U = 21, p = .010 
Component 4 U = 8, p = .001* 
Component 5 U = 2, p < .001* 
Component 6 U = 3, p < .001* 
Component 7 U = 17, p = .005 
Component 8 U = 5, p < .001* 
Component 9 U = 2, p < .001* 
Component 10 U = 13, p = .002* 
Supplementary Table 2 – Summary of the U-statistics based on the 
comparison between the early and advanced Braak group. Significant 
differences that survived multiple comparison correction are highlighted 
with an asterisk.  
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Supplementary Fig. 1 – Independent component analysis with the default setting of 20 allowed components. The 
peak coordinates, the brain projection, and the z-score range are depicted for each component.  
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Supplementary Fig. 2 – Independent component analysis with 5 allowed 
components. The peak coordinates, the brain projection, and the z-score range are 
depicted for each component.  
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Supplementary Fig. 3 – Independent component analysis using z-images smoothed 
with a FWHM kernel of 8mm instead of 12mm. The peak coordinates, the brain 
projection, and the z-score range are depicted for each component. 
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Supplementary Fig. 4 – Three exemplary independent components from the 
independent component analysis using z-images of patients with a positive amyloid 
PET scan. The peak coordinates, the brain projection, and the z-score range are 
depicted for each component. 
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a b s t r a c t
Cognitive reserve (CR) is defined as the ability to maintain functionality despite accumulating pathology.
Education has been used as a proxy for CR. For example, by using positron emission tomography imaging,
higher educated Alzheimer’s disease (AD) patients presented increased amyloid b pathology than lower
educated patients despite equal symptomatology. Whether similar associations exist for in vivo tau
pathology remains elusive. We utilized [18F]AV-1451 positron emission tomography imaging to examine
whether high-educated AD patients (n ¼ 12) present more severe tau pathology compared with low-
educated patients (n ¼ 12) despite equal clinical severity in regions of interest corresponding to the
pathologic disease stages defined by Braak & Braak. We report tau pathology in advanced Braak stages
associated with parietal and frontal regions in high-educated AD patients, whereas in low-educated AD
patients tau accumulation is still confined to lower Braak stages associated with temporal and cingulate
regions. Highly educated AD patients seem to be able to tolerate more tau tangle pathology than lower
educated patients with comparable cognitive impairment supporting the cognitive reserve hypothesis.
 2017 Elsevier Inc. All rights reserved.
1. Introduction
Sporadic Alzheimer’s disease (AD) is the most common cause of
dementiawith aworld-wide prevalence of approximately24million
people (Reitz and Mayeux, 2014). The neuropathologic hallmarks of
AD are extracellular amyloid b (Ab) plaque deposition and intra-
cellular aggregation of misfolded tau proteins (neurofibrillary tan-
gles). Based on the observed disparities between the extent of brain
pathology and the individual clinical expression in patients with AD
(Katzman et al., 1988), the theoretical construct of cognitive reserve
(CR) has been introduced to explain this existing variance.
CR is defined as the ability to preserve functionality despite
brain damage and/or accumulating pathology (Stern, 2002, 2006).
So far, the precise neural implementations of CR-related mecha-
nisms are still not completely understood. It has been suggested
that CR may act through the recruitment of additional brain areas
and/or through the more efficient use of pre-existing resources
(Stern, 2002, 2016). Recently, it has further been argued that task-
invariant neural networks may contribute to the CR-mediated
maintenance of functioning despite increasing pathology and
dysfunction of task-related networks (Stern, 2016). Several factors
have been identified to be associated with greater CR such as pa-
rameters of individual’s lifetime experiences including education,
occupation as well as leisure activities (Stern, 2012). These factors
possibly explain some heterogeneity in the clinical expression
among patients with AD (Stern, 2012).
The degree of CR posits important implications for the time of
diagnosis of AD as clinical symptoms may remain undetected for a
longer period of time in AD patients with higher CR. Moreover,
individuals with high levels of CR show a more rapid deterioration
in cognitive function from the point of diagnosis compared with
patients with lower CR (Andel et al., 2006; Stern et al., 1995). This
accelerated decline is likely due to greater accumulation of patho-
logic burden already present by the time of diagnosis. Thus, these
patients may have already progressed to more advanced Braak
neuropathologic stages leading to severe neurodegeneration,
which can no longer be counteracted via compensatory strategies
by the time of diagnosis. Indeed, it was shown in a histopathologic
study that higher levels of education were related to better cogni-
tive function when AD neuropathology was still absent or mild,
whereas the positive effect of education on cognition was
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attenuated when a person presented advanced neuropathology
(Koepsell et al., 2008). Interestingly, recent positron emission to-
mography (PET) studies using the [18F]AV-1451 tracer for the
visualization of tau pathology indicated that the spreading pattern
of tau pathology measured in vivo corresponded with the estab-
lished neuropathologic stages of tangle deposition as described by
Braak and Braak (1995) potentially allowing staging of the disease
using this tracer (Cho et al., 2016; Schöll et al., 2016; Schwarz et al.,
2016).
In the past decade, PET has provided valuable insights into the
association between CR, cognitive function, and the extent of AD
pathology. Higher educated AD patients demonstrated better
cognitive function in the presence of similar levels of Abpathology in
comparison to lower educated patients (Roe et al., 2008). Further-
more, focusing on prodromal (Morbelli et al., 2013) or probable AD
stages (Kemppainen et al., 2008), patients with high CR showed
greater Ab burden and significantly more pronounced hypo-
metabolism when compared with lower educated patients with
similar clinical symptoms. These observations gave rise to the hy-
pothesis that higher educated people might be able to use reserve
mechanisms to compensate for the functional impairment resulting
from the structural damage due to the AD-related brain pathology.
In addition to Ab deposition, AD is characterized by the aggre-
gation of pathologically misfolded tau proteins. Recent studies
demonstrated that the degree of cognitive impairment or neural
dysfunction was more closely correlated with the extent of tau pa-
thology than the distribution of Ab plaque deposition (Bischof et al.,
2016; Brier et al., 2016; Nelson et al., 2012; Ossenkoppele et al.,
2016). Whether this association is modulated by CR remains
elusive. Just recently, first indications have been collected, sug-
gesting that the negative association between tau pathology and
cognitive function measured in vivo may be stronger in individuals
with lower CR than in individuals with higher CR (Rentz et al., 2016).
Based on these results, the authors proposed that AD patients with
high CR might be able to preserve better cognitive function even
when tau pathology has started to spread to neocortical areas. This
assumption may require further substantiation, given that the
examined study cohort included 133 clinically normal patients, 17
patients with mild cognitive impairment, and only 6 AD patients.
Moreover, tau pathologywas solely assessed in the inferior temporal
region limiting the interpretation of these results regarding the ef-
fects of CR on the association between the global cortical spread of
tau pathology and co-occurring cognitive decline.
Given the current body of evidence indicating that AD patients
with high CR are able to cope better with increased brain pathology,
we aimed to assess whether higher educated AD patients showed
greater tau pathology burden and whether they had already pro-
gressed to more advanced Braak stages in comparison to lower
educated AD patients with similar clinical expression. For that
purpose, we analyzed tau pathology in different regions of interest
(ROIs) representing a respective Braak stage in a sample of AD pa-
tients fromwhomwe obtained [18F]AV-1451 PET scans. Referring to
the CR hypothesis, we anticipated that at comparable levels of
cognitive impairment, patients with higher levels of educational
attainment would demonstrate more severe tau burden as well as a
more advanced distribution of tau pathology than patients with
lower educational attainment.
2. Methods and materials
2.1. Participants
We included data from 14 healthy older adults and 24 patients
with typical AD, who were diagnosed with probable AD dementia
using the recommended NIA-AA guidelines (McKhann et al., 2011)
and based on the results of the diagnostic PET imaging or CSF liquor
measurements. All participants underwent a [18F]AV-1451 PET scan
for the in vivo assessment of tau pathology. The [18F]AV-1451 PET
scans of 17 AD patients were acquired in the Nuclear Medicine
Department of the University Hospital Cologne. The remaining 21
scans of the 14 healthy controls and the 7 AD patients were
collected on 3 sites as part of the multicenter trial investigating the
clinical application of [18F]AV-1451 conducted by AVID Radiophar-
maceuticals, Inc, Philadelphia (NCT 02016560). Key inclusion
criteria for the patient sample were: (1) diagnosis of probable
typical AD according to the NIA-AA criteria; (2) age range: >55 
80; (3) Mini Mental State Examination (MMSE) score 20; (4)
evaluable [18F]AV-1451 scan; and (5) self-report on educational
attainment. The study was approved by the local ethic committees
at the respective sites. All participants signed informed consent
regarding the scientific evaluation and publication of their data.
2.2. Educational attainment and cognitive function
Educational attainment was defined as the sum of schooling and
the following professional education in years (e.g., years of voca-
tional or university training). The AD patients were grouped
according to their level of educational attainment into a high-
educated AD (HEAD) group and a low-educated AD (LEAD) group
using a median split (Mdn ¼ 15.50 years). The group of healthy
controls consisted of 7 high-educated and 7 low-educated partici-
pants again based on a median split (Mdn ¼ 15 years). Global
cognitive function was assessed by the MMSE, which had been
recorded during the clinical visit within 3 months before the
scanning procedure (Folstein et al., 1975).
2.3. Positron emission tomography
The PET scans were acquired on a PET/CT Siemens BiographmCT
Flow 128 Edge (Siemens, Knoxville, TN, USA), a Siemens Biograph
64 PET/CT (Siemens, Erlangen, Germany), a Siemens HRþ (Siemens,
Erlangen, Germany), and a GE Discovery PET/CT 600 (GE Health-
care, Milwaukee, WI, USA). PET scans collected on the Siemens
BiographmCT Flow 128 Edge (n¼ 17) were acquired in list mode for
15 minutes after an intravenous injection with a mean dose of 225
MBq of [18F]AV-1451 and a rest period of 90 minutes. PET scans
collected on the Siemens Biograph 64 (n¼ 16), the HRþ (n¼ 3), and
the GE Discovery PET/CT 600 (n¼ 2) were acquired as 4  5 minute
frames for 20 minutes after 90 minutes after injection of a mean
dose of 384 MBq [18F]AV-1451.
2.4. Data processing
All [18F]AV-1451 PET scans were preprocessed using statistical
parametric mapping (SPM), version 8 (Wellcome Trust Centre for
Neuroimaging, Institute of Neurology at University College London,
London, UK). The images were spatially normalized to a tau tem-
plate in Montréal Neurological Institute (MNI) space and smoothed
with a Gaussian filter of 5 mm FWHM. The tau template was pre-
viously established by our group based on a dataset of [18F]AV-1451
PET scans from 19 healthy controls (M(age) ¼ 56.63  16.66 years)
provided by AVID Radiopharmaceuticals (Hammes et al., 2016).
Normalization of the individual [18F]AV-1451 scans to this template
resulted in successful preprocessing of the scans. Standard uptake
value ratios (SUVRs) were calculated employing in-house scripts in
MATLAB R2016a (The MathWorks, Inc, Natick, MA, USA) using the
cerebellum as reference region. The cerebellum is a preferable
reference region for tau-PET given that previous studies have
shown that cerebellar regions are relatively spared of tau pathology
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in AD (Braak and Braak, 1991; Marquie et al., 2015). The individual
SUVR images were then submitted to further analyses.
2.5. Statistical analysis
2.5.1. Region of interest analysis for in vivo Braak staging
To assess whether HEAD patients had already advanced to
higher Braak neuropathologic stages compared with LEAD patients
with a comparable level of cognitive function, we conducted an ROI
analysis by extracting mean SUVRs for ROIs representing different
Braak stages. The set of ROIs (Table 1) was adapted from Schoell
et al. (2016). Data from these ROIs were extracted using the auto-
mated anatomical labeling atlas (Tzourio-Mazoyer et al., 2002).
Mean SUVRs for each ROI belonging to one respective Braak stage
were averaged and submitted to the analysis. Proof of tau pathology
within the ROIs belonging to one Braak stage was considered to
represent the progression to the respective Braak stadium. A
multivariate analysis of variance including age as a covariate was
conducted looking at the main effect of group on tau pathology load
at different Braak stages. Next, post hoc pairwise comparisons of
the mean SUVR of the respective Braak stages between the 3 groups
were carried out using SPSS, version 21 for Windows (SPSS Inc,
Chicago, IL, USA). For the post hoc comparison between the AD
groups with the healthy control group, respectively, we included
age as a covariate, whereas for the post hoc comparison between
the 2 AD groups we included age and MMSE as covariates. Multiple
comparisons were corrected using the Sidak method (Sidák, 1967).
2.5.2. Voxel-wise whole brain analysis
To examine regions that were distinctly different between the
AD groups and to assure that regional differences in tau pathology
loadwere notmasked out by the ROI analysis, we further conducted
voxel-wise t-test comparisons between the 2 AD groups using
SPM8 including age and MMSE score as covariates. Moreover, to
investigate the spatial pattern of tau pathology in both AD groups,
we compared the LEAD and the HEAD groups against the healthy
control group, respectively, including age as a covariate. The voxel-
based contrasts were set to investigate in which regions HEAD
showed greater tau pathology than LEAD as well as in which re-
gions AD groups presented greater tau burden compared with
healthy controls, respectively. Reverse contrasts were performed to
control for possible inverse relationships. For all comparisons, a
binary grey matter mask was used as an explicit mask to reduce the
number of voxel-wise comparisons to grey matter areas. The sig-
nificance levels for the conducted comparisons were set to p 
0.001 (uncorrected). To rule out that the observed effects might
have been influenced by different scanner types, we conducted a
confirmatory analysis, comparing the scans of the HEAD (6 pa-
tients) and LEAD (11 patients) groups which had exclusively been
scanned on the PET-CT Siemens Biograph mCT Flow 128 Edge
against the healthy control group, respectively.
3. Results
3.1. Demographics of the groups
In total, scans of 24 AD patients and 14 scans of healthy controls
were used for analysis. The demographics of the 3 groups are
summarized in Table 2. No significant difference in the degree of
global cognitive function as assessed with the MMSE was observed
between the 2 AD groups. The 3 groups did not significantly differ
in age, although the healthy control group was on average slightly
younger.
3.2. Regional differences in tau load between high- and low-
educated AD patients
The ROI analysis revealed that HEAD patients already presented
tau pathology in regions, which were associated with Braak stages
V and VI, whereas LEAD showed increased tau pathology still
confined to regions associated with stages III and IV when
compared with healthy controls. No significant differences were
observed between groups for Braak stages I/II. The ANOVA cor-
rected for age yielded a significant main effect of group on tau
pathology load in Braak stages III (F[2,34] ¼ 7.229, p ¼ 0.002), IV (F
[2,34] ¼ 7.665, p ¼ 0.002), V (F[2,34] ¼ 9.362, p ¼ 0.001), and VI (F
[2,34] ¼ 12.352, p < 0.001). No significant main effect of group on
tau pathology load was observed for Braak stages I/II (p ¼ 0.411).
The post hoc comparison between the HEAD and LEAD group
corrected for age and MMSE resulted in significantly higher tau
pathology load in the HEAD group for stage V (F[1,20] ¼ 13.285,
p ¼ 0.002) and VI (F[1,20] ¼ 19.302, p < 0.001). The remaining re-
gions did not significantly differ between groups. The post hoc tests
between the LEAD and healthy control group corrected for age
revealed significant differences for Braak stages III (F[1,23] ¼
19.062, p < 0.001) and IV (F[1,23] ¼ 6.800, p ¼ 0.016), whereas the
remaining Braak stages I/II, V, and VI did not significantly differ
between the 2 groups. Comparing the HEAD group against the
healthy controls correcting for age yielded significant differences
for Braak stages III (F[1,23] ¼ 8.443, p ¼ 0.008), IV (F[1,23] ¼ 11.170,
p ¼ 0.003), V (F[1,23] ¼ 10.972, p ¼ 0.003), and VI (F[1,23] ¼ 12.221,
p ¼ 0.002), but not for Braak stages I/II. A summary of the F-sta-
tistics can be found in the Supplementary Data (Table S1). Themean
SUVRs of the respective Braak stages for each group are depicted in
Fig. 1.
3.3. Effect of education on tau pathology burden in high- and low-
educated AD patients
The voxel-wise comparison between HEAD and LEAD patients
yielded significantly increased tau pathology burden in parietal and
frontal regions in HEAD patients when compared with the LEAD
cohort (Fig. 2) confirming the results of the ROI analysis. Further-
more, the voxel-wise comparisons of the 2 AD groups against the
healthy control group, respectively, revealed different spatial pat-
terns of tau pathology for the high- and low-educated groups
(Fig. 3). The HEAD group showed increased tau burden in temporal,
parietal, and frontal regions, whereas tau pathology in the LEAD
group was confined to temporal and partly to inferior parietal re-
gions when compared to the healthy control sample. The reverse
contrasts comparing the healthy group against the AD groups and
the LEAD against the HEAD group did not reveal significant differ-
ences. The peak activations and MNI coordinates of the voxel-wise
comparisons are summarized in the Supplementary Data (Table S2).
Table 1
Braak regions of interest
Braak stage AAL ROIs
I/II Hippocampus
III Parahippocampal gyrus; fusiform gyrus; lingual gyrus;
amygdala
IV Inferior temporal cortex; middle temporal cortex; temporal
pole; thalamus; posterior cingulate; insula
V Frontal cortex; parietal cortex; occipital cortex; superior
temporal cortex; precuneus; caudate nucleus; putamen
VI Precentral gyrus; postcentral gyrus; paracentral gyrus; cuneus
The ROIs of each Braak stage used for the ROI analysis are summarized. Regions were
adapted from Schoell et al. (2016) and extracted from the automated anatomical
labeling atlas.
Key: AAL, automated anatomical labeling atlas; ROI, region of interest.
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In the confirmatory analysis in the sample exclusively scanned on
one identical scanner, we obtained very similar results
(Supplementary Data, Fig. S3).
4. Discussion
This study demonstrated that tau pathology is more advanced in
HEAD than in LEAD patients with comparable level of cognitive
impairment. The ROI analysis revealed that HEAD patients pre-
sented tau pathology in regions, which are associated with Braak
stages V and VI, whereas the LEAD group demonstrated increased
tau pathology in regions still confined to stages III and IV when
compared to healthy controls. Interestingly, no significant differ-
ence in tau pathology load in mediotemporal regions, associated
with Braak stages I/II, were observed between the 3 groups. All of
these results were further confirmed by a voxel-based whole brain
analysis, which revealed that HEAD patients show a different
spatial tau pattern compared with LEAD patients. In particular,
HEAD patients demonstrated increased tau pathology load in pa-
rietal and frontal areas when compared with LEAD patients.
Importantly HEAD and LEAD patients did not significantly differ in
age and their global cognitive function.
4.1. Role of education on reserve capacity
Our results from the ROI and voxel-based analyses showed that
the accumulation of tau pathology measured in vivo differs given
the level of educational attainment as HEAD patients show more
advanced tau pathology burden compared with LEAD patients with
equal cognitive impairment. Thus, the relation between tau burden
and symptomatic appearance in AD patients seems to be mitigated
by CR-mechanisms acquired through factors such as education.
These results are in line with the observation that the effects of
other biomarkers of AD on cognitive function, such as the amount
of Ab burden or hypometabolism, are influenced by the level of
education (Ewers et al., 2013; Kemppainen et al., 2008; Morbelli
et al., 2013). Histopathologic studies revealed that higher levels of
education were associated with better cognitive functioning, in-
dependent of the level of AD-related brain pathology (Bennett et al.,
2003, 2005). In vivo PET studies investigating CR-related changes
reported that higher levels of education were related to greater Ab
plaque deposition in frontal areas (Kemppainen et al., 2008), and a
significant lower glucose metabolism rate (Ewers et al., 2013;
Kemppainen et al., 2008; Morbelli et al., 2013) and greater deple-
tion of blood flow in temporoparietal areas (Stern et al., 1992)
compared with lower levels of education.
Given the provided body of evidence, it appears that education
does not decelerate the accumulation of pathology, but may serve
to alter the clinical expression of the underlying pathology by
slowing down the progressive cognitive decline caused by the
neurotoxic effects of pathology such as tau pathology. Education is a
factor occurring early in life, when the brain is still developing and
considered most plastic. It is widely accepted that early lifetime
factors can have profound impact on a person’s health status later
in life. Indeed, evidence provided recently showed that early life
factors such as general cognitive ability and parental education
positively influenced age-related structural brain trajectories and
cognition late in life (Walhovd et al., 2016). Aside from these early
factors, higher education has consistently been associated with
healthier lifestyles, less chronic stress, better socioeconomic status,
lifelong mental stimulation and lower exposure to toxic factors.
These variables may all subserve reserve capacities throughout life,
which likely protect against the harming effects of age-related pa-
thology (Adler et al., 2013; Fritsch et al., 2007; Kiecolt-Glaser et al.,
2011; Springer et al., 2005).
Table 2
Group characteristics
Characteristic HC group (n ¼ 14) LEAD group (n ¼ 12) HEAD group (n ¼ 12) Group differences (p values)
HC versus LEAD HC versus HEAD LEAD versus HEAD
Age 62.86  11.57 68.08  6.91 69.33  6.08 n.s n.s n.s
Sex (M/F) 6/8 7/5 9/3 n.s n.s n.s
Education 14.71  2.43 12.00  1.76 17.33  0.99 p < 0.001 p < 0.001 p < 0.001
MMSE 29.50  0.52 25.50  3.43 25.42  3.15 p < 0.001 p < 0.001 n.s.
The demographic characteristics of the studied groups are depicted including the average age in years, sex distribution, years of education, and cognitive function as assessed
by the MMSE. Statistical differences between groups are highlighted in the last column.
Key: F, female; HC, healthy control; HEAD, high-educated AD; LEAD, low-educated AD; M, male; MMSE, Mini Mental State Examination; n.s., not significant.
Fig. 1. Tau pathology load in different Braak stages. The mean SUVRs and the standard
error across the respective ROIs for each Braak stage are depicted for the healthy
control, the low-educated AD group, and the high-educated AD group. Significant
differences (p < 0.05) between the groups, which survived the multiple comparison
correction, are highlighted. Abbreviations: a, significant difference healthy controls
versus low-educated AD group; b, significant difference healthy control versus high-
educated AD group; c, significant difference between low-educated versus high-
educated AD group; HEAD, high-educated AD patients; LEAD, low-educated AD
patients; ROI, region of interest; SUVR, standard uptake value ratio.
Fig. 2. HEAD versus LEAD. Voxel-wise comparison of tau pathology load between
high-educated and low-educated AD patients corrected for age and MMSE score using
statistical parametric mapping. Significance level was set to p < 0.001 (uncorrected).
Abbreviations: HEAD, high-educated AD patients; LEAD, low-educated AD patients.
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Based on the current knowledge, it appears that early lifetime
variables such as education contribute to late-life brain function.
Education being associated with other lifetime factors may act on
CR-related compensatory mechanisms, which render some in-
dividuals more resilient to the consequences of accumulating
pathology than others, and in the current study more resistant to-
ward the effects of accumulating tau pathology in the brain. Given
that education is a relative term constantly shifting upward, it will
be particularly important to develop tests with higher ceilings
allowing detection of individuals with high levels of CR in clinical
routine (Stern, 2012). Moreover, it will be crucial to determine
whether other CR proxies such as lifelong cognitive and social
engagement are more sensitive than the level of education in re-
gard to CR-related changes.
4.2. Level of education and tau pathology load in Braak stages
Although both patient groups of this study were characterized
by similar global cognitive function, the HEAD group showed a
wider distributed tau pathology burden, which corresponded to
advanced Braak stages (V and VI), reflecting the expansion of tau
pathology to parietal and frontal regions. In contrast, the tau pa-
thology load of the LEAD group only complied with moderately
advanced Braak stages (III and IV), still largely restricted to temporal
areas and the posterior cingulate cortex. These findings comply
with the assumption by Rentz et al. (2016), mentioned earlier,
presuming that CR exerts mitigating effects on cognition evenwhen
tau pathology has advanced to isocortical regions.
Several explanations for CR-related mechanisms have been put
forward such as CR might act via increases in functional connec-
tivity, via the recruitment of additional brain areas or via improved
physiological properties such as increased dendrite density or
enhanced vascular coupling (Soldan et al., 2015). Magnetic reso-
nance imaging studies have reported increased functional con-
nectivity, in particular, in the default mode network (Bozzali et al.,
2015; Sole-Padulles et al., 2009) and CR-related changes in struc-
tural connectivity (Wook Yoo et al., 2015) in highly educated AD
patients. Regarding CR-related mechanisms on physiological
properties, higher CR levels were associated with enhanced
acetylcholine esterase activity in hippocampal and cingulate areas
(Garibotto et al., 2013) and elevated glucose metabolism rate in
frontal areas (Morbelli et al., 2013). Overall, these changes on the
functional, structural, and molecular levels are presumed to allow
compensation for the aggregating pathologic burden, such as, for
example, for accumulating tau pathology in temporal, parietal, and
frontal areas as observed in this study.
Interestingly, when comparing the 3 groups regarding tau pa-
thology load in regions, which were associated with Braak stages I/
II, we did not observe any significant differences. Also in the voxel-
wise comparison hippocampal areas remained spared of any group-
related differences. These observations may be explained by the
initial occurrence of tau pathology in medial temporal lobe regions
in AD and the notion of primary age-related tauopathy (PART). PART
is based on the findings from several postmortem studies demon-
strating aggregation of tau pathology in medial temporal lobe re-
gions in the absence of Ab pathology in people, who were
cognitively normal or only slightly cognitively impaired before
death (Crary et al., 2014; Iseki et al., 2002). This process was
recognized as part of the normal aging process given that PART was
generally detectable at autopsy in elderly individuals. Also in this
study, we observed slightly elevated levels of tracer retention in
hippocampal regions in the healthy control group as compared
with the retention rates of this group in other brain regions asso-
ciated with more advanced Braak stages. Interestingly, the reten-
tion rates of the AD groups in this area did not significantly differ
from the healthy group, but nonetheless were marginally higher.
These findings suggest that tau pathology in hippocampal regions
may be less disease specific and may occur as part of the aging
process, whereas tau pathology in regions associated with Braak
stages IIIeVI is related with AD (Crary et al., 2014). However, we
cannot exclude that some of the healthy controls already presented
an early form of AD possibly driving the observed increase of tau
pathology in hippocampal regions. Recently, it has been suggested
that the accumulation of tau in the absence of Abmight present an
early phase of AD (Duyckaerts et al., 2015). Moreover, it was argued
that the current body of evidence is not sufficient to conclude that
PART and AD are driven by different processes prompting for
further investigation (Duyckaerts et al., 2015).
Assessing tau pathology at different Braak stages showed that
HEAD patients can maintain their cognitive functioning despite a
more extensively distributed pathologic burden compared with
LEAD patients. These CR-related differences in disease manifesta-
tion have crucial implications for early detection of AD, prognosis of
the disease progression, and the assessment of drug treatments. For
example, the individual degree of CR might particularly be
considered when assessing the efficacy of anti-tauebased phar-
macotherapies. First of all, the response to these drugs could differ
by the extent of underlying pathology. Second, groups which are
not matched according to their level of CR may show different rates
of cognitive decline that are actually not caused by the drug but by
the level of CR as individuals with high CR tend to decline more
rapidly after the initial diagnosis. Future longitudinal studies are,
therefore, warranted to further investigate the mitigating effects of
CR on the functional and structural levels in regard to accumulating
AD-related pathology.
4.3. Limitations
Certain limitations need to be considered when interpreting the
presented results of our study. In this study, the PET scans were
acquired on different scanners. Although this inconsistency has
likely introduced some noise to the data, all scans were successfully
preprocessed and spatially normalized to a common template.
Furthermore, the observed results did hold up, when re-assessed in
a confirmatory analysis in a sample of subjects exclusively scanned
Fig. 3. Spatial patterns of tau pathology in HEAD and LEAD. Voxel-wise comparison of
tau pathology load between (A) high-educated AD patients versus healthy controls and
(B) low-educated AD patients versus healthy controls corrected for age using statistical
parametric mapping. Significance level was set to p < 0.001 (uncorrected). Abbrevia-
tions: HEAD, high-educated AD patients; LEAD, low-educated AD patients.
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on one specific scanner. Moreover, the relative small sample size of
the groups limits the interpretation of the findings in regard to the
general population. In addition, although not significant, the
healthy control group was slightly younger than the AD groups.
Furthermore, with regard to the clinical level of impairment we
only had access toMMSE data of all patients. AlthoughMMSE is one
of the most widely used assessments, a broad neuropsychological
test battery would have allowed us a more detailed and accurate
description of cognitive function. For future studies, it will be of
interest to examine to what extent education and other proxies of
CR moderate the deleterious effect of tau pathology on cognition.
5. Conclusion
In sum, AD patients with higher levels of educational attainment
demonstrate more extensive tau burden than lower educated pa-
tients with equal cognitive function as measured with the MMSE.
This corresponds well to previous studies investigating the concept
of CR with regard to AD-related pathology. These findings may have
important implications for the clinical diagnosis which may be
delayed in individuals with high CR as compared with individuals
with lower CR. Better understanding of CR-related mechanisms on
the clinical expression of ADmay improve the clinical diagnosis and
prognosis regarding the disease and additionally promote the
investigation of protective treatment strategies. Given the findings
of this study, further investigations need to elucidate the role of CR
and tau pathology in regard to cognitive function. Multimodal im-
aging approaches may thereby shed light into underlying mecha-
nisms that render some individuals more resilient to disease-
related changes than others.
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Table S1 – F-Statistics for comparison of tau pathology in Braak Stages 
Braak stages HEAD vs LEAD LEAD vs Healthy HEAD vs Healthy 
I/II F(1,20)=.063,  
p=.805 
F(1,23)=.918,  
p=.348 
F(1,23)=1.633, 
 p=.214 
III F(1,20)=.388,  
p=.540 
F(1,23)=19.062, 
p<.001 
F(1,23)=8.443,  
p=.008 
IV F(1,20)=4.310,  
p=.051 
F(1,23)=6.800,  
p=.016 
F(1,23)=11.170, 
p=.003 
V F(1,20)=13.285, 
p=.002 
F(1,23)=1.177, 
 p=.289 
F(1,23)=10.972, 
p=.003 
VI F(1,20)=19.302, 
p<.001 
F(1,23)=1.632,  
p=.214 
F(1,23)=12.221, 
p=.002 
Table S1 depicts the F-statistics for the comparison of the mean SUVRs in the six Braak stages 
between the high educated and low educated AD group corrected for age and MMSE score, and 
the comparison of the low educated and high educated AD groups with the healthy control group 
corrected for age, respectively (p < .05). HEAD = High Educated AD Patients, LEAD=Low 
Educated AD Patients; SUVR = Standard Uptake Value Ratio. 
  
Tau pathology and cognitive reserve in AD 
 
S2 
 
Table S2 – Peak activation of voxel-wise comparisons 
HEAD > LEAD 
Region t-value x-coordinate y-coordinate z-coordinate 
Left and Right Postcentral 
Gyrus/Right Supplementary 
Motor Area 
5.29 32 -36 64 
5.83 -52 -2 50 
5.73 10 10 68 
Right Superior Frontal Gyrus 4.98 12 46 44 
Right Inferior Frontal Gyrus 4.56 48 30 18 
Left Postcentral Gyrus 4.31 -52 -4 16 
Left Supplementary Motor 
Area 
4.22 -10 18 62 
Right Angular Gyrus 4.07 36 -66 50 
Left Inferior Parietal 3.87 -30 -72 46 
3.77 -36 -66 50 
LEAD > Healthy 
Left Fusiform Gyrus &  
Left Parahippocampal Gyrus  
6.27 -34 -20 -26 
6.16 -30 -4 -34 
6.11 -28 -24 22 
Right Fusiform Gyrus & 
Right Inferior Temporal 
5.75 30 -2 -36 
4.85 46 -40 -18 
4.72 38 -14 -32 
Right inferior parietal, Right 
Middle Occipital & Right 
Supramarginal Gyrus 
5.24 36 -48 40 
3.97 30 -60 38 
3.66 50 -40 34 
Middle Cingulate 4.66 -2 -30 36 
Right Cuneus 4.33 20 -72 22 
4.25 24 -62 24 
Left Middle Frontal 4.11 -26 22 44 
Left Precuneus 3.96 -10 -58 38 
HEAD > Healthy 
Right Middle Occipital, 
Left Middle Cingulate & 
Left Cuneus  
5.11 30 -64 34 
5.00 -6 -22 -38 
4.93 -18 -58 20 
Right Precentral Gyrus & 
Right Supplementary Motor 
Area 
4.41 26 -14 58 
4.39 10 -4 56 
4.27 26 -8 48 
Left Middle Frontal Gyrus 4.31 -28 10 50 
4.31 -26 20 44 
4.01 -34 32 44 
Left Inferior Frontal Gyrus 4.16 -36 12 26 
Left Middle Frontal Gyrus/ 
Left Supplementary Motor 
Area 
4.12 -12 -4 66 
4.00 -26 -10 48 
3.95 -10 -4 58 
Left Inferior Parietal 4.04 -58 -30 46 
Left Precentral 4.01 -48 0 52 
Table S2 summarizes the t-statistics and MNI coordinates for voxel clusters with an extent threshold 
k=50 for the contrasts investigating in which regions high educated AD patients show more tau 
pathology than low educated AD patients and in which regions low educated AD and high educated 
AD patients present more tau pathology than healthy controls, respectively. HEAD = High Educated 
AD Patients, LEAD=Low Educated AD Patients. 
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Figure S3 – Exclusion of systematic error due to scanner differences 
 
Figure S3 illustrates the results of the voxel-wise comparisons of tau pathology load between 
(1a-c) the AD groups only scanned on the Siemens Biograph mCT Flow 128 Edge (HEAD=6 
patients; LEAD= 11 patients) against the healthy control group and (2a-c) the comparison of 
the AD groups including scans from the nuclear medicine department of the University 
Hospital Cologne and AVID Radiopharmaceuticals against healthy controls. a) HEAD vs 
LEAD, b) HEAD vs healthy control group, c) LEAD vs healthy control group. The p-value was 
set to p<.001 (uncorrected). Age and MMSE score were included as covariates for comparison 
a) and age was included as covariate for comparison b&c). HEAD = High Educated AD 
Patients, LEAD=Low Educated AD Patients. 
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Abstract
Purpose Using PET imaging in a group of patients with Alzheimer’s disease (AD), we investigated whether level of education, a
proxy for resilience, mitigates the harmful impact of tau pathology on neuronal function.
Methods We included 38 patients with mild-to-moderate AD (mean age 67 ± 7 years, mean MMSE score 24 ± 4, mean years of
education 14 ± 4; 20 men, 18 women) in whom a [18F]AV-1451 scan (a measure of tau pathology) and an [18F]FDG scan (a
measure of neuronal function) were available. The preprocessed PETscans were z-transformed using templates for [18F]AV-1451
and [18F]FDG from healthy controls, and subsequently thresholded at a z-score of ≥3.0, representing an one-tailed p value of
0.001. Next, three volumes were computed in each patient: the tau-specific volume (tau pathology without neuronal dysfunction),
the FDG-specific volume (neuronal dysfunction without tau pathology), and the overlap volume (tau pathology and neuronal
dysfunction). Mean z-scores and volumes were extracted and used as dependent variables in regression analysis with years of
education as predictor, and age and MMSE score as covariates.
Results Years of education were positively associated with tau-specific volume (β = 0.362, p = 0.022), suggesting a lower impact
of tau pathology on neuronal function in patients with higher levels of education. Concomitantly, level of education was
positively related to tau burden in the overlap volume (β = 0.303, p = 0.036) implying that with higher levels of education more
tau pathology is necessary to induce neuronal dysfunction.
Conclusion In patients with higher levels of education, tau pathology is less paralleled by regional and remote neuronal dys-
function. The data suggest that early life-time factors such as level of education support resilience mechanisms, which ameliorate
AD-related effects later in life.
Keywords Glucosemetabolism . Brain reserve . Brainmaintenance . Resilience . [18F]AV-1451 . [18F]FDG
Introduction
The neuropathological hallmarks of Alzheimer’s disease
(AD), beta-amyloid (Aβ) plaques and neurofibrillary tangles,
appear to evolve in temporal order with Aβ becoming abnor-
mal first, followed by tau pathology and subsequently neuro-
nal injury [1]. During these pathophysiological processes, tau
pathology, in contrast to Aβ pathology, is more closely asso-
ciated with neuronal dysfunction [2, 3] and symptom severity
[4, 5] in individuals with typical AD and variants of AD such
as posterior cortical atrophy, the logopenic variant and the
behavioural variant [2, 6, 7].
While the direct relationship between tau pathology and
neuronal injury in space and time is now better understood,
substantial heterogeneity in clinical severity in individuals
with comparable degrees of pathology remains a puzzling
feature. To accommodate this heterogeneity, resilience-
related concepts such as cognitive reserve, brain reserve
(BR) and brain maintenance (BM) have been introduced,
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and have been suggested to weaken the relationship between
AD-related pathophysiology and symptom severity. Cognitive
reserve refers to the adaptability of cognitive processes to main-
tain functionality and BR accounts for differences in brain
integrity [8, 9]. In turn, the concept of BM is associated with
neuroprotective mechanisms supporting the preservation of
brain integrity [10, 11].
Consistent with these concepts, we recently showed that
patients with typical AD with higher levels of education are
able to tolerate more severe and spatially extended tau pathol-
ogy than AD patients with lower levels of education but
similar cognitive impairment [12]. One possible explanation
for this finding is that the impact of tau pathology on neuronal
function is less harmful in patients with higher levels of edu-
cation due to mechanisms associated with BR and BM. These
mechanisms potentially support resilience to brain pathology
[13] by, for example, boosting neuronal plasticity through the
upregulation of neuronal growth factors.
To investigate these possibilities, we used a novel volume-
based PET imaging approach to assess whether a resilience-
related proxy, namely education, affects the association be-
tween tau pathology (i.e. [18F]AV-1451 PET) and neuronal
dysfunction (i.e. [18F]FDG PET) in patients with typical AD
and variants of AD. In each patient, we extracted three distinct
volumes: (1) the tau-specific volume (all regions showing only
significant tau pathology in the absence of neuronal dysfunc-
tion); (2) the FDG-specific volume (all regions showing signif-
icant neuronal dysfunction in the absence of tau pathology);
and (3) the overlap volume (all regions showing significant
tau pathology load and neuronal dysfunction). Assuming that
level of education mitigates the effects of tau pathology on
glucose metabolism, we hypothesized the following: (1) the
tau-specific volume is larger despite relative preservation of
regional glucose metabolism in individuals with higher levels
of education; (2) the mean tau pathology load in the overlap
volume is positively correlated with years of education; and (3)
irrespective of level of education, the volume of reduced glu-
cose metabolism is smaller than the tau volume given the pre-
sumed temporal evolution of AD biomarkers [14].
Materials and methods
Participants
The study group comprised 38 patients with mild-to-moderate
AD recruited from the interdisciplinary memory centres of the
University Hospital Cologne and the University Hospital
Bonn. The patients were diagnosed with probable AD demen-
tia using the recommended NIA-AA criteria [15] including
diagnostic amyloid PET imaging or CSF measurements. All
participants underwent a PET scan with [18F]AV-1451 for the
in-vivo assessment of tau pathology and a PET scan with
[18F]FDG for the evaluation of neuronal dysfunction at the
Department of Nuclear Medicine of the University Hospital
Cologne. All participants provided signed informed consent
regarding the scientific evaluation and publication of their
data.
PET acquisition
PETscans were performed on a Siemens Biograph mCT Flow
128 Edge scanner (Siemens, Knoxville, TN) and were itera-
tively reconstructed using a 3-D OSEM algorithm (four itera-
tions, 12 subsets, gaussian filter, 5 mm full-width at half-max-
imum, matrix 128 × 128, slice thickness 3 mm). The two PET
scans were acquired no more than 3 months and on average
less than 1 month apart. Administration parameters are sum-
marized in Table 1.
PET image processing
In each individual, the [18F]AV-1451 scan was coregistered to
the [18F]FDG scan using SPM12 (Wellcome Trust Centre for
Neuroimaging, Institute of Neurology, University College
London, London, UK). The coregistered [18F]AV-1451 scan
and the native [18F]FDG scan were then normalized to a
[18F]FDG PET template in MNI space [16]. Using in-house
scripts in MATLAB R2016a (The MathWorks, Inc., Natick,
MA, USA), the normalized scans were intensity-standardized
to the whole cerebellum, which was used as the reference
region. The preprocessed images were then z-transformed
Table 1 Descriptive characteristics
Characteristic Value
Number of patients 38
Men 20
Women 18
Age (years), mean (SD) 67.11 (6.97)
MMSE score, mean (SD) 23.87 (4.45)
Years of education, mean (SD) 13.85 (3.92)
[18F]AV-1451, mean (SD)
Dose (MBq) 236.26 (48.11)
Administration time after injection (min) 94.81 (26.87)
[18F]FDG, mean (SD)
Dose (MBq) 216.92 (49.22)
Administration time after injection (min) 36.24 (10.55)
SD standard deviation, MMSEMini Mental State Examination
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using an [18F]AV-1451 PET template and an [18F]FDG PET
template from a healthy control sample (n = 15, mean age at
FDG scan 67.47 years, mean MMSE score at FDG scan
28.87, mean years of education 16.67) acquired at two differ-
ent time points and provided by the Alzheimer's Disease
Neuroimaging Initiative database (http://adni.loni.usc.edu/).
The control sample was age-matched to our AD sample.
Numerically, the mean years of education in the healthy con-
trol sample was slightly higher than in the patient sample,
most likely reflecting differences in the German and North
American educational systems (U = 148, p = 0.007). For fur-
ther information on the processing of the healthy control tem-
plates see the Supplementary material.
The z-transformed images were thresholded at a z-score
of ≥3.0 approximately corresponding to an one-tailed p
value of 0.001. In a next step, using a batch script
employing the imcalc function implemented in SPM12,
three volumes were extracted: (1) the tau-specific volume
comprising regions characterized by significant tau pa-
thology but no significant change in glucose metabolism;
(2) the FDG-specific volume comprising regions with sig-
nificant changes in glucose metabolism in the absence of
tau pathology; and (3) the overlap volume comprising
regions in which both the [18F]AV-1451 and the
[18F]FDG scan showed a z-score of ≥3.0. The difference
between the tau-specific volume and the FDG-specific
volume was also extracted. A positive difference value
indicated a larger tau-specific volume than FDG-specific
volume, whereas a negative value indicated the reverse.
All computed volumes, the volume difference and z-
scores of the volumes were then used for further statistical
analysis.
To ensure that the results were not predominantly driven by
the predefined z-score threshold of ≥3.0, the same analysis
was performed with the PET scans thresholded at a more
liberal z-score of ≥2.0, representing an one-tailed p value of
0.02. A subanalysis (z ≥ 3.0) was also performed limiting the
dataset to data from patients with typical AD to ensure that the
results were not solely driven by the data from patients with
variants of AD.
Statistical analysis
Multivariable regression analysis was performed with SPSS
version 21 (IBM Corp., Armonk, NY USA). Years of educa-
tion (that is, schooling and subsequent professional education
including vocational or university training) was employed as
the predictor with the volumes, mean z-scores within these
volumes and the difference in volume as dependent variables,
controlling for age andMMSE score. The models were further
tested for a potential gender effect. As the gender effect was
not significant, it was excluded from the final analysis.
Moreover, one-tailed bivariate correlation analysis was per-
formed to evaluate the association between the mean z-scores
of the respective volumes. The significance threshold for all
analyses was set at p < 0.05.
The graphs of the results were computed using R (R: A
language and environment for statistical computing, 2018; R
Core Team, R Foundation for Statistical Computing, Vienna,
Austria. https://www.R-project.org/). The brain surface
illustrations were created using the CAT12 toolbox
implemented in SPM and the Surf Ice toolbox (https://www.
nitrc.org/projects/surfice/).
Results
Descriptive data
Of the 38 patients, 26 were diagnosed with typical AD,
six with the logopenic variant, three with posterior corti-
cal atrophy, two with the behavioural variant, and one
with atypical AD without further specification. The pa-
tients with lower levels of education had on average
11 years of education, whereas the patients with higher
levels of education level had on average ≥18 years of
education (see Supplementary material for information
on the German education system). Descriptive data of
the group are presented in Table 1. One extreme outlier
was removed from the analysis to fulfil the underlying
assumptions for regression analysis.
Associations with level of education
A significant positive association was observed between years
of education and tau-specific volume (β = 0.362, t = 2.414,
p = 0.022). In other words, higher levels of education were
associated with more brain areas showing preserved metabo-
lism despite the presence of tau pathology. Furthermore, in
regions with tau pathology and hypometabolism overlap,
years of education was positively correlated with tau patholo-
gy load (β = 0.303, t = 2.183, p = 0.036), but not with the de-
gree of hypometabolism (β = −0.057, t = −0.385, p = 0.703).
Moreover, no significant effect was observed in the regression
analysis between level of education and FDG-specific volume
(β = −0.242, t = −1.423, p = 0.164). Furthermore, a significant
positive relationship was observed between years of education
and the difference between the tau-specific volume and the
FDG-specific volume (β = 0.342, t = 2.190, p = 0.036). The
difference values were not exclusively positive, meaning that
in patients with the lowest levels of education the FDG-
specific volume was even larger than the tau-specific volume.
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The results of the regression analysis are summarized in
Table 2 and respective plots are shown in Fig. 1 and
Supplementary Fig. 1a. Figure 2 illustrates a brain projection
showing the increase in tau-specific volume with increasing
years of education.
Aside from this, a positive trend for an association was
found between the respective average z-scores for
hypometabolism and tau pathology within the overlap vol-
ume (r = 0.264, p = 0.057; Supplementary Fig. 1b). In con-
trast, the average z-scores of the FDG-specific volume
were not correlated with the average z-scores of the tau-
specific volume (r = −0.109, p = 0.260; Supplementary
Fig. 1c). Moreover, the subanalysis including only patients
with typical AD showed a trend for significance of the
main variables of interest (Supplementary Table 1). In ad-
dition, the confirmatory analysis using a threshold z-score
of ≥2.0 yielded similar results, supporting our approach
(Supplementary Table 2).
Discussion
Several studies using PET imaging have shown that the spatial
extent of tau pathology is closely related to changes in glucose
metabolism, a measure of neuronal dysfunction. Here, we
report evidence that level of education mitigates the local im-
pact of tau pathology on neuronal function. We observed that
the volume of brain regions with relatively preserved metab-
olism despite the presence of significant tau pathology (i.e. the
tau-specific volume) is greater in patients with higher levels of
education. Furthermore, our data suggest that in regions char-
acterized by coexisting tau pathology and neuronal dysfunc-
tion (i.e. the overlap volume), a greater tau burden is required
to cause comparable metabolic dysfunction in individuals
with higher levels of education. Taken together, our findings
point towards the existence of protective mechanisms against
tau pathology, which may be associated with the early life-
time factor of education. We discuss below the current find-
ings based on the concept of BR continued by an argumenta-
tion relating to resilience factors supporting BM.
An explanation based on the concept of brain reserve
Numerous studies have shown that life-time factors, such as
education, play an important role in prolonging and slowing
cognitive decline following the advent of brain pathology [12,
17–22]. Education, an early life-time factor, has consistently
been associated with higher socioeconomic status, better
health, less chronic stress and life-long mental stimulation,
factors that probably contribute to better brain health later in
life [23–26]. With an accumulating body of evidence across
neurological conditions, it is believed that education can pro-
tect and provide resilience against the harmful effects of pa-
thology [27]. In line with this, we found that higher levels of
education are associated with less pronounced effects of tau
pathology on neuronal function. Moreover, more tau patholo-
gy appears necessary to induce changes in glucose metabo-
lism in individuals with higher levels of education.
Table 2 Results of regression analysis
t β P 95% CI F df p Adjusted R2
Tau-specific volume 5.306 3,33 0.004 0.264
Level of education 2.414 0.362 0.022 0.002, 0.025
MMSE score −1.903 −0.293 0.066 −0.021, 0.001
Age −2.558 −0.376 0.015 −0.014, −0.002
Mean tau burden in overlap volume (tau-specific/FDG-specific overlap) 8.109 3,33 <0.001 0.372
Level of education 2.183 0.303 0.036 0.016, 0.465
MMSE score −2.835 −0.403 0.008 −0.511, −0.084
Age −3.150 −0.428 0.003 −0.317, −0.068
FDG-specific volume 1.704 3,33 0.185 0.055
Level of education −1.423 −0.242 0.164 −0.016, 0.003
MMSE score 1.827 0.319 0.077 −0.001, 0.017
Age 0.595 0.099 0.556 −0.004,0.007
Volume difference (tau-specific – FDG-specific) 4.061 3,33 0.015 0.203
Level of education 2.190 0.342 0.036 0.001, 0.039
MMSE score −2.086 −0.334 0.045 −0.037, 0.000
Age −1.855 −0.284 0.072 −0.020, 0.001
The table includes the statistical model summaries of all regression analyses
CI confidence interval, df degrees of freedom, MMSEMini Mental State Examination
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These findings may first be explained based on the concept
of BR, which accounts for the individual neurobiological cap-
ital such as neuron count and synaptic density [9].
Accordingly, individuals with a high BR will show less severe
symptoms than individuals with a low BR despite similar
brain pathology, because they possess more BR to counteract
the brain damage. Hence, although the same numbers of neu-
rons or synapses are rendered dysfunctional by misfolded tau
aggregates in individuals with low and high levels of educa-
tion, an individual with a higher level of education will be able
to counteract the brain damage given that he/she possesses
enough resources in the form of yet-unaffected neurons or
synapses. Due to the activation of these (thus far) spared re-
sources, the metabolic rate (i.e. FDG uptake on PET) in indi-
viduals with higher levels of education may in turn not signif-
icantly deviate from that detected in healthy controls despite
tau aggregation. Furthermore, according to the BR-concept, a
greater pathological burden is necessary to eventually affect
the compensatory resources in individuals with higher levels
of education, which may account for our finding of greater tau
burden in the overlap volume in patients with higher levels of
education.
Importantly, it has been postulated that glucose metabolism
reflects synaptic function rather than overall neuronal function
[28]. The possible BR-related compensatory process may thus
be a matter rather of synaptic density and plasticity than of
total neuron count. Indeed, several studies using rodent
models have demonstrated that enriched environments, which
are used to study the benefits of life-long cognitive stimula-
tion, promote neuronal plasticity in the form of increased syn-
aptic density [29–31] and dendritic branching [32, 33]. Similar
effects are believed to occur in humans. With the recent devel-
opment of PET tracers to visualize changes in synaptic density
[34], future studies will be able to directly elucidate the protec-
tive effect of education on AD-related pathology.
Concerning our reasoning based on the BR concept, it must
be emphasized that the neurotoxic effects of tau pathology on
neuronal function are considered similar at different levels of
education. Yet, the detectable and measurable outcome (i.e.
the FDG PET signal) of regional tau pathology on neuronal
function differs according to the individual extent of underly-
ing compensatory resources. One may, however, also argue
a Tau-specific volume
b Overlap volume 
c FDG-specific volume 
Fig. 1 Regression analysis including years of education (residuals)
corrected for MMSE and age as predictor and mean tau burden (z-score)
and volumes (litre) as dependent variables (a blue tau-specific volume, b
green mean tau burden in overlap volume, c red FDG-specific volume;
grey areas 95% confidence intervals). Brain projections of the respective
volumes are illustrated below each scatterplot. a and c show the volume
extents in a patient with a low level of education (left) and a patient with a
high level of education (right), and b depicts the average overlap volume
in patients with typical AD. The respective volumes were rendered on a
brain surface in MNI space using the CAT toolbox implemented in
SPM12
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that in individuals with higher levels of education the impact
of tau pathology on neuronal function is ameliorated by resil-
ience factors supporting BM, as discussed below.
An explanation based on resilience factors supporting
brain maintenance
Again, rodent studies have provided valuable information on
resilience factors that are associated with life-long engagement
and facilitate clearance or decreases in tau pathology and neu-
roinflammation, thereby supportingmaintenance of brain integ-
rity. These factors are potentially associated with level of edu-
cation in humans and thus contribute to the current findings.
Given the complexity of these resilience factors, we mention,
within the scope of this discussion, only a few examples that
may have contributed to the current findings.
Over the past decade, several cellular growth factors have
been reported to be neuroprotective, such as the brain-derived
neurotrophic factor (BDNF). BDNF has been demonstrated
in vitro to alter the phosphorylation of tau [35] and has con-
sistently been found to positively affect memory processes
even in subjects with dementia (for review see [36]). More
recently, elevated CSF levels of vascular endothelial growth
factor [37] and increased serum levels of insulin growth factor
[38] have also been associated with healthier brain ageing and
brain volume late in life. Aside from the upregulation of these
growth factors, distinct proteomic signatures [39] and genes
[40, 41] have been related to neuronal resilience. For example,
increased expression of genes involved in the control of lyso-
somes has been found after long-term physical exercise. This
upregulation appears to ameliorate the neurotoxic effects of
hippocampal tau pathology in rodents [41]. Interestingly, the
lysosomal pathway has been suggested to mediate the degra-
dation of tau isoforms [42, 43].
So far, it remains unknown whether these molecular under-
pinnings are directly associated with early life-time factors,
such as education, or whether they are more closely related
to life-long cognitive and physical engagement. Longitudinal
studies, including elaborate questionnaires of life-time cogni-
tive and physical activities, are necessary to gain further in-
sights into the relationship between early life-style factors and
protective molecular signatures later in life.
Downstream effects of regional tau pathology
Despite the observation that tau pathology appears to be
less harmful to neuronal function in individuals with
higher levels of education, we conversely observed that
changes in neuronal function in the absence of local tau
pathology appear to be potentiated in individuals with
lower levels of education. These changes may represent
effects of neuropathology aggregation in remote but
functionally connected brain regions in the sense of func-
tional deafferentation or diaschisis.
Interestingly, molecular studies have shown that tau pathol-
ogy preferentially affects long-range projection neurons rather
than locally projecting neurons [44, 45]. Thus, signal changes
detected on [18F]FDG PET probably represent downstream
projection sites from the neuron affected by tau pathology.
This may cause a topographic discordance between the
[18F]AV-1451 and [18F]FDG signals. Indeed, recently, it has
been suggested that the topographic overlap between tau pa-
thology and neuronal dysfunction becomes less coherent as
the disease progresses [46]. Given these findings, it may be
that the disease in individuals with lower levels of education in
Fig. 2 Brain projection showing the tau-specific volume in relation to
level of education: green average overlap volume (i.e. significant tau
pathology and neuronal dysfunction) in patients with typical AD, blue
average tau-specific volumes in three groups with different levels of ed-
ucation (average 11, 16 and 20 years) surrounding the overlap volume.
Importantly, the volumes shown were derived solely from patients with
typical AD, because those with atypical AD showed different
topographical patterns. Moreover, the tau-specific volume in the patients
with an average of 16 years of education is in addition to the volume of
those with an average of 11 years of education. Likewise, the volume in
the patients with an average of 20 years of education is in addition to the
two volumes of the groups with less education. The respective volumes
were rendered on a brain surface in MNI space using the Surf-Ice toolbox
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our sample had already progressed to more advanced stages.
Furthermore, the downstream effects of tau pathology could
be more severe in patients with lower levels of education,
because they do not possess sufficient compensatory or main-
tenance mechanisms to counteract the local upstream effects
of misfolded tau aggregates. This would explain why in pa-
tients with lower levels of education the FDG-specific vol-
umes were greater than the tau-specific volumes.
Limitations
We used a volume-based approach with a predefined threshold,
whichmay have led to underestimation or overestimation of the
overall tau pathology and hypometabolism pattern. Yet the anal-
ysis based on a more liberal threshold yielded similar results,
supporting the current findings. Moreover, with the approach
used, we were able to perform a group analysis including indi-
viduals with different variants of pathology distribution.
However, as the patient groups with atypical ADwere relatively
small, we could not run subsequent analyses for each group.
Moreover, the potential contribution of Aβ pathology could not
be considered in the analyses as amyloid PET scans were
not available in all patients. Nonetheless, all patients were
amyloid-positive based on either CSF or PET imaging mea-
sures. Moreover, we cannot rule out the possibility that our
findings, although less likely, were driven by a faster spatial
spread of tau pathology in patients with higher levels of educa-
tion. Lastly, we used an indirect proxy of neuronal resilience,
namely educational attainment, as there is no direct measure
available yet. It is possible that more elaborate measures of
resilience such as life-long cognitive engagement, physical ac-
tivity or even nutrition may be more closely associated with the
observed effects. Overall, future studies in larger cohorts using
elaborate questionnaires on life-time experience are required to
establish direct measures of neuronal resilience.
Conclusion
The results of this study indicate that level of education is
associated with resilience capacity, which ameliorates the neu-
rotoxic effects of misfolded tau aggregates on neuronal func-
tion in AD. This finding potentially explains why AD patients
with higher levels of education can tolerate more tau patholo-
gy than those with lower levels of education and similar cog-
nitive impairment. It would be of interest to examine whether
the current findings are transferrable to other tauopathies such
as progressive supranuclear palsy, corticobasal syndrome and
frontotemporal dementia. These tauopathies are characterized
by morphological differences in tau aggregates, but the dis-
ease mechanisms appear similar, at least to some degree [47].
Thus, the elucidation of resilience mechanisms may lead to
treatment interventions that are relevant not only to AD but
also to other neurodegenerative diseases.
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Supplementary Data 
 
German educational system:  
In Germany, there are five potential schooling-leaving qualifications: board school (8 years), 
main school (9 years), middle school (10 years), vocational baccalaureate diploma (12 years), 
A-levels (13 years). Depending on the schooling-leaving qualification, people can either start 
a vocational training (3 years) or go to university. A-level graduates can go to university, 
whereas individuals with a vocational baccalaureate diploma can study at a university of 
applied science (similar to a college). 
 
Healthy control template: 
The PET imaging data for the healthy control template was acquired from the ADNI platform. 
In ADNI, most of the cognitively normal subjects are above the age of 70 years. That it is 
why only a relatively small sample remained for the creation of the template in this study after 
age-matching the healthy control subjects to our patient sample. The respective and available 
co-registered, averaged images were downloaded and processed with the same pipeline as the 
PET imaging data of the patient sample. 
 
Supplementary Fig. 1 – Scatterplots of difference volume and bivariate correlation 
analyses 
a 
 
b 
 
c 
 
a: Scatterplot of volume difference (y-axis) and 
residuals of education (x-axis). b-c: Correlation 
analysis: Correlation between mean tau burden in 
overlap volume by mean hypometabolism in 
overlap volume (b, purple), correlation between 
mean tau burden in tau-specific volume and mean 
hypometabolism in FDG-specific volume (c, 
orange). Respective confidence intervals (95%) 
are depicted for each scatterplot. 
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To ensure that the results were not driven by the atypical AD group, we performed a 
subanalysis on the typical AD group. Trend significance was reached for the main variables of 
interest (i.e., tau-specific volume and tau burden in the overlap volume). 
Supplementary Table 1 – Results of regression analysis limited to the typical AD group 
 t β p  F df p Adj. R2 
Tau-Specific Volume    3.012 3,22 .053 .201 
 Education 1.943 .392 .066      
 MMSE -.912 -.186 .372      
 Age -2.280 -.424 .033      
Mean Tau Burden in Overlap Volume (Tau ∩ FDG)  7.591 3,22 .001 .452 
 Education 1.802 .301 .086      
 MMSE -.943 -.160 .356      
 Age -4.341 -.668 <.001      
FDG-Specific Volume   .804 3,22 .506 -.025 
 Education -.345 -.079 .734      
 MMSE .323 .075 .750      
 Age 1.446 .304 .163      
Volume Difference (Tau-Specific- FDG-Specific)   2.365 3,22 .100 .146 
 Education 1.461 .305 .159      
 MMSE -.759 -.160 .456      
 Age -2.188 -.421 .040      
The table includes the statistical model summaries of all regression analysis based on the typical AD group. CI= 
confidence interval; MMSE = Mini Mental State Examination. 
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To ensure that the results were not predominantly driven by the predefined threshold of z >= 
3.0, we conducted the same analyses, but thresholding the PET scans at a more liberal z-score 
level of z >= 2.0, representing a one-tailed p-value of p < .02. 
Supplementary Table 2 – Results of regression analysis using data threshold of z >= 2.0 
 t β p  F df p Adj. R2 
Tau-Specific Volume    3.062 3,33 .042 .147 
 Education 1.758 .284 .088      
 MMSE -1.483 -.246 .147      
 Age -1.960 -.310 .058      
Mean Tau Burden in Overlap Volume (Tau ∩ FDG)  9.320 3,33 <.001 .409 
 Education 2.370 .319 .024      
 MMSE -2.922 -.403 .006      
 Age -3.466 -.456 .001      
FDG-Specific Volume   2.875 3,33 .051 .135 
 Education -1.771 -.288 .086      
 MMSE 2.093 .349 .044      
 Age 1.246 .199 .221      
Volume Difference (Tau-Specific- FDG-Specific)   3.462 3,33 .027 .170 
 Education 1.928 .307 .063      
 MMSE -1.974 -.323 .057      
 Age -1.727 -.270 .093      
The table includes the statistical model summaries of all regression analysis. CI= confidence interval; MMSE = 
Mini Mental State Examination. 
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Given that we observed a significant effect of age in our regression models, we further tested 
for the interaction effect between age and education. No significant interaction effect with age 
and education was found. 
 
Supplementary Table 3 – Regression analysis (threshold: z >= 3.0) including interaction 
of age x education 
 t β p  F df p Adj. R2 
Tau-Specific Volume    3.941 4,32 .010 .246 
 Education -.235 -.369 .816      
 MMSE -1.925 -.303 .063      
 Age -1.105 -.636 .278      
 Age x Education .467 .799 .643      
Mean Tau Burden in Overlap Volume (Tau ∩ FDG)  6.322 4,32 .001 .372 
 Education 1.194 1.715 .241      
 MMSE -2.682 -.385 .011      
 Age .140 .074 .889      
 Age x Education -.988 -1.543 .331      
FDG-Specific Volume   1.283 4,32 .297 .030 
 Education -.522 -.932 .605      
 MMSE 1.738 .310 .092      
 Age -.223 -.146 .825      
 Age x Education .388 .754 .700      
Volume Difference (Tau-Specific- FDG-Specific)  2.956 4,32 .035 .179 
 Education .124 .203 .902      
 MMSE -2.048 -.336 .049      
 Age -.555 -.333 .583      
 Age x Education .085 .152 .933      
The table includes the statistical model summaries of all regression analysis including the interaction term age x 
education. CI= confidence interval; MMSE = Mini Mental State Examination. 
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